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SOMMARIO 
Le α-dystroglycanopatie rappresentano un gruppo molto eterogeneo di distrofie 
muscolari, causate da un deficit di glicosilazione della proteina α-distroglicano. Dal 
momento che i domini glicosilici dell’α-distroglicano favoriscono il legame tra le 
proteine della matrice extracellulare e le proteine del citoscheletro della miofibra, 
l’ipoglicosilazione della proteina causa una rottura di questo legame, con 
conseguente sviluppo di fragilità della membrana sarcolemmatica e necrosi della 
miofibra. Ad oggi, non esistono terapie risolutive applicabili alle α-distroglicanopatie. 
Sono stati identificati diversi geni principali coinvolti nello sviluppo del fenotipi clinico; 
tutti questi geni codificano per glicosiltransferasi: enzimi coinvolti nella glicosilazione 
dell’α-dystroglycano. Tra questi, la mutazione del gene FKRP comporta l’insorgenza 
di un ampio spettro di fenotipi distrofici: da forme lievi quali la distrofia muscolare dei 
cingoli di tipo 2I (LGMD2I), a forme molto severe con possibile coinvolgimento del 
sistema nervoso, quali la distrofia muscolare congenita di tipo 1C (MDC1C), la 
sindrome di Walker Warburg (WWS), e la distrofia conosciuta come Muscle-Eye-
Brain (MEB). La proteina FKRP esercita la sua funzione di glicosiltransferasi 
trasferendo un gruppo ribitolo fosfato da una molecola di CDP-ribitolo all’ α-
dystroglycano. Studi recenti hanno dimostrato che, cellule seminate in vitro, posso 
secernere l’FKRP nel loro terreno di coltura. Benchè il pathway di glicosilazione delle 
proteine avvenga a livello intracellulare, in accordo con quanto osservato in vitro, è 
stata riportata la presenza di glicosiltransferasi circolanti, genericamente definite 
‘’glicosiltransferasi extracellulari’’. Queste ultime possono circolare liberamente nel 
torrente circolatorio o, in alternativa, all’interno di una sottopopolazione di 
microvescicole di dimensioni nanometriche fisiologicamente secreta dalle cellule: gli 
esosomi. Partendo da queste osservazioni, abbiamo ipotizzato che la proteina 
FKRP, sia libera nella circolazione sanguigna che trasportata dagli esosomi, possa 
raggiungere ed esercitare la sua funzione glicosiltransferasica anche in siti molto 
distanti da quello di secrezione. In primo luogo, sono state isolate le cellule staminali 
multipotenti CD133+ dal sangue di un paziente MDC1C e le cellule satelliti da un 
modello murino di LGMD2I: il topo L276IKI. Le cellule sono state ingegnerizzate con 
un vettore lentivirale esprimente la forma wild-type del gene FKRP umano. Inoltre, 
l’espressione della proteina esogena è stata valutata anche negli esosomi rilasciati 
dalle due popolazioni di cellule infettate. Successivamente, è stato eseguito un 
trapianto intramuscolare autologo delle cellule SCs infettate nel modello murino ed 
è stato valutato il recupero di espressione della proteina e il ripristino della sua attività 
glicosiltransferasica nei muscoli iniettati. Per valutare la presenza di FKRP nel 
torrente circolatorio, gli esosomi del plasma dei topi trapiantati sono stati isolati e 
caratterizzati. Gli esosomi sono risultati positivi per l’espressione della 
glicosiltransferasi. Inoltre, è stato evidenziato che la distribuzione sistemica di FKRP 
veicolata dagli esosomi favorisce il recupero di espressione della proteina in siti 
distati da quello del rilascio, determinando un recupero della glicosilazione dell’α-
distroglicano in altri distretti muscolari (ad esempio il cuore) e un conseguente 
incremento della forza muscolare e della performance dei topi trapiantati, come 
dimostrano i risultati ottenuti dai test funzionali. L’utilizzo di un bioreattore per 
microfluidica ha permesso di mimare i processi di diffusione degli esosomi fra le 
cellule, fornendo dettagli importanti sulla cinetica di distribuzione propria degli 
esosomi e sui meccanismi alla base dell’interazione fra cellule target ed esosomi.  I 
dati ottenuti supportano la possibilità di sviluppare un approccio terapeutico 
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trivalente, basato sulla combinazione di terapia cellulare e genica, che 
fisiologicamente promuovono lo sviluppo di una terapia esosoma-mediata. Il 
trapianto autologo di cellule staminali ingegnerizzate potrebbe simultaneamente 
favorire il recupero di espressione della proteina e un effetto di rigenerazione del 
tessuto distrofico, superando così il limite di un approccio basato solo sulla terapia 
genica. Inoltre, gli esosomi secreti dalle cellule staminali ingegnerizzate e trapiantate 
nel muscolo, potrebbero mediare un effetto terapeutico sistemico ottenendo un 
generale miglioramento del fenotipo distrofico. L’approccio basato sull’uso di 
esosomi è estremamente pioneristico e promettente, soprattutto nel campo delle 
miopatie metaboliche e delle distrofie muscolari la cui insorgenza è dovuta a deficit 
enzimatici e non a deficit di proteine strutturali. 
Infatti, esosomi che trasportano target terapeutici (quali enzimi di natura esogena), 
diffondono rapidamente nel torrente circolatorio e raggiungono le cellule target, 
determinando un effetto terapeutico molto rapido, favorito da un recupero immediato 
dell’attività enzimatica.  
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ABSTRACT  
α-Dystroglycanopathies are a group of heterogeneous dystrophic phenotypes 
associated to reduced levels of α-DG glycosylation. 
Since the glycosylated domains of α-DG exert a key role in extracellular matrix 
proteins (ECM) binding to the myofiber cytoskeleton, the hypoglycosylation leads to 
the disruption of this linkage and, consequently, to sarcolemma fragility and myofiber 
necrosis. To date, any successful therapeutical approach has been developed in the 
field of α-dystroglycanopathies. Many genes have been found to be implicated in the 
α-DG glycosylation process; all these genes encode for glycosyltransferase 
enzymes. Of note, mutations occurring in one of these genes, the fukutin related 
protein (FKRP) give rise to different subtypes of clinical phenotypes, ranging from 
the mild limb girdle muscular dystrophy 2I (LGMD2I), to the severe congenital 
muscular dystrophy 1C (MDC1C), to Walker-Warburg Syndrome (WWS) and 
Muscle-Eye-Brain disease (MEB). FKRP glycosyltransferase exerts its 
glycosyltransferasic function by conveying a ribitol phosphate group from a CDP –
ribitol to α-DG. Recent findings have reported cells ability to release FKRP in vitro. 
In line with this evidence, it has also been reported that some glycosyltransferases, 
generally referred to as ‘’extracellular glycosyltransferases’’, freely circulate in the 
bloodstream or, alternatively, packed with a subpopulation of microvesicles (MVs) 
physiologically secreted by cells, named exosomes.  Thus, we hypothesize that 
freely or exosome-carried FKRP might circulate as an extracellular 
glycosyltransferase, reaching distal compartments and acting as a “glycan 
remodeller”. Interestingly, we firstly established a successful transduction of blood-
derived CD133+ multipotent stem cells isolated from an MDC1C patient and FKRP 
L276IKI murine satellite cells, exploiting a lentiviral vector expressing the wild-type 
isoform of human FKRP gene. Furthermore, we reported FKRP expression in 
infected LV-FKRP cells- derived exosomes. Subsequently, we performed an 
autologous intramuscular transplantation of LV-FKRP infected SCs in the L276IKI 
mouse model and we evaluated the recovery of the exogenous protein expression 
and function. Similarly, we investigated the presence of FKRP positive exosomes in 
the plasma of transplanted FKRP L276IKI mice. The exosome-mediated systemic 
distribution of FKRP glycosyltransferase favoured its rescue at distal sites, 
determining an overall recovery of α-DG glycosylation and improved muscle 
strength, as suggested by functional measurement performances. An in vitro model 
based on an optically accessible microfluidic bioreactor allowed us to mimic the 
exosome diffusion between cells in vivo, providing further details of functional kinetic 
and mechanisms underlying exosome uptake. Overall, observed data suggest the 
possibility to develop a trivalent therapeutical approach, based on the combination 
of: cell therapy, gene therapy, leading to a physiological exosome-mediated therapy. 
The autologous transplantation of engineered stem cells would simultaneously 
provide the recovery of the wild-type isoform of the mutated protein and tissue 
regeneration, thus overcoming the limits related to single gene therapy. Moreover, 
intramuscularly transplanted engineered cells- derived exosomes would allow 
toobtain a systemic amelioration of the dystrophic phenotype. This exosome-based 
approach is extremely pioneering and promising, particularly in the field of metabolic 
myopathies and all muscular dystrophies presenting an enzymatic defect, rather 
than a structural protein disruption. Indeed, vesicles carrying the exogenous 
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therapeutic enzyme rapidly diffuse through the bloodstream reaching target cells and 
promoting a fast response mediated by the stabilization of the enzymatic activity. 
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1 INTRODUCTION 
1.1 The skeletal muscle 
1.1.1 Origins and Structure 
Skeletal muscle has two key roles in the human body: it guarantees 
movements by attaching the skeleton through tendons, thus producing force. 
Moreover, it also provides the body thermoregulation, generating heat.  
In vertebrates, the skeletal muscle develops in the embryo from the somites, 
which are mesoderm paraxial bodies, localizing parallel to the neural tubes 
and the notochord [13]. The skeletal muscle progenitors are multi-potent 
stem cells, localizing in the hipoaxial dermamyotome (one of the two 
components constituting the somites, together with the sclerotome). These 
multi-potent stem cells migrate from the dermamyotome to developing limbs, 
tongue and diaphragm after delamination [14, 15]. The myogenic 
commitment is a deeply regulated mechanism which is primary determined 
by Wnts and sonic hedgehog (Shh). Wnts and Shh are secreted by axial 
structures [16] and stimulate both Paired Box (Pax) genes and directly MRFs 
(Myogenic Regulation Factors). Oppositely the process of delamination, 
determining the formation of migratory myoblasts, is regulated by HGF 
(hepatocyte growth factor), which is in turn initiated by c-met. C-met function 
is fundamental for the migration of muscle progenitor cells and it is 
administered by Pax3 and its paralogue, Pax7 [17, 18]. Then, the activation 
of Notch, a regulator factor released by different cell populations including 
myoblasts, favours proliferation and inhibits the premature differentiation of 
myoblasts. The process of differentiation is extremely dynamic and 
principally orchestrated by MRF genes. MRF genes pertain to the bHLH 
(basic helix-loop-helix) protein family, comprehending the Myogenic Factor 5 
(Myf5), Myoblast Determination protein (MyoD), Muscle specific Regulatory 
Factor 4 (MRF4) and Myogenin (Myog) [19]. At first, Myf5 and MyoD are 
activated to induce differentiation, probably driven by Pax3 and Pax7 [20, 
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21]. Myog is targeted by MyoD and coordinates the transition of myoblasts 
to myocytes and myotubes by directly activating structural muscle genes. 
Finally, MRF4 has a fundamental role in the last stages of differentiation [22, 
23]. Muscle is constituted by many elements and multiple structural systems. 
The whole muscle is enclosed by a membrane called epimysium. The total 
structure is constituted by a variable number of fasciculi and each fasciculus 
is enveloped by a connective sheath, named perimysium. Then, each 
fasciculus can be further subdivided in fibers (representing muscle cells), 
which are surrounded by endomysium [24]. Muscle fibers are multinucleated 
cells and all these nuclei localize in the periphery of the cell. Fibers are 
connected to an extensive and complex membrane network. The 
sarcolemma (corresponding to the plasmalemma) represents the main 
membrane system, directly surrounding each fiber. The sarcolemma is 
composed of three layers: the plasmalemma, the basal lamina and 
collagenous fibrils. Then, the transverse tubular system (T-system) and the 
sarcoplasmatic reticulum (SR) are complex membranous systems with a 
fundamental role in the communication of the external stimulus determined 
by the motoneuron inward to the myofiber [24]. Thus, these two structures 
are responsible for the excitation-contraction coupling. Briefly, the T-system 
is composed of plasmalemma membranes which invaginate into the inside 
of the cell and associate to the SR. SR forms two terminal cisternae, running 
parallel to the T-system and constituting the triad. The excitation stimulus 
spreads along the T-system to the SR. When SR receives the stimulus, 
calcium ions are released along the whole fiber and contraction is activated. 
The contractile basic unit of muscle fibers is the sarcomere: serial 
sarcomeres are the unique generators of shortening and force. Sarcomeres 
are made of thick and thin filaments, which are principally composed of two 
contractile proteins: myosin and actin. Moreover, other regulatory proteins 
(tropomyosins and troponins) and scaffold proteins (such as titin and nebulin) 
contribute to the sarcomere contractile function [25]. 
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1.1.2 Muscle Regeneration 
Although adult skeletal muscle is a stable tissue, characterized by a 
restricted nuclear turnover [26], it has the potential to fast regenerate when 
damaged. This process is based on the equilibrium between pro- and anti-
inflammatory events; this equilibrium is fundamental for determining a 
successful repair of the damage allowed by new fibers substitution, and the 
consequent recovery of muscle contractility. Independently from the origin of 
the damage (i.e. direct trauma, tissue ischemia, genetic defects or aging), 
the process of muscle regeneration undergoes three steps: degeneration, 
repair and maturation. Failing of one of these steps turns out in reduced 
muscle performance and muscle wasting [27, 28]. Degeneration of muscular 
tissue consists in muscle fibers necrosis and consequent disruption of the 
sarcolemma, causing an increase of some proteins in the serum, such as 
creatine kinase and myoglobin [29, 30]. In the starting phase of the damage, 
the affected muscle stimulates an inflammatory response orchestrated by T 
helper Th1 cytokines, such as tumor necrosis factor (TNF) and Interferon 
(INF). Soon after, neutrophils and macrophages intervene and contribute to 
further induce muscle membrane lysis and eliminate cellular debris with their 
phagocytic activity [26]. Subsequently, the quiescent Pax7+ myogenic stem 
cell population, the satellite cells (SCs), activation is promoted by insulin-like 
growth factor 1 (IGF-1) and fibroblast growth factor 2. Once activated, SCs 
start to proliferate and migrate to the site of damage [31]. SCs were firstly 
identified in 1961 by electron microscopy and described as an apparently 
quiescent population of stem cells localizing on the surface of the myofiber, 
beneath its basement membrane [32]. After muscle damage these stem cells 
are able to activate and eventually form new fibers, thus exerting the role of 
myogenic precursors. 
During this migration step, satellite cells differentiate into proliferating MyoD+ 
and Myf5+ myoblasts. Pro-inflammatory macrophages (M1) are replaced by 
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anti-inflammatory macrophages (M2) stimulated by Th2 cytokines, such as 
interleukin 4 (IL-4), 10 (IL-10) and 13 (IL-13) [33]. 
 
When the SC proliferation phase is concluded, Myog and MRF4 expression 
is upregulated and myoblasts leave the cell cycle and conclude their 
differentiation: they fuse with fibers thus replenish the injured muscle cells 
[26]. 
1.1.3 Myogenic Stem Cells 
Adult stem cells can be generally depicted as characterized by two main 
functions: self-renewal and multi-lineage differentiation.  Multi-lineage 
differentiation provides the classification of totipotent, pluripotent, multipotent 
progenitors and precursors. In the course of the first stages of development, 
a totipotent zygote originates a completely differentiated adult organism. 
Following this totipotency, pluripotent cells give rise to 3 germ layers and 
then multipotent cells produce the whole organism. Multipotent cells still 
FIGURE 1. Once activated, satellite stem cells undergo an asymmetric division 
(Tedesco et al.; The Journal of Clinical Investigation, 2010) [5]. 
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reside in adult tissues, were they activate and proliferate prompted by 
environmental signals.  
In healthy adult tissues stem cells exert a key role in homeostasis 
maintenance: tissue waste is immediately counterbalanced by injured cells 
substitution, favoured by an asymmetric stem cell division. These cells give 
rise to one cell undergoing differentiation and an identical daughter stem cell. 
This way, stem cells guarantee the development and replenishment of both 
tissues and organs [34]. Satellite cells (SCs) act as a heterogeneous 
subpopulation of stem cells with a fundamental role in muscular tissue 
growth, regeneration and maintenance. As previously mentioned, SCs 
localize in niches beneath the sarcolemma and the basal lamina and they 
represent approximately the 90% of post-natal muscle progenitors in muscle 
[35]. SCs are normally quiescent, but during muscle regeneration SCs 
activate and proliferate undergoing a self-renewal process, which is 
characterized by both asymmetric division and stochastic differentiation. 
Although SCs represent the main muscular resident stem cells, other skeletal 
muscle resident cells, which can differentiate into skeletal muscle, may 
contribute to muscle regeneration under physiological or pathological 
conditions. 
Muscle-derived cells (MDSC) 
In 1999, Gussoni and his group identified for the first time a pluripotent stem 
cell population localized in the skeletal muscle. These cells, identified as a 
side population (SD), were able to differentiate into variable lineages when 
systemically transplanted in vivo into host mice [36]. Moreover, they exhibited 
a hematopoietic differentiation capacity [37]. This cell population, together 
with other precursor cells successively identified in the bone marrow [38], the 
neuronal compartment [39] and different mesenchymal tissues [40], were all 
capable to differentiate into the myogenic lineage and were all Pax7-. This 
observation suggested the existence of progenitor cells, other than satellite 
cells, displaying a myogenic potential. In 2002, Qu-Petersen’s group 
6 
identified 3 populations of muscle-derived stem cells (MDSC), in accordance 
with their proliferation behaviour and adhesion characteristic [41]. Briefly, 
after enzymatic dissociation, the muscle extract was seeded on a collagen-
coated dish; different unique populations were isolated on the basis of their 
adhesion features. The first pre-plating passage (PP1) represented primary 
fibroblasts; heterogenous population of myogenic and not-myogenic cells 
were obtained in the following passages (PP2-PP6, 24 hours intervals). PP2 
and PP3 desmin+ cells were re-plated in combination with PP4 and PP5 and 
they represented the EP population. PP6 cells were seeded 72 hours after 
PP5 passage. These cells were recognized as LP population. LP half-life 
was about 1-2 weeks; surviving cells formed clonal colonies, called MDSC 
[41]. The early pre-plate cells (EPs) and the late pre-plate cells (LPs) were 
recognized as satellite cells due to their patterns of myogenic markers 
expression. EPs were desmin, m-cadherin and myogenin positive and, 
similarly to SCs, they showed fast proliferation and differentiation into 
myotubes when cultured in vitro. On the contrary, the role of LPs remained 
unclear: these cells demonstrated a limited capacity to proliferate and 
differentiate. The third population, the quintessential MDSCs likely deriving 
from myofibers, represented a novel type of pluripotent stem cells. MDCS 
were highly proliferating cells, showing good self-renewal capacity in vitro. 
When injected in vivo, MDCSs demonstrated their multipotent nature. When 
transplanted in the mdx mouse model of Duchenne Muscular Dystrophy 
(DMD), they were able to deliver dystrophin to targeted myofibers and restore 
the histology of dystrophic muscle for at least three months after 
transplantation. Moreover, they exhibited an immune-privileged behaviour, 
probably due to MHC-I lack of expression on their surface; no CD4+ or CD8+ 
lymphocytes were identified in the transplanted muscles after injection. 
Overall, if compared to EP cells treatment, MDCS transplantation produced 
better outcomes [34, 41, 42]. The advantage of MDCS for muscle 
regeneration has been linked not only to their proliferation, self-renewal and 
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multipotent differentiation capabilities, but also to their resistance to hypoxic 
and oxidative stress [43].  
Myo-endothelial cells 
In 2007, Zheng and his colleagues examined the correlation between 
myogenic and endothelial cells in human skeletal muscle (Zheng et al, 2007). 
Previous studies had shown that some MDSCs, displaying endothelial cell 
markers on their surface, differentiated into endothelial cells after injection in 
the skeletal muscle [41, 43, 44]. They proved the existence of a stem cell 
population co-expressing endothelial and myogenic markers (CD56+, 
CD34+, CD144+). This cell population was called ‘’myo-endothelial’’. When 
cultured in vitro, myo-endothelial cells showed the same regeneration 
capability upon extended culture as myogenic (CD56+CD34-CD144-) cells 
and endothelial (CD56-CD34+CD144+) cells; however their proliferation and 
resistance to oxidative stress were extremely higher. Moreover, when these 
cells were injected intramuscularly into an immuno-deficient mouse model 
(SCID), in which skeletal muscles were injured by cardiotoxin, they were able 
to regenerate muscle similarly to endothelial cells but more efficiently than 
committed myogenic cells [41, 42]. According to Dr. Zheng observations, 
regenerated myofibers nuclei were all of human origin, thus underlining that 
these cells exerted their role by fusing each other. Moreover, donor-derived 
cells were all localized beneath the sarcolemma, thus suggesting an 
additional function in replenish satellite cells compartment [45]. 
Mesoangioblasts  
Mesangioblasts (MABs) are multipotent precursors for vascular and 
extravascular mesodermal tissues. They physically localize within the 
embryonic dorsal aorta in both avian and mammal species. When isolated 
and cultured in vitro, mesangioblast clones express early endothelial markers 
(Flk1+CD34+vascular-endothelialVE-cadherin+) and a variable number of 
cells co-express α-smooth muscle actin (α-SMA), generally found on the 
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surface of skeletal myoblasts. If cell clones are seeded onto collagen-coated 
flasks added with horse serum and chick embryo extract, they also express 
Myf5 and MyoD myogenic regulator factors and thus differentiate into 
skeletal muscle cells [46]. Thanks to their myogenic differentiation potential, 
MABs have been extensively exploited for the regeneration of injured 
muscular tissue in animal models of muscular dystrophy. MABs isolated from 
embryonic dorsal aorta (murine D16 MABs) were systemically transplanted 
in an α-sarcoglycan (α-SG) null mouse model; cells restored the wild-type 
protein expression in 20% of the muscle fibers and favoured a decrease in 
fibrosis, thus determining an amelioration of the animals endurance [47, 48]. 
Moreover, it was proved that these MABs express specific receptors on their 
surface, favouring their homing and engraftment to damaged tissues. The 
overexpression of these receptors deeply increases the outcome of MABs 
transplantation [49]. The main limit related to embryonic MABs is the difficulty 
of the isolation procedure. The isolation of MABs from human aorta during 
by-pass surgery may be a promising source; however it has been recently 
discovered that a population closely similar to mesangioblasts can be also 
isolated from the skeletal muscle, the bone marrow [50] and the atria and 
ventricles of the heart [51]. Skeletal-muscle isolated MABs display a short 
half-life and no self-renewal capability. In 2006, Sampaolesi’s group 
exploited skeletal muscle’s MABs to rescue dysferlin expression in a 
dysferlin-deficient mouse model. The systemic cell transplantation allowed 
the recovery of the protein expression in 9-12% of total myofibers [52]. 
According to these observations, skeletal muscle-derived MABs were also 
isolated, genetically corrected and intra-arterially transplanted in dystrophic 
animal models of Duchenne muscular dystrophy: the mdx mouse model and 
the GRMD dogs. MABs were able to determine the restoration of dystrophin 
in a variable percentage of myofibers in both the two experiments [52, 53]. 
Finally, in 2015, Cossu and his group reported the first phase I, IIa clinical 
trial based on MABs transplantation. Cells were isolated from HLA-matched 
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donors; 5 DMD patients were treated. Escalating doses of MABs were 
systemically transplanted after immunosuppressive therapy. Although a boy 
reported a thalamic stroke without clinical consequences, the study was 
considered as safe. MRI demonstrated that 4/5 showed a slight amelioration 
of the disease, but without functional progression [54].  
Pericytes 
Pericytes localize around the vascular tube, interdigitating with endothelial 
cells in the basement membrane of the vessels. Physiologically, they play a 
key function in the support of microcirculation. Even though they originally 
demonstrated a mesenchymal-stem cell nature, showing the capability to 
differentiate into osteoblasts and adipocytes, recent studies demonstrated 
that they had also a good capacity of myogenic differentiation [55]. Human 
skeletal muscle blood vessels- derived cells were found to express pericytes 
markers: NG2 proteoglycan and ALP alkaline phosphatase. These cells 
showed a good proliferation rate in vitro and the ability to spontaneously fuse 
to form myotubes with high efficiency. After transplantation into the 
SCID/mdx mouse model, they were able to generate a high percentage of 
human dystrophin+ myofibers. These cells were also isolated from 
Duchenne patients, engineered with the human mini-dystrophin and 
transplanted in vivo. Once again, they showed a myogenic potential and the 
capability to restore the human mini-dystrophin expression in SCID/mdx 
muscles [55]. In 2009, it was also observed that in the case of focal injury, 
pericytes are released from their position to exert an immunomodulatory 
function [56]. 
CD133+ cells 
In 2004, Torrente and his group isolated a population of human skeletal 
muscle-derived stem cells positive for CD133 antigen. These stem cells were 
defined as multipotent precursors, as they were able to differentiate into 
myogenic, hematopoietic and endothelial cells when cultured in vitro in the 
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presence of certain cytokines [57]. The expression of CD133+ antigen was 
also observed in a subpopulation of circulating stem cells, showing a 
myogenic potential too. This cell population was isolated and characterized 
in vitro: cells were positive for several myogenic precursors: Myf5, Pax7 and 
M-cadherin. As they were not spontaneously able to differentiate into 
myogenic cells, they were induced to undergo myogenesis when co-cultured 
with myogenic cells or in the presence of a specific myogenic signalling. 
Moreover, human circulating CD133+ cells were intra-arterially and intra-
muscularly transplanted in a dystrophic immunodeficient mouse model: the 
SCID/mdx mice. Their capacity to rescue dystrophin expression and to 
replenish the SCs pool was then evaluated. It was found that up to 10% 
muscle fibers were positive for human dystrophin expression; injected cells 
partially localized beneath the basal lamina and co-expressed M-cadherin, 
thus suggesting a replenishment of SCs pool. Furthermore, RT-PCR analysis 
of injected fibers demonstrated the expression of myogenic markers, 
evidencing that blood-derived CD133+ cells profoundly contributed to the 
regeneration of dystrophic muscle [57]. In 2007, Torrente’ group extended 
previous observations investigating the therapeutic potential of a combined 
cell and gene based therapy. Following the isolation of CD133+ cells from 
DMD patients’ blood and muscle, they engineered dystrophic cells exploiting 
the exon-skipping technique to restore the correct reading frame of mutated 
dytrophin and finally they intramuscularly transplanted engineered cells in 
the SCID/mdx mouse model. They demonstrated that both skipped blood- 
and muscle- derived CD133+ cells could differentiate in vivo into satellite 
cells and mature myofibers. These myofibers were human dystrophin 
positive but expressed also α- and β-sarcoglycans, thus suggesting the 
recovery of the dystrophin-associated protein complex. However, the 
intramuscular transplantation produced a local regeneration, whereas DMD 
disease compromises the whole skeletal muscle system. Thus, they 
performed a systemic transplantation of muscle-derived CD133+ stem cells 
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and they observed an amelioration of muscle morphology and consequently 
of SCID/mdx mice endurance [58]. The same year, the safety of an 
autologous transplantation of muscle-derived CD133+ cells in 8 Duchenne 
boys in a 7-month double- blind phase I clinical trial was tested. Produced 
data demonstrated the absolute safety and feasibility of these stem cells 
transplantation. Treated patients showed an increase in muscle fibers 
vascularization and in fast myosin myofibers [59]. 
Mesenchymal stem cells (MSCs) 
One of the main problems related to cell therapy is associated to immune 
rejection. In the field of muscular dystrophies, the process of rejection 
accelerates the dystrophic progression, causing an increased inflammation. 
To this aim, MSCs cell therapy has shown promising results. Mesenchymal 
stem cells are generally considered as adherent, non-hematopoietic cells, 
positive for CD90, CD105, CD73 and negative for CD14, CD34, and CD45 
markers. They were originally isolated from the bone marrow; however they 
have been identified also in many other tissues: adipose tissue [60], heart 
[61], peripheral blood [62], dental pulp [63], cord and menstrual blood [64]. 
MSCs are pluripotent stem cells, with a well-known ability to differentiate into 
condro, adipo and osteo lineages [65]. However, it has been observed that 
they are also able to differentiate into cells-resembling neurons [66], muscle 
[67], hepatocytes [68] and pancreatic islets [69]. The regenerative capacity 
of MSCs has been extensively investigated in post-myocardial infarct 
models, stroke [70], pulmonary fibrosis [71], kidney damage [72], as well as 
muscular dystrophy [73]. MSCs are able to restore full-length dystrophin in 
dystrophic myotubes by directly fusing with dystrophin-/- cells. MSCs exert a 
fundamental role in controlling inflammation. Firstly, they express specific 
receptors determining their homing towards injured tissues. Then, they inhibit 
macrophage activation [74], Th1 and Th17 generation [75] and they suppress 
NK and T cytotoxic cell function [76] within these damaged tissues. Recently, 
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it has been discovered that the therapeutic effects of MSCs may be related 
not only to their proper regenerative and immunomodulatory ability, but also 
to the release of paracrine factors, such as cytokines and extracellular 
microvesicles, which cooperate with cells to exert their role, inhibiting 
apoptosis, stimulating endogenous cell proliferation and activating resident 
stem cells in the damaged tissue [77].  
1.2 The Congenital Muscular Dystrophies (CMDs) 
1.2.1 Generalities and Clinical Phenotypes 
Muscular dystrophies (MDs) include a clinically and genetically 
heterogeneous group of inherited muscle diseases.  To date, MDs have been 
classified in six groups: Duchenne Muscular Dystrophy (DMD, 310200), 
Becker Muscular Dystrophy (BMD, 300376), Limb Girdle Muscular 
Dystrophies (LGMDs), Fascioscapular Muscular Dystrophies (FCMDs), 
Myotonic Muscular Dystrophies (MMDs), Dystal Myopathies (DMs) and 
Congenital Muscular Dystrophies (CMDs).  Recent epidemiological data 
suggest that the prevalence for CMDs seems to be between 2,6 – 4,5 in 
10000 [10], identifying CMDs as the most popular autosomal recessively 
inherited neuromuscular diseases [78]. CMDs are principally characterized 
by skeletal muscle diffused weakness, usually presenting from infancy. 
Infants are generally defined as ‘’floppy’’, with very low muscle tone and poor 
spontaneous movements [79]. Muscle alterations occurring in CMD patients 
depend on an anomalous muscular structure due to mutations occurring in 
genes encoding mainly for structural components of the extracellular matrix.  
Affected children may present delayed or arrested motor development and 
they can develop joint and spinal rigidity. They usually encounter feeding 
difficulties, leading to poor nutrition. Muscle weakness may worsen or 
stabilize. The worst consequences of muscle weakness are respiratory 
insufficiency and cardiac involvement, which can deeply influence patients’ 
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quality of life and life span. Moreover, these diseases may involve also the 
central nervous system (CNS), eyes and connective tissue [79].  
1.2.2 Classification of CMDs 
So far, different classifications of CMDs have been proposed. Originally, 
CMDs have been classified on the basis of patients’ clinical phenotype. 
However, pathological phenotypes due to various mutations in different 
genes are significantly overlapping. Mutations occurring within a specific 
gene are able to give rise to a wide spectrum of disorders. For this reason, 
nowadays the clinical classification of CMDs is based on the genes in which 
the pathogenic mutation occurs and the cellular localization of the involved 
mutated protein [79] [1] [80]. Extracellular matrix protein mutations, such as 
Laminin alpha-2 (LAMA2, 156225) and Collagen VI (COL6A1, 120220, 
COL6A2, 120240, COL6A3, 120250), respectively lead to the development 
of merosin-deficient CMD (MDC1A, 607855) and Ulrich CMD (UCMD, 
254090)/Bethlem myopathy [81]. External sarcolemmal protein mutations, 
such as integrin α7 (ITGA7, 600536) and integrin α-9 (IGTA9, 603963), 
cause integrin α7 and integrin α-9 –related CMDs [82].  
Defects of α-dystroglycan glycosylation, depending on mutations occurring 
in genes encoding for glycosyltransferases, such as fukutin (FKTN, 607440), 
fukutin-related protein (FKRP, 606596), glycosyltransferase-like protein 
large1 (LARGE1, 603590), O-linked mannose β1,2-n-
Acetylglucosaminyltransferase (POMGNT1, 606822), protein-O-
mannosyltransferase1 (POMT1, 607423), protein-O-mannosyltransferase2 
(POMT2, 607439), isoprenoid synthase domain-containing protein (ISPD, 
614631), lead to the development of different forms of dystroglycanopathies. 
Defects of proteins residing in the endoplasmic reticulum, such as 
selenoprotein-N (SELENON, 606210), cause rigid spine syndrome (RSMD1, 
602771) and defects of proteins localized in the nuclear envelope lamin A/C 
(LMNA, 150330) cause the Dropped-head syndrome, (EDMD, 310300). 
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Finally, mutations arising in sarcolemmal and mitochondrial membrane 
proteins, such as choline kinase β (CHKB, 612395), give rise to protein-
related muscle disease-CMD [83].  
Other less common CMD subtypes have been identified (i.e. SYNE1-related 
CMD caused by SYNE1 mutation encoding enaptin protein, a nuclear 
envelope protein, 608441), as well as ‘’CMDs of unknown origin’’ caused by 
unknown mutations of genes [84] [79]. However, data for all CMDs are still 
inadequate to define a specific genotype/phenotype correlation and a 
consequent concluding prognosis. 
1.2.3 Diagnosis, Treatment and Surveillance 
The diagnosis of CMDs is principally based on clinical findings, brain and 
muscle imaging, molecular genetics analysis, immunohistochemical staining 
and biopsy histology. Muscle biopsies are fundamental for the evaluation and 
precise diagnosis of congenital muscular dystrophies. Correlation with the 
clinical picture is necessary to have a correct biopsy interpretation, given the 
variability of similar morphologic findings, the variability in the performance 
of commercial antibodies to detect protein deficiency by 
immunohistochemistry and the absence of specific stains in some subtypes 
of CMDs. Muscle biopsies may appear very heterogeneous; for instance 
each subgroup of disorders, previously identified in CMDs classification, 
presents unique features. 
For example, MDC1A muscle biopsy exhibits a high heterogeneity in fiber 
size with connective tissue proliferation and fat infiltration in specific muscle 
areas; the immune staining (IS) must underline the complete absence of 
laminin-α2 expression. UCMD biopsy shows changes from mildly myopathy, 
with limited fibers size variability, to a profound dystrophic phenotype, with 
prominent connective and fat tissue infiltrations and replacement of muscular 
tissue; IS shows no signal for collagen VI protein staining. Among α-
dystroglycanopathies, the differences in muscle biopsies are related to the 
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amount of residual glycosylation of α-dystroglycan (α-DG). The lower α-DG 
is glycosylated, the more compromised is the muscle. In RSMD1, fiber size 
variability and type-1 fiber predominance are the main features and 
sometimes multiple core-like areas of sarcoplasmic disorganization 
associated with mitochondrial depletion may be found in muscle biopsy 
analysis. The presence of basophilic fibers underlines the regenerative 
activity, but not all basophilic fibers are also regenerating. The analysis of 
foetal and neonatal myosis may be very helpful. Moreover, other 
abnormalities may be found, including different types of vacuoles. [85].  
So far, no decisive therapeutic approaches for CMDs have been found. 
Treatments just allow the amelioration of the development of the disorder 
and focus on the prevention of pulmonary and cardiac failure. Multi-
disciplinary medical care aims to the improvement of patients’ quality of life 
and longevity:  respiratory insufficiency always requires assisted cough 
devices, supplemented oxygen and non-invasive ventilation via 
tracheostomy. Physical therapy, based on stretching exercise, is suggested 
to avoid contractures and to promote mobility; mechanical devices including 
wheelchairs are generally exploited to support children mobility. Sometimes, 
surgical intervention for preventing and treating spinal and limb deformities 
is required. Throughout the pathology course, surveillance is mandatory for 
constantly monitoring the respiratory functions, the orthopaedic 
complications, and the cardiac and neurological functions. 
1.3 Alpha-Dystroglycanopathies 
1.3.1 DAG1 gene and Dystroglycan protein 
After its discovery in 1987 as a new laminin-binding protein in the plasma 
membrane of different cell types [86], dystroglycan (DG) and its 
corresponding gene (DAG1, 128239) were deeply characterized by the 
group of Kevin Campbell from the beginning of the 90s. The dystroglycan 
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gene (DAG1) localizes in human chromosome 3p21. The coding sequence 
of the gene is organized in two exons, the first consisting of 285 pair bases 
and the second incorporating the rest of the coding sequence (2400 pair 
bases). The two exons are divided by a single large intron. The cDNA 
encodes for a 97 KDa precursor protein (895 amino acids), which goes 
through a post-transcriptional cleavage, thus producing two independent 
subunits: α-dystroglycan (a 156 KDa highly glycosylated protein) and β-
dystroglycan (a 43 KDa transmembrane protein). mRNA is 5.8 Kb and its 
expression has been found to be positive in many different muscular and 
non-muscular tissues [87]. α-DG possesses three domains: an N-terminal, a 
serine-threonine-rich mucin-like and a C-terminal domain. This highly 
glycosylated peripheral membrane functionally interacts with extracellular 
matrix (ECM) proteins, such as laminin, biglycan, neurexin, perlecan, agrin, 
pikachurin and slit [88]. α-DG C-terminal domain binds with high affinity the 
N-terminus of β-dystroglycan. β-DG, in turn, has a unique transmembrane 
domain; its  cytoplasmic  C-terminus domain associates with the last 15 
amino acids to the cys-rich domain of dystrophin [89].  This domain is also 
proline-rich and includes a Tyr- phosphorylation site. The cytosolic domain 
of β-DG acts also as a junction to other proteins, such as rapsyn, caveolin-3 
and Grb2 [90]. This linkage is considered as fundamental in sustaining the 
integrity and stability of the sarcolemma from mechanical stress induced by 
skeletal muscle. α-DG N-terminal region is cleaved by proteases after the 
glycosylation process is concluded. α-DG has a wide tissue distribution 
throughout human body, with high expression in muscle, in the CNS and 
peripheral nervous system (PNS), in the epithelial and endothelia [91]. The 
massive presence of α-DG suggests a key function not only in supporting 
muscle fibers structure and functionality, but also in neuronal migration, axon 
guidance, neuromuscular junction formation, and in the formation of optic 
tissue [92]. 
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The main feature of a functional α-DG, starting from the physiological 
development of the embryo, is a tissue specific glycosylation. For this reason, 
even though the amino acid sequence predicts a 74 KDa core protein, α-DG 
looks like a smear in SDS-PAGE analysis with a variable molecular weight 
of about 156 KDa in skeletal muscle and 120 KDa in brain and peripheral 
nerves, thus suggesting a tissue-specific pattern of glycosylation. By electron 
microscopy, α-DG is a dumbbell-shaped molecule characterized by two 
globular domains divided by a rod-like region corresponding to its mucin 
domain.  
 
FIGURE 2. Representation of the DCG complex and other proteins involved in the 
development of dystrophic phenotypes (J. Kirschner and C. G. Bönnemann;  
The Archives of Neurology, 2004)[12]. 
This central region contains more than 40 Ser/Thr residues that constitute an 
O-glycan cluster. α- and β- DG proteins were initially classified as 
components of the dystrophin-glycoprotein complex (DCG), together with 
sarcoglycans, dystrobrevins, syntrophins and sarcospan. DCG represents 
an essential component of the sarcolemma, which has a key role in the 
structural stability of the cytoplasmic membrane. The loss of function of any 
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protein belonging to DGC leads to the disruption of the whole complex and 
causes the instability of the linking between extracellular matrix and 
intracellular cytoskeleton, and the consequent development of muscular 
dystrophies.  
1.3.2 α-Dystroglycan Glycosylation 
There are three main categories of sugar-peptide linkages; N-linked, O-
linked glycans and glycosaminoglycans (GAGs), found on proteoglycans. N-
linked glycans and various O-linked glycans have been found on α- 
dystroglycan. In this latter, the reducing terminal sugar is usually N-
acetylgalactosamine (GalNAc), which associates to the hydroxyl group of 
serine (Ser) and threonine (Thr). Aside from GalNAc, O-linked mannose 
linkage plays a significant role for α-dystroglycan functionality, favouring its 
connection to extracellular matrix proteins. O-mannoglycosylation begins in 
the endoplasmic reticulum with protein-O- mannosyltransferase 1 (POMT1) 
and 2 (POMT2) exerting their function [89, 93]. These two proteins share the 
same hydropathy profiles and they are predicted to be integral membrane 
proteins with multiple transmembrane domains. POMT1 needs to interact 
with POMT2 for exerting its enzymatic function. These two proteins are 
present in all human tissues, with a predominance of POMT1 expression in 
foetal brain, testis and skeletal muscle and POMT2 in testis. The complex 
cooperates to form a β-1,2 linkage with N-acetylglucosamine (GalNAc) to 
catalyze O-mannosylation of proteins. O-linked mannose β1,2-N-
acetylglucosaminyltransferase 1 (POMGnT1) operates by transferring a 
GlcNAc from UDP-GlcNAc to O-mannosyl glycoproteins, demonstrating a 
specific O-mannose β1,3-N-acetylglucosaminyl transferase activity. 
POMGNT1 can be further branched by GlcNac and/or elaborated by 
galactose, fucose or sialic acid to generate the M1 and M2 glycans [94, 95]. 
A small group of O-Man modified domains on α-DG is extended in the 
endoplasmic reticulum by a GalNac in a beta- 1,4 linkage by O-linked 
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mannose β1,2-N-acetylglucosaminyltransferase 2 (POMGNT2, 614828) and 
forms the M3 glycans [95]. Subsequently, GlcNAcβ1-4Man is further 
modified and transformed into a trisaccharide by β1,3-N-
acetylgalacosaminyltransferase 2 (B3GALNT2, 610194) and the protein 
kinase-like POMK, a specific O-mannose kinase [95]. Processes leading to 
the constitution of GalNAcβ1-3GlcNAcβ1-4(phosphate-6)Man occur in the 
ER. Following unknown elaboration of the phospho-trisaccharide in a 
phosphodiester linkage, β-1,4-Glucuronyltransferase 1 (B4GAT1, 605517) 
adds a glucuronic acid (GlcA) in a beta 1,4  linkage to a β-linked xylose [94, 
96]. This mechanism functions as a primer for glycosyltransferase-like 
protein LARGE (LARGE) enzyme. LARGE acts as a bifunctional 
glycosyltransferase, generating polymers of alternating xylose (Xyl) and 
glucoronic acid (GlcA), by producing units in this sugar moiety acting as 
receptors for ECM proteins [94, 97]. The precise mechanism by which the 
xylosyl-glucoronyl polysaccharide is attached to α-DG is still unknown, but 
recent evidences suggest the formation of a linkage via phosphorylate O-
mannosyl structures. LARGE is widely expressed in brain, heart and skeletal 
muscle whereas LARGE2, a paralogue of LARGE, is highly expressed in 
placenta and kidney. In 2016, Well’s group reported a M3 glycan structure 
with a phosphodiester linked ribitol on which transmembrane protein 5 
(TMEM5, 605862), B4GAT1, and LARGE act to generate the functional 
receptor for ECM proteins. They identified isoprenoid synthase domain-
containing protein (ISPD) protein as a CDP-ribitol pyrophosphorylase, an 
enzyme that can synthesize CDP-ribitol from ribitol-phosphate and CTP. 
Moreover, they also speculated that TMEM5, a xylose transferase, is further 
elongated by B4GAT1 and acts as a primer for LARGE addition of 
matriglycan [94]. Recently, the group of Toda et al., identified also a 
mechanism by which ISPD, fukutin (FKTN) and fukutin-related  (FKRP) 
proteins sequentially act as ribose-5-phosphate (Rbo5P) transferases, 
exploiting CDP-Rbo as a substrate [98]. 
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1.4 α-Dystroglycan Hypoglycosylation 
Muscular dystrophies characterized by hypoglycosylation of α-dystroglycan, 
due to O-mannosylation lacking, are generally referred to as 
dystroglycanopathies. Alpha-dystroglycanopathies are group of disorders, 
extremely heterogeneous from both a clinical and genetical point of view, 
presenting with various phenotypes ranging from severe disorders of CMDs 
to milder LGMD forms, with and without CNS involvement and often 
characterized by optical damage.  
 
 
TABLE 1. Genotype and phenotype correlations alpha-dystroglycanopathies (U.C. Reed; 
Arquivos de Neuro-Psiquiatria, 2009)[10]. 
Similar phenotypes can be determined by mutations in different genes: 
various mutations localizing in the same gene are able to give rise to 
heterogeneous phenotypes [1, 88, 99].  
For this reason, a classification of these disorders has been proposed based 
on the age of the onset of the weakness, the presence or absence of 
structural brain abnormalities/ mental retardation and eye involvement, 
rather than the specific gene mutation or the original clinical entity [100].  
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Fukuyama Congenital Muscular Dystrophy (FCMD) 
FCMD (Muscular dystrophy-dystroglycanopathy type A, 4: MDDGA4, 
253800) is reported as one of the most prevalent autosomal recessive 
disorders of childhood muscular dystrophies in Japan [101]. FCMD is due to 
a mutation in the FUKUTIN gene on chromosome 9q31. It is a very severe 
form of CMD, characterized by brain abnormalities such al polymicrogyria of 
the cerebrum, lissencephaly and hypomyelination, leading to severe to mild 
mental retardation. 80% of patients may have epileptic attacks or suffer from 
insomnia. Decreased foetal mobility may occur in utero, and in the neonatal 
period patients are weak and floppy. Clinical manifestations range from 
contractures appearing in the first year of age, to muscle hypertrophy of 
tongue and calf in FCMD patients. Usually, they are not able to walk, and if 
they walk, severe scoliosis brings to the loss of ambulation. Most patients die 
by 20 years, due to cardiomyopathy and cardiac failure.  
Muscle-Eye Brain (MEB) disease 
MEB (Muscular dystrophy-dystroglycanopathy type A, 3; MDDGA3, 253280) 
pathology is an autosomal recessive disease primary caused by loss-of- 
function mutations occurring within the POMGnT1 gene on chromosome 
1p34-p32. Mutations in other genes including POMT1, POMT2, FKTN and 
GMPPB can also lead to the development of the pathology.   
MEB is considered the second most severe type of alpha-
dystroglycanopathy. The hallmarks of MEB patients include brain defects 
(hypoplastic cerebellar vermis and cerebellar hypoplasia). MEB patients 
present a severe hypotonia in the neonatal period and an impaired motor 
development. They show very severe optic symptoms such as retinal 
defects, optic atrophy, glaucoma and congenital myopia. The life expectancy 
of MEB patients is 10-30 years. Nowadays, FCMD and MEB are referred to 
as a unique phenotype, since there is a significant overlapping of these two 
disorders. 
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Walker-Warburg Syndrome (WWS) 
WWS is typically considered as the most compromising form of 
dystroglycanopathy. It is inherited as an autosomal recessive disorder, 
caused by mutations generally occurring in the POMT1 gene (chromosomal 
locus 9q34.1) (Muscular dystrophy- dystroglycanopathy type A,1; MDDGA1, 
236670) or the POMT2 gene (chromosomal locus 14q24.3) (MDDGA2, 
613150), causing an identical clinical phenotype. However, also mutations in 
FKTN, FKRP, LARGE, ISPD, B4GAT1, B3GALNT2, POMK, DAG1, 
POMGNT and TMEM5 genes have been found to be associated to the 
development of this pathology [88]. The onset usually begins at early foetal 
phase, with profound abnormalities in the CNS, such as lissencephaly, 
hydrocephalus or cerebellar hypoplasia, representing dangerous 
complications [102].  
 
FIGURE 3. Disruption of the subsarcolemma cytoskeleton-extracellular matrix link in 
dystrophin-glycoprotein complex-related muscular dystrophies (Y.M. Kobayashi; 
Neuromuscular disorders, 2012) [8]. 
WWS patients always show severe intellectual disabilities and ocular 
abnormalities, such as microphthalmia, cataracts and myopia. At birth, WWS 
patients present absence of spontaneous movements, notable hypotonia 
and inability to see. Life expectancy is generally less than 3 years, due to the 
insurgence of systemic complications like pneumonia and heart failure [88]. 
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In addition to these principal pathological phenotypes, other minor forms of 
α-dystroglycanopathies have been identified: the Congenital Muscular 
Dystrophy Type 1D (MDC1D) (Muscular Dystrophy-Dystroglycanopathy 
Type B, 6; MDDGB6, 608840), caused by a mutation in LARGE gene, 
encoding for a putative glycosyltransferase [80], and the Congenital 
Muscular Dystrophy Type 1C, linked to a mutation in the FKRP gene. 
1.5 Congenital Muscular Dystrophy Type 1C (MDC1C) and 
Limb-Girdle Muscular Dystrophy type 2I (LGMD2I) 
1.5.1 MDC1C and LGMD2I clinical features 
MDC1C disorder (Muscular Dystrophy-Dystroglycanopathy Type B, 5; 
MDDGB5, 606612) is due to a mutation occurring within the FKRP gene. FKRP 
mutations lead to the development of a wide range of disorders, including both 
severe forms of muscular dystrophy (MDC1C, WWS, MEB), some of which 
affecting the central nervous system, and a milder disease classified as limb 
girdle muscular dystrophy type 2I (LGMD2I) (Muscular Dystrophy-
Dystroglycanopathy Type C, 5; MDDGC5, 607155).  
 
FIGURE 4. FKRP mutations and correlated clinical spectra (J. van Reeuwijk; Clinical 
Genetics, 2010) [2] 
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MDC1C patients exhibit an acute muscle weakness compromising also the 
respiratory muscles. Immediately after birth, they present severe hypotonia 
and feeding complications. Hypertrophy occurs in the calf muscles and other 
lower limb muscles. The progressive dystrophic process hampers motor 
milestones and children never acquire normal functional ambulation. 
Although FKRP is expressed also in the brain, MDC1C patients may either 
show or not an involvement of central or peripheral nervous system 
associated with mental retardation. Microcephaly, mild mental retardation 
and cerebellar cystis can sometimes occur [103]. Usually, death occurs in 
the first decade or shortly thereafter, due to pulmonary dysfunction or cardiac 
failure. The muscle symptomology is undistinguishable from other CMDs 
phenotypes; MDC1C muscle shows a marked depletion of α-DG 
glycosylation, as determined by immunocytochemistry analysis.  
 
FIGURE 5. MDC1C (a) and LGMD2I (b, c) phenotypes (E.Mercuri; Annals of Neurology, 
2003) [1]. 
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In addition, the muscular biopsies of some patients carrying specific 
mutations (such as 1387A>G, N463D) also show a reduced 
immunoreactivity to β-dystroglycan, α-, β-, -ү sarcoglycans, underlining a 
widespread pathological effect of FKRP mutation causing a disruption of the 
dystrophin glycoprotein complex (DCG) [104]. LGMD2I is one of the most 
frequent autosomal recessive forms of LGMDs forms of limb dystrophy, 
especially in Northern Europe [105].  While in CMDs the onset of symptoms 
is usually at birth or within the first 6 months of life, in LGMD it usually occurs 
in late childhood, adolescence or even adult life. Although this peculiar 
difference, it is now clear that LGMD and CMDs clinically and genetically 
overlap, thus suggesting that these pathologies follow a similar pathway. In 
LGMD2I, patients’ muscle weakness results in frequent falls and ‘wadding 
gait’ with difficulties in specific exercises, such as running or climbing stairs. 
With the progression of the disease, these symptoms slowly increase. As 
well as lower limb weakness, also shoulders and arms are interested. 
LGMD2I subject’s life expectancy and quality of life depend on the early 
identification and treatment of the pathology. Reports show that a majority of 
LGMD2I patients display cardiomyopathies. Specifically, they may have a 
reduced left ventricular ejection fraction, visualized by cardiovascular 
magnetic resonance imaging (CMR), cardiac conduction failure and dilated 
cardiomyopathy. CMR analysis also identifies a progressive fatty deposition 
and fibrosis in the septum and inferior wall. However, it seems that the 
severity of the cardiac defects is not directly correlated to the severity of 
clinical skeletal muscle or the involvement of brain. Unfortunately, LGMD2I 
patients often die because of left ventricular failure [106] [107]. 
1.5.2 Fukutin- Related Protein gene and protein 
In 2011, Brockington and his group identified for the first time a new gene, 
encoding for a member of the fukutin-protein family: the fukutin-related 
protein (FKRP).  
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The 12-Kb FKRP gene maps on chromosome 19q13.3 between markers 
D19S219 and D19S606, thus suggesting that MDC1C and LGMD2I may be 
allelic disorders [108]. The gene is composed of three non-coding exons and 
a single large coding exon of 3.8-kb, containing part of the 5′ untranslated 
region (5’UTR), the whole open reading frame, and 3′ untranslated region 
(3’UTR). Biochemical analysis shows a transcript of ∼4.0-kb in all body 
tissues. The protein is principally expressed in skeletal muscle, placenta, and 
heart; however it has been also weakly detected in the remaining tissues, 
such as brain [109]. The cDNA encodes for a 495 amino acids protein, with 
a corresponding molecular weight of 54.6 KDa. However, in the majority of 
reported studies, immunobiochemical analysis highlighted a protein 
molecular weight of ˷58 KDa. These observations suggest that FKRP 
undergoes a post-translational modification of ˷3.5 KDa: the protein contains 
two putative N-gycosylation sites: AsnValSer (NVS) and AsnLeuSer (NLS), 
at amino acid positions 172 and 209. N-linked glycans may explain the slight 
shift observed in the previous analysis [9]. FKRP sequence analysis predicts 
the presence of a hydrophobic transmembrane-spanning region (amino 
acids 4–28), followed by a “stem region” and a catalytic domain. The protein 
N-terminus contains a hydrophobic Golgi signal anchor sequence (amino 
acids Met1-Asn33) [110], coinciding with the transmembrane region. This 
region includes a RxxR-motif (amino acids Arg2 to Arg5).  
As a similar molecular organization was found in several Golgi-resident 
glycosyltransferases, even though the exact role of FKRP was initially poorly 
understood, the protein was immediately considered as a putative 
glycosyltransferase. The putative glycosyltransferasic DxD-motif is localized 
from amino acid 362 to 364. Murine and human FKRP gene sequences show 
94% of identity. FKRP protein localization is very controversial. Previous 
studies have examined the localization of fukutin related protein both in 
cultured cells and tissues, underlining a variable detection in the Golgi 
apparatus [9, 110], the endoplasmic reticulum [111], or the perinuclear region 
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[112]. In 2011, Nillsen’s group performed immunobiochemical analysis of 
lysates from FKRP positive cells under reducing conditions; these 
experiments revealed for the first time a specific FKRP detection both as a 
monomer (58 KDa), as well as an additional band at ˷116 KDa. Thus, they 
investigated if FKRP was able to interact with other proteins or with itself by 
performing a co-immune precipitation experiment, discovering that FKRP 
protein is able to form dimers depending on an N-terminal interaction 
interface and a Cys6-Cys6 disulfide linkage [9]. Recent works suggest that 
different mutations occurring in the FKRP gene may influence its position 
within the cell, thus explaining the wide range of clinical phenotypes. 
 
For example, the severe MDC1C phenotype has been associated with 
mutations causing a retention of the protein in the ER compartment [110]. 
However, in 2005 Muntoni and his group reported an indistinguishable 
localization of FKRP in the muscle of MDC1C and LGMD2I patients 
surrounding the myo-nuclei [112]. Moreover, this observation was confirmed 
FIGURE 6. Representation of FKRP hypothetic localization in the Golgi cisternae of 
muscle fibers. The protein forms disulfide-linked homodimers via an N-terminus 
Interaction (M.Alhamidi; Plos One, 2011) [9]. 
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with in vitro experiments, suggesting that FKRP protein localization is 
dependent on cell type rather than specific mutations [113]. In 2007, 
Campbell’s group firstly reported FKRP localization in the sarcolemma of 
both wild-type and dystrophic mice skeletal muscles.  
They suggested that an FKRP-DGC association might represent a sort of 
protein complex, hypothesizing a unique role in DCG stable expression [114]. 
FKRP sequence analysis suggests that its transmembrane domain is a 
signal peptide associated to the protein secretion [115]. According to this 
observation, fukutin, which shares high sequence homology with FKRP, can 
be secreted into culture media. Although the exact physiological role of the 
secreted FKRP is still unknown, it is noteworthy that glycosyltransferase 
modifications, such as the proteolytic cleavage leading to secretion as a 
soluble isoform of the protein, might be useful processes to modify the 
enzymes activity. For example, β 1,6-N-acetylglucosaminyltransferase V 
(GnT-V), a glycosyltransferase released by human colon carcinoma cells, 
has a fundamental role in tumor angiogenesis in a glycosylation-independent 
way, thus demonstrating that secreted glycosyltransferase might exert 
precise functions [116]. Patients harbouring mutations in FKRP have a 
secondary deficiency of laminin-α2 and a significant decrease of α-
dystroglycan immunostaining [108]. In addition, the molecular weight of α-
DG is reduced in muscle, suggesting that FKRP gene mutations inevitably 
entail abnormal glycosylation of α-DG. Recent reports demonstrate that the 
precise structure necessary for the complete functional maturation of α-DG 
is Rbo5P-1Rbo5P-3GalNAcb1,3 GlcNAcb1,4Man(6P)- O [98, 117]. Rbo5P 
tandem repeats are fundamental components of the post-phosphoryl moiety 
and they are extremely necessary for a correct binding of α-DG to ECM 
proteins. 
In 2016, Kanagawa and his group focused on isoprenoid synthase domain-
containing protein (ISPD), fukutin, and FKRP genes and their putative 
involvement in Rbo5P glycosylation. It was found that ISPD protein acts as 
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a CDP-Rbo synthase, exploiting Rbo5P and CTP [98, 117]. Thus, the 
intracellular levels of Rbo5P and CTP directly regulate Rbo5P-mediated 
modification of α-DG. Fukutin and FKRP are expected to convey a ribitol 
phosphate group to an acceptor, so that a phosphodiester link is generated. 
Thus, fukutin and fukutin-related proteins are both Rbo5P transferases, 
taking advantage of CDP-Rbo as a common donor substrate. These two 
enzymes are able to transfer ribitol phosphate groups from CDP-ribitol to α-
DG both in vitro and in vivo, since patients with mutations in either FKRP or 
FKNT show a deficiency in mature α-DG glycosylation. FKTN acts 
independently of FKRP and FKRP also transfers ribitol phosphate 
independently from FKTN [117]. As these two enzymes are not able to 
convey Rbo5P directly to GalNAc or to the first Rbo5P residue, the 
assemblage of a tandem Rbo5P structure needs to be achieved in a 
sequential way [98, 117]. 
 
 
FIGURE 7. Schematic representation of α-DG structure and glycosyltransferasic enzymes 
involved in α-DG glycosylation (Q. Zhu et al.; eLife, 2016) [6]. 
30 
As previously described, mutations in FKRP gene underlie both MDC1C and 
LGMD2I, and are associated to a wide spectrum of clinical severity. In 2004, 
Muntoni’s group identified for the first time three broad categories of patients, 
correlating FKRP mutations, α-DG hypoglycosylation and patients’ 
phenotype.  
Children presenting the acute clinical spectrum of MDC1C are compound 
heterozygote between a null allele and a missense mutation or carry two 
missense mutations and show a marked depletion of α-DG glycosylation. 
Patients with LGMD2I, displaying DMD-like phenotype, have a moderate 
hypoglycosylation of α-DG and are compound heterozygotes between 
C826A (Leu276Ileu) mutation and either missense or a nonsense mutation. 
Finally, individuals with the milder form of LGMD2I are almost all 
homozygous for the Leu276Ileu FKRP mutation and exhibit a less severe 
hypoglycosylation of α-DG [109]. Until 2010, no homozygous or compound 
heterozygous null mutations were identified in FKRP, suggesting that null 
mutations could result in embryonic lethality. However, it was also reported 
the example of two siblings carrying an homozygous mutation in the starting 
codon of FKRP, resulting in the complete absence of the protein function. 
The siblings showed a typical Walker-Warburg syndrome phenotype [2]. 
1.5.3 Animal Models of MDC1C /LGMD2I 
Nowadays, the knowledge of the molecular mechanisms underlying FKRP 
function is continuously increasing. However, the need to develop a 
universally recognized animal model resembling MDC1C and LGMD1C 
phenotypes is becoming progressively fundamental to improve the 
understanding of these disorders pathogenesis and to develop promising 
therapies. Efforts to create a homozygous FKRP knockout mouse were not 
successful because the complete absence of FKRP protein gave rise to 
embryonic lethality before day 12 of embryogenesis [105]. 
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a) LARGEmyd; LARGEmyd mice present an autosomal recessive 
neuromuscular phenotype. Grewal and colleagues showed that the mutated 
gene (LARGE) encodes a putative glycostyltransferase, with a dual role. 
LARGE has two separate Asp- Xaa- Asp motifs, and two coiled-coil regions 
flanking the glycosyltransferase family 8 domains, which are typical sites of 
protein-protein interaction. These mice carry the deletion of exons 5-7 of the 
LARGE gene, resulting in frameshift and a concomitant premature 
termination codon (PTC).  LARGEmyd mice display a typical muscular 
dystrophy phenotype. Moreover, they present both cortical and cerebellar 
abnormalities, reduced lifespan, pronounced kyphosis, muscle atrophy and 
a characteristic hindlimb paralysis [118].  Even though the clinical phenotype 
resembles more closely the MDC1C disorder, this mouse model has been 
extensively exploited in the field of both MDC1C and LGMD2I research, 
because of the lack of other animal models.  
b) P448L; P448L mice were firstly produced by the McColl-Lockwood 
Laboratory for Muscular Dystrophy Research. They show a homozygous 
missense mutation (c1343C>T, p. Pro448Leu) in the FKRP gene. FKRPP448L 
mutant mice present a moderate dystrophic phenotype, characterized by 
myofiber regeneration and degeneration cycles, consistent fiber size 
variability, mononuclear cell infiltration, and fibrosis arising around 26 weeks 
of age. The decreased α-DG glycosylation in all skeletal muscles except in a 
small proportion of fibers, the revertant fibers, determines a diffused muscle 
weakness, witnessed by limb muscle retraction.  These mice present 
elevated serum CK and ALT levels and a dystrophic pathology typically 
associated with LGMD phenotype, without clear defects of the CNS [106, 
118]. 
c) L276IKO ;  L276IKO animal model was firstly created by Vissing’s group in 
2015, in collaboration with Polygene AG (Rümlang, Switzerland). Mice were 
created as an FKRP L276IKI model with a neomycin selection cassette, 
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flanked by frt domains and excised by mating mice to Flp1 recombinase 
expressing mice. FKRP is flanked by LoxP sites, leading to an FKRPKO, if 
mated to a Cre-expressing mouse, or alternatively a hemizygous FKRP 
L276I, if mated to an FKRP L276IKI mouse. Vissing’s group analysed the 
histopathology and the level of FKRP in the mouse model at various ages 
and found that homozygous FKRP L276I mice develop a mild phenotype with 
progressive increase of muscle regeneration and fibrosis, probably due to 
the growing hypoglycosylation of α-dystroglycan. The homozygous FKRPKO 
is embryonic lethal, but the hemizygous L276I model resembles the age-
matched homozygous FKRP L276I model [119]. 
d) L276IKI ; L276IKI mice were generated by creating a knock in mutation, the 
human mutation (nucleotide C826 to A), into the coding sequence of FKRP 
gene, resulting in the aminoacidic replacement [120]. Mutated mice display 
a very late onset of muscular dystrophy pathology. The mouse model 
displays a normal level of physical activity, viability and fertility. At 6 months, 
mice biopsies histology of the EDL, tibialis anterior and quadriceps appear 
as normal, with no significant signs of myopathy; only at 12 months muscles 
start to show evidence of progressive fibrosis and ongoing regeneration. At 
20 months, the progression of the pathology is more pronounced. Moreover, 
it has been demonstrated that this mutation principally affects proximal 
muscles (tibialis anterior and quadriceps), rather than distal muscles (EDL) 
and muscles with oxidative or mixed oxidative/glycolytic fiber type 
composition are more prone to degeneration/regeneration cycles than 
glycolytic fibers  [119]. The homozygous L276IKI has reduced muscle 
functions, such as shorter treadmill running distance and lower in vitro 
isometric force production [120]. The mild progression in the homozygous 
FKRP L276I knock in model mirrors patients’ phenotype associated to 
LGMD2I, who are homozygous for the same mutation [119]. If compared to 
the severe phenotype of P448L mutated mice, L276IKI show less fibrosis and 
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cellular infiltration in their muscles, often focal and not uniform in the same 
muscle groups. The most severely -affected muscle is the diaphragm; 
similarly heart tissue fibrosis has been observed, signifying the insurgence 
of cardiomyopathy [120]. Many other mouse models for FKRP- related 
muscular dystrophy were generated throughout the years, however most of 
them did not display visible muscle abnormalities since they died either 
prenatally or in the early post-natal age [106, 121]. 
1.5.4 Therapeutical approaches in α-Dystroglycanopathies 
Despite all the efforts carried out for finding effective therapies for α-
dystroglycanopathies, so far a cure has yet to come. However, some 
outstanding achievements and progresses have been recently achieved by 
researches, hopefully opening the way for new generation treatments of 
these disorders. 
Exon skipping  
This therapeutic technique is aimed at directly remove the molecular damage 
on the messenger RNA (mRNA) of the mutated gene, restoring the correct 
reading frame, and permitting a functional rescue of a part of the protein.  
The exon skipping strategy exploits the antisense olygonucleotides (AONs), 
which are short RNA fragments, or synthetic oligonucleotides such as 
morpholino (PMO, phosphorodiamidate morpholino oligo), matching to their 
complementary sequence and promoting the skipping.  
In 2011, Tanigushi-Ikeda and his group experimented the exon-skipping 
strategy in a mouse model of FCMD. The introduction of AONs targeting the 
splicing modulating regions restored the normal FKTN mRNA expression 
and normal protein levels, with a recovery of alpha-DG glycosylation and 
binding to laminin. However, FCMD and most of other forms of alpha-
dystroglycanopathies are characterized by symptoms arising in early infancy 
or even during the fetal phase and are determined by CNS complications. 
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Thus, since oligonucleotides are unable to cross the blood-brain barrier and 
blood-placental barrier [122], AONs could not be considered a resolving 
therapy [88]. Another deleterious limit of exon skipping –based therapy is the 
necessity to deal with a protein in which specific domains can be skipped 
without irreparably invalidating the protein function. To solve these 
limitations, an alternative therapeutic strategy could be represented by gene 
replacement, based on the injection of viral vectors (adeno-associated 
viruses, AAVs). 
Adeno-associated viruses (AAVs)  
Adeno-associated virus (AVV)-mediated gene therapy has been 
experimented for the treatment of various diseases. AAVs are not-
pathogenic vectors, which are able to replicate and infect not-proliferating 
cells, such as muscle fibers and neurons and vehicle the wild-type cDNA, 
corresponding to a specific mutated protein. In the field of muscular 
dystrophies different groups focused on the application of this therapeutic 
strategy to obtain the rescue of a mini-dystrophin gene in both the mdx and 
the GRMD animal models of DMD, trying to partially recover dystrophin 
expression and function [123, 124]. This therapeutic approach was also 
investigated in the field of alpha-dystroglycanopathies. In 2004, Barresi and 
his group performed gene therapy exploiting the Largemyd mouse.  Barresi 
showed that the expression of LARGE, mediated by the injection of adeno-
associated viral vectors expressing the wild-type isoform of LARGE gene, 
ameliorated the dystrophic phenotype of Largemyd mice and induced the 
synthesis of glycan-enriched α-DG with high affinity for extracellular ligands 
[125]. In 2013, Kaganawa and his group also achieved systemic gene 
delivery: they injected Myf5-fukutin-cKO mice, resembling a distinct 
dystrophic phenotype with considerable muscle fibrosis and fat infiltration 
and consequent reduced muscle force. They obtained an unexpected 
amelioration of the mice phenotype and muscle function [126]. At the same 
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time, the group of Qilong Lu published interesting results regarding the 
possibility to restore the expression of FKRP functional protein by an adeno-
associated virus serotype 9 vector (AAV9)-mediated gene therapy in a 
mutant mouse model characterized by a proline to leucine missense 
mutation (P448L) [127]. These observations suggest that even small 
quantities of exogenously delivered genes expressing normal enzymatic 
activity could be sufficient to restore the correct enzymatic function. However, 
the problem with this technology for CMDs treatment are developmental 
neurological symptoms associated with these pathologies, so that an in utero 
intervention should be performed. Although different clinical trials reported 
undesirable effects provoked by the systemic injection of AAVs, such as host 
immune reaction against the viral vector and the transgene products, AAVs 
still represent one of the most potentially promising therapies for many types 
of alpha-dystroglycanopathies [128]. 
Enzyme replacement  
In 2002, Nguyen and his group demonstrated that the overexpression of 
GalNac transferase from cytotoxic T cells in skeletal muscle is able to 
ameliorate the symptoms of muscular dystrophy in the mdx mouse model. 
The enzyme favours the linkage of a terminal GalNac residue to cytotoxic T 
cells. This enzyme ectopic expression determines dystroglycan to 
abnormally express CT antigen and the altered glycosylation pattern of 
dystroglycan favours an amelioration of therapeutic benefit. According to 
these observations, the ectopic expression of various glycosyltransferases 
may be a successful strategy to treat CMDs associated to α-dystroglycan 
hypoglycosylation [129]. Among them, LARGE protein exerts an important 
role in the process of O-glycosylation of alpha-DG. In 2004, the group of 
Campbell demonstrated that the overexpression of LARGE gene determines 
a hyperglycosylation of α-DG, thus promoting an increased laminin-binding 
activity not only in the LARGEmyd animal model, but also in FKTN-mutated 
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cells, POMGnT1-mutated patients and even wild-type myogenic cells. Many 
groups of research investigated the effects of AAVs-based transfer of 
LARGE wild type gene into different animal models of alpha-
dystroglycanopathies, always obtaining promising results [118] [105]. 
However, the in vivo therapeutic benefit of LARGE activity is controversial. 
In 2015, Toda and his group explored the contrasting effects of LARGE gene 
therapy in the LARGE-deficient and FKTN-deficient mouse models for 
MDC1D and FCMD, respectively. Even though LARGE expression via 
systemic adeno-associated viral gene transfer ameliorates the dystrophic 
pathology of Large-deficient mice, the same strategy fails to ameliorate the 
dystrophic phenotype of fukutin conditional KO mice [130]. Finally, it was also 
reported that an overexpression of LARGE may even results in the 
worsening of the dystrophic phenotype. For instance, they observed that 
FKRPMD mice (a mouse model generated with a knock-down mutation in 
FKRP limited to muscle tissue) overexpressing LARGE have a reduced 
lifespan, if compared to FKRPMD mice. Specifically, they displayed a more 
severe pathology with an increased variation in fiber size, centrally nucleated 
muscle fibers, fibroadipose tissue infiltration and inflammation [105].   
Metabolite supplementation 
An innovative attempt to treat α-dystroglycanopathies was made by 
Kanagawa in 2016. After the discovery of ISPD and its role as a CDP-ribitol 
synthase, his group was prompted to perform a supplementation of CDP-
Rbo in a ISPD-deficient cell line. They showed that the addition of CDP-Rbo 
restores the functional glycosylation of a-DG in targeting cells, suggesting 
that metabolic components such as Rbo5P and CDP-Rbo in the Rbo5P 
glycosylation pathway can be exploited to develop a molecular 
supplementation therapy for a-dystroglycanopathy. This strategy was found 
to be successful, however further studies on animal models should be 
performed to verify the safety and feasibility of this approach [98]. Moreover, 
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since it has been proved that an hypoglycosylation of α-DG contributes to 
the worsening of cancer cells behaviour in terms of proliferation and invasive 
potential [131, 132] and the downregulation of ISPD favours renal carcinoma 
cells mortality [132], CDP-Rbo supplementation may be also experimented 
in cancer therapy. 
Corticosteroids  
The use of corticosteroids represents nowadays the standard therapy for 
DMD patients in many countries. Their beneficial effects have been clearly 
demonstrated. Steroids principally act by reducing muscle necrosis and 
inflammation, but also by favouring the proliferation of myogenic precursor 
stem cells and myoblasts, leading to an increased muscle regeneration and 
deceleration of the pathology progression [133]. Corticosteroids 
administration has been found to produce beneficial effects also in LGMD2I 
patients [134]. Of course, corticosteroids can’t represent a radical therapy, 
but a first palliative treatment to decrease patients’ physical pain. 
Rapamycin 
In 2016, Beedle and his colleagues firstly investigated signalling cascades in 
models of dystroglycanopathies. They showed that disruption of α-DG and 
laminin interactions may result in downstream signalling consequences. 
Specifically, a dysregulation of the serine/threonine kinase Akt may occur, 
causing an increased apoptosis in cultured myotubes. The activation of Akt 
leads to the activation of mTOR complex 1 (mTORC1), which stimulates 
muscle growth and hypertrophy by increasing proteins synthesis. By 
inhibiting mTOR, it is possible to decrease muscle necrosis and the 
infiltration of T cells in the mdx mouse model.  
These findings underline the possible contribution of an abnormal regulation 
of cell growth to the development of the disease. The authors tested the 
therapeutic benefit of rapamycin (RAPA) treatment in a model of FKTN- 
deficient mice. They observed that RAPA treatment is capable of delaying 
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disease progression, but it is unable to reverse dystrophy. Furthermore, mice 
with a more severe muscle involvement at the beginning of the treatment, 
present a weaker response to the drug [135]. 
Stem Cell Therapy 
Very recently, Lin’s group firstly exploited induced pluripotent stem cells 
(iPSCs), generated from cortical neurons of a patient with a mutation in 
FKRP gene, to evaluate targeted gene correction using CRISPR/Cas9-
mediated genome editing. They demonstrated that targeted gene correction 
of FKRP recovers α-DG physiological glycosylation and they proved the 
feasibility of using CRISPR/Cas9-engineered human iPSCs for modelling 
dystroglycanopathies. Even though they only performed in vitro experiments, 
this is the first evidence in the field of α-dystroglycanopathies of a stem cell- 
based approach, providing the basis for an in vivo application. 
1.6 Glycosyltransferases 
1.6.1 General introduction to glycosyltransferases 
The process of proteins and lipids glycosylation has a wide range of biologic 
functions.  Glycosylation is the most frequent protein modification in 
eukaryotic cells: between 0,5% and 1% of the genes in the human genome 
encode proteins involved in the synthesis, degradation and function of glyco-
conjugates, which have a key role in enhancing other proteins stability, 
mediating ligand-receptor interactions and controlling the quality of secreted 
proteins [136].  
There are many potential roles of glycosylation in peculiar physical 
properties, including folding, trafficking, packaging, stabilization, protease 
protection, quaternary structure and organization of water structure. 
Changes in sugar prints may lead to physiological changes and cause 
disorders, i.e. cancer, rheumatoid arthritis and the development of muscular 
disorders such as CMDs [137].  
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Glycosyltransferases (GTs) represent a wide family of enzymes that are 
responsible for the biosynthesis of oligosaccharides, polysaccharides, and 
glycoconjugates. 200 glycosyltransferases have been identified in nucleated 
cells. The glycosylation machinery is located in the endoplasmic reticulum 
(ER) and in the Golgi, throughout the so called ‘’secretory pathway’’. In 
eukaryotes most of the glycosylation reactions, giving rise to the variety of 
oligosaccharide motifs of eukaryotic cells, occur in the Golgi apparatus.  
Golgi resident GTs are type-II transmembrane proteins characterized by a 
large C-terminal globular catalytic domain facing the luminal side. Two of the 
most abundant forms of glycosylation are N-linked (to asparagine) or mucin-
type-O-linked glycosylation (to serine or threonine) [138]. 
1.6.2 O-Glycosylation 
O-glycosylation process begins with the addition of a GalNAc sugar to the 
hydroxyl group of serine or threonine residues. These glycans are very rich 
of mucins, proteins characterized by domains rich in proline, threonine, and 
serine (PTS domains).  
The wide O-glycosylation present within these repeating domains favours the 
extension of the protein backbone of mucins, transforming it from a globular 
structure to an extended rod-like structure. Moreover, O-glysosylated 
domains protect proteins from proteolysis. Mucin-type O-glycans can be also 
identified on many other cell membranes and secreted proteins, proving an 
active and functional recruitment to modulate recognition, adhesion, and 
communication between cells and their surrounding environment. Several 
studies in animal models have shown crucial roles for O-glycans in signalling 
pathways of embryonic development, organogenesis, and tissue 
homeostasis. These studies have further suggested that O-glycosylation 
may also be involved in perceiving and directly regulating the secretory 
apparatus [139]. 
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1.6.3 Circulating Glycosyltransferases 
Even though the canonical understanding of the glycosylation pathway 
identifies glycosyltransferases residing intracellular, many of these enzymes 
are also in the systemic circulation and are known as ‘’extrinsic- 
glycosyltransferases’’. Originally, the physiologic function of these blood 
glycan-modifying enzymes was enigmatic, principally due to the absence of 
circulating sugar-donor substrates.  However, the clinical association of 
these blood-residing GTs with a wide range of pathological disorders, such 
as liver diseases, atheroscleroris, diabetes and leukemia, prompted 
researchers to investigate their origin and role. Recently, it has been 
discovered that while many of these glycosyltransferases are freely 
circulating in the plasma, platelets may be the carriers for others, such as 
ST3Gal-1 and β4GalT released upon platelet activation [140]. These results 
highlighted the ability of plasma and activated platelets to supply active 
glycosyltransferases with the potential to remodel functionally key glycan 
motifs on the surface of target cells [141]. Platelets (PLTs) are 
megakaryocyte subfragments that participate in haemostatic and host 
defence reactions and deliver pro- and antiangiogenetic factors throughout 
the vascular system. PLTs have a life span of only 8 to 10 days in the 
circulation [142]. Glycosyltransferase activities in platelets are proposed to 
mediate different aspects of platelets functions; these findings were 
surprising because platelets lack an organized glycosylation apparatus. In 
2012, Wandall and his group investigated the mechanisms of platelets 
glycosyltransferases. They showed that human platelets express three 
functionally distinct classes of genes encoding for glycosyltransferases: 
GalNac-Ts, Gal-Ts and syal-Ts. Moreover, since glycosyltransferases are 
predominately packaged inside platelets, they elucidated the role of platelets 
as a reservoir of glycosyltransferases that are released during platelets 
activation. Platelets activation due to PAR-1 release, mediate the activation 
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of about 50% of total GalNac-T, Gal-T ad sialyl-T GTs. As previously 
mentioned, a variety of carbohydrate moieties are exposed on the membrane 
of mammalian cells. Such carbohydrates are generally linked to specific 
biomolecules to create the so-called glyco-conjugates [143]. This glyco-
conjugate expression changes, depending on the stage of development, 
differentiation, cell activation, and apoptosis. Thus, the variability in certain 
protein glycosylation of tissues, cells and cell-released microvesicles (MVs) 
may be considered as a promising biomarker of health or disease.  To date, 
only a few published studies have connected MVs directly or indirectly with 
glycoproteins and glycosyltransferases. For example, recent findings show 
that urine-derived EVs contain a complex and biologically important glycome. 
As in certain kidney-associated diseases the physiological process of 
glycosylation is abnormal, EV-associated glycans analysis may lead to the 
identification of a pathological process ongoing. In 2012, Larsen and his 
group isolated and characterized MVs membrane proteins released by a 
pancreatic β-cell line (NHI 6F Tu28), before and after cytokine stimulation. 
The proteomic analysis revealed the presence of several sialyltransferases 
and glycosyltransferases in MVs, changing in abundance as a consequence 
of cytokine treatment [144]. 
1.7 Extracellular Microvesicles (EVs) and Exosomes 
1.7.1 General introduction to Extracellular Vesicles (EVs) 
Both prokaryotic and eukaryotic cells physiologically release vesicles: 
spherical microparticles delimited by a phospholipid bilayer [145]. These 
particles dimensions range from 30 nm to 5 µm. Their peculiar role in the 
intercellular communication among different cell populations throughout the 
whole body immediately inspired researchers from all over the world, and the 
interest in these microvesicles is still continuously increasing. Specifically, 
there is a growing curiosity about their potential in clinical applications, as it 
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has been recently discovered that they may represent an outstanding 
therapeutic approach for various disorders, with a key role in their prognosis. 
Moreover, they have also been identified as biomarkers of disease. EV 
subpopulations differ in their distinct biogenesis, nature, feature and 
proposed function.  
They have been classified in three main categories: exosomes, 
microvesicles (MVs) and apoptotic bodies. However, in 2009, Théry and her 
group proposed the existence of another subgroup of EVs, called ectosome, 
exosome-like vesicles and membrane particles. These particles could be 
distinguished on the basis of their physical-chemical characteristics, 
including size dimensions, appearance in microscopy, sedimentation, lipid 
composition and protein markers. However, there is still insufficient evidence 
to support their real existence.  
MVs are generally referred to as 50-1000 nm vesicles, originating from the 
outward budding of cell membranes and released from the plasma 
membrane during cell stress.  
Apoptotic bodies are PS-exposing vesicles, released by cells undergoing 
apoptosis with dimensions ranging between 1 to 5 µm. Finally, exosomes are 
specialized nano-sized vesicles, derived from the endocytic compartment. 
Morphologically, they can be considered as the smallest vesicles released 
by cells [146]. 
1.7.2 Exosomes: Biogenesis, Composition and Physiological Function 
Exosomes were firstly described in the 1980s as small microvesicles of 30-
100 nm, released by reticulocytes [147]. Originally, they were identified as a 
mechanism for elimination of unfolded proteins or other undesirable 
molecules from the cell [148]. 
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FIGURE 8.  Exosomes biogenesis and release mechanisms (J.S. Schorey et al.;  
EMBO Reports, 2014)[11]. 
 
In the last decade, the exosome role as mediators of intercellular 
communication has emerged. So far, exosomes have been isolated from 
various body fluids, including blood, plasma, serum, urine, saliva, breast milk, 
amniotic fluid, ascites, bile, semen and cerebrospinal fluid. Exosomes carry 
out a wide range of functions and sometimes they exert opposing effects on 
targeting cells, depending on their tissue of origin and molecular content. 
Their morphology has been reported as cup-shaped after visualization by 
transmission electron microscopy (TEM) [146].The pathway of exosomes 
biogenesis is extremely dynamic.  
Early endosomes develop into late endosomes, accumulating intra-luminal 
vesicles (ILVs). ILVs generate by the inward budding of late endosomes. 
These structures are known as multi-vesicular bodies (MVBs). 
MVBs undergo two possible faiths: the fusion with lysosomes or the fusion 
with the plasma membrane (PM), with the consequent release of the so 
called ‘exosomes’ [3]. However, an alternative pathway has also been 
described, based on the direct gemmation of exosomes from the PM. Once 
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released, exosomes are captured by receiving cells following three main 
routes.  
They may activate cell signalling by physical ligand/receptor interactions or 
by fusing with their target cells and transferring their contents. They may also 
be endocytosed by target cells or they may directly release their contents 
into the extracellular space. In 2007, Valadi and his group discovered that 
exosomes carry nucleic acids, principally mRNA and miRNA. It has been 
demonstrated that these mRNAs may be translated in target cells, thus 
cooperating with miRNA in the influence of recipient cells gene expression 
[149]. Recent studies also suggest that mRNA and miRNA are not randomly 
included into exosomes, but the process is strictly regulated through the 
recognition of export sequences. However, this mechanism has not been 
deeply investigated yet. Some research has also reported the presence of 
mtDNA in different EVs preparations. Proteomic studies have shown that 
exosomes display a wide range of proteins: some of them mirror their 
secreting cells, while others seem to be expressed regardless of cell type. 
 
 
FIGURE 9. Exosomes mechanisms of fusion to target cells (G.Turturici et al.;  
The American Journal of Physiology, 2014) [4]. 
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Exosome proteins principally derive from the PM and the cytosol, whereas 
those originating in the nuclear, mitochondrial, and reticular compartments 
are almost absent.  
Various protein complexes cooperate to determine exosome biogenesis and 
fusion to PM. Proteins belonging to these complexes are ubiquitously 
expressed.  
The tetraspanins CD63, CD9 and CD81 are the most enriched proteins in 
microvesicles, so that they are generally considered as exosome key 
markers in biochemical analysis. Finally, as concerns lipid composition, this 
group of EVs shows enrichment in sphingomyelin, PS, cholesterol, 
ganglioside M3 and ceramide, thus suggesting the inclusion of PM lipid rafts 
in their phospholipidic bilayer [3]. 
 
FIGURE 10.  Exosomes composition (Colombo M. et al; Annual Review of Cell and 
Developmental Biology, 2014)[3]. 
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1.7.3 Exosomes isolation techniques 
To date, various procedures have been experimented to isolate exosomes. 
Both biochemical and biophysical characteristics can be employed to isolate 
exosomes, including their solubility, charge, dimensions, mass density and 
antigen expression. Briefly, the most performed procedures are: 
- Differential ultracentrifugation 
- Size Exclusion Chromatography 
- Immuno-capture 
- Density gradient centrifugation 
- Ultrafiltration 
- Commercial kits 
Of note, each technique presents its own advantages and limitations [150] 
[151]. 
A) Differential ultracentrifugation (UC) has been the most popular 
procedure so far. Basically, it isolates exosomes according to their 
dimensions by progressively augmenting the centrifugal force. However, 
UC usually suffers from contamination of other EVs, since the distance 
to pellet is extremely similar among the different EVs subpopulation and 
since culture medium affects EVs shape and density. Moreover, it is 
well- known that very high-speed centrifugations create protein 
aggregates which co- precipitate with the exosome pellet. Furthermore, 
this method is extremely time-consuming and low throughput [150]. 
Some authors have combined UC to Density Gradient Centrifugation 
(DCG), based on a sucrose or iodinaxol gradients. DCG isolates 
exosomes according to their size and mass density. However, this 
method is unable to overcome contamination issue as it has been 
reported that HDL lipoproteins density is comparable to the one of 
exosomes and LDL are able to interact with EVs.  Moreover, as well as 
DC, DCG is a very laborious method.  
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B) Size Exclusion Chromatography (SEC) favours size-based exosomes 
isolation. SEC excludes 99% of soluble plasma proteins and 
lipoproteins; it avoids the formation of protein aggregates and allows to 
recover very rapidly and efficiently (40% to 90%) exosomes, without 
affecting their biological properties. In comparison with DC and DCG, 
SEC-isolated exosomes are biophysically intact although at the expense 
of dilution, causing a very low final concentration. 
C) Immuno-capture assay exploits monoclonal antibodies to capture 
exosomes, thanks to their binding to specific ligands expressed on their 
surface. Although the assay is rather time-consuming, it is recognized 
as a clinically suitable approach. It may capture exosomes of a unique 
cell origin and discriminate among subpopulations of exosomes with 
specific exosomal tags. This method provides the yield of very pure 
despite a very low dose of recovered exosomes. 
D) Density gradient centrifugation favours the achievement of exosome 
isolation on the basis of their mass, size and density. When the sample 
is subjected to a centrifugal force in a centrifuge tube with a decreased 
density from bottom to top, particles move to individual zones through 
the density gradient, according to their sedimentation rate. This 
technique allows to overcome the limits related to other exosome 
contamination associated to differential ultracentrifugation. 
Unfortunately, this procedure is extremely expensive and time-
consuming.  
E) Ultrafiltration (UF) is based on particles separation according to their size 
and molecular weight. UF determines exosome separation by applying 
a filter in an ultracentrifuge and exerting a specific pressure. Membrane 
filters possess a specific cut-off to select a unique population of interest. 
UF guarantees a very high efficiency in exosome recovery (up to 80%) 
and it is very time effective. Unfortunately, it suffers from clogging and 
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vesicle trapping since exosomes can easily attach onto filters and 
samples become unavailable for downstream analysis. 
F) Finally, various commercial kits have been produced. Kits are usually 
based on the use of polyethylene glycol, which is a water-soluble and 
volume-excluding polymer. The buffer co-precipitates both exosomes 
and non-EVs components, although exosomes recovery can be very 
high (around 90%). Commercial kits are not too much expensive and the 
procedure is extremely fast and simple [150, 151]. 
1.7.4 Exosomes physiological and clinical relevance 
Exosomes participate in the preservation of normal physiology, such as stem 
cell maintenance and tissue repair. Exosomes have been recognized as 
morphogen carriers during development and differentiation. Moreover, they 
have been implicated in stem cells maintenance and plasticity, indicating 
their key role in tissue regeneration after injury. In the contest of pathological 
tissues, exosomes may determine an increased cell survival and may 
activate endogenous mechanisms of tissue repair and regeneration in a 
paracrine way. Moreover, they may exert an autocrine effect on the cell itself. 
Exosome release is regulated in a calcium-dependent manner; an increase 
in the intra-cytoplasmic influx of Ca2+ favours the EVs efflux. Moreover, 
some pathogenic conditions considerably influence the amount of exosome 
release. For example cancer cells, which are exposed to a hypoxic 
environment, are known to produce a higher number of MVs. During hypoxia, 
exosomes are secreted by tumor cells, causing an increase in angiogenic 
factors and metastatic potential. This observation suggests that tumor cells 
are able to adapt to a hypoxic microenvironment by the secretion of 
exosomes to promote angiogenesis and facilitate metastasis to a more 
appropriate microenvironment [152].  
In the field of regenerative medicine, the most investigated cells are 
mesenchymal stem cells (MSCs). Adult stem cells, including MSCs, isolated 
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from different sources, confer a regenerative effect in animal models of injury 
and disease and they are in the phase I or II of clinical trials for limb ischemia, 
heart failure and myocardial infarction. Firstly, it was supposed that 
transplanted stem cells integrate in the damaged tissue end differentiate to 
substitute damaged cells. However, it was demonstrated that the systemic 
transplantation of cells, resulted in a very low efficiency of cells homing in the 
target tissue (1%). Cells probably followed other routes, and localized in the 
lungs, spleen, liver and kidney.  Accumulating evidence suggested that the 
predominant, immunosuppressive therapeutic effects of adult stem cells was 
exerted by secreting molecules, such as growth factors, cytokines, 
chemokines and extracellular MVs into the surrounding environment via a 
paracrine mechanism. This concept has been summarized as the so called 
‘’paracrine-autocrine hypothesis’’. EVs are now considered as a prominent 
and universal form of cell –to-cell communication. Fundamentally, all cells in 
the organism release EVs that are taken up by cells at distance. Thus, EVs 
mediate autocrine, paracrine and endocrine effects that can be exploited 
therapeutically. MSCs and other progenitor cells normally used in cell 
therapy studies, mediate cytoprotective, angiogenic and regenerative 
effects, which can be explained by exosome release [153]. This observation 
introduces the concept of ‘’cell therapy without the cells’’. 
Exosomes as biomarkers of disease.  As previously cited, exosomes 
released in the peripheral blood and in other body fluids mirror their deriving 
cells, thus showing a specific content. Healthy subjects’ and patients’ 
exosomes display a different pattern of protein and RNA expression. So, they 
may be measured as potential diagnostic biomarkers [154]. For example, 
tumor-released exosomes are enriched in specific miRNAs, usually 
considered as tumor biomarkers. In 2008, Skog and his group investigated 
circulating exosomes of patients suffering from glioblastoma and found 
increased level of EGFRVIII mRNA; this observation suggested the idea of 
replacing the classical invasive tissue biopsy with a liquid biopsy [155]. 
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Similarly, in 2015 Melo and his group detected proteoglycan glypican-1 
(GP1)-positive exosomes in the serum of patients suffering from pancreatic 
cancer. The levels of GP-1 positive exosomes were strictly correlated to the 
tumor burden and survival of pre- and post- surgical patients, thus suggesting 
a prognostic relevance of this marker [156]. EVs were also evaluated as 
indicators of disease of multiple organs, including the CNS, the liver, kidney 
and lung. 
Therapeutic potential of naturally secreted EVs.  It was proved that EVs 
physiologically secreted by certain cell types retain their therapeutic 
potential. For example, MSC-derived exosomes possess the same 
immunomodulatory and cyto-protective characteristics of their parental cells; 
exosomes isolated from bone marrow (BM) derived MSCs guarantee 
protection in the contest of myocardial ischemia or reperfusion injury, 
hypoxia-induced pulmonary hypertension and brain injury. It was recently 
reported that human adult cardiac-resident progenitor cells secrete 
exosomes with a cardio-protective and pro-angiogenic potential [157]. In 
2014, Barile and his group performed an intra-myocardial injection of these 
exosomes and they observed an improved cardiac function after myocardial 
infarction in rats [158].  Differentiating neuronal cells- secreted microvesicles 
were shown to stimulate neuronal differentiation in human MSCs [154]. The 
finding that EVs released by B-cells carry MHC-II, co-stimulatory and 
adhesion molecules, suggested that such vesicles could directly stimulate 
CD8 T-cells clones. This idea was further supported by the demonstration 
that vaccination of mice with tumor peptide-pulsed DC- derived exosomes 
primes specific CTLs and suppresses tumor growth in a T-cell dependent 
manner. The capacity of EVs to stimulate T cells, including T naïve, can be 
enhanced by the interaction of vesicles with DCs. AVs harbour ligands that 
participate in binding to target cells or extracellular matrix proteins. Once 
internalized by DCs, exosomes can be degraded and used as a source of 
peptides to interact directly with T cells. Exosomes also transfer native 
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antigens to APCs: tumor -deriving exosomes carrying tumor specific Ags can 
be efficiently taken up by DCs for antigens processing and presentation to 
tumoral CTLS [159]. Mice vaccination with tumor- derived exosomes 
produced a massive CD8 T cell-mediated anti- tumoral effect. Finally, EVs 
released by immune cells may induce either an immune stimulation or 
inhibition under different conditions [159]. In 2010, Viaud’s group showed 
dendritic cells (DCs)- released exosomes capability to present antigens to 
the immune system and introduced the concept of an exosome-based 
vaccine against cancer and infection [160]. Tumor-derived exosomes have 
been reported either to stimulate or suppress tumor specific and non-specific 
immune response. As exosomes mirror the protein composition of their 
parent cells, tumor-derived exosomes are enriched in tumor antigens. 
Therefore, these EVs have been used as a source of tumor antigens to 
stimulate an anti tumoral response. As well as carriers of protein Ags, 
exosomes favour the intercellular passage of genetic information, principally 
RNAs, thus suggesting their potential role in gene therapy. 
Therapeutical potential of loaded and targeted exosomes.  Exosomes 
may be loaded with therapeutic cargo molecules. There are two alternative 
approaches for exosome loading: an ex vivo extracellular strategy and an in 
vitro intracellular approach, exploiting the mechanisms of physiological EVs 
biogenesis [154]. Exosomes may be loaded with therapeutic miRNA, mimic 
or antagonists, by co-transfecting producing cells with two plasmids, one 
encoding the precursor miRNA and the other one the fusion targeting 
peptide. Otherwise, electroporation may be used to produce transient pores 
in the membrane, thus supporting small RNAs crossing of the phospholipidic 
bilayer. Electroporation was also employed to load EVs with small-molecule 
drugs. A lot of exosome-based drug delivery systems have been already 
developed. Among them, curcumin encapsulated exosomes have been 
systemically injected to target the central nervous system across the blood 
brain barrier (BBB) and different chemotherapeutic agents, such as 
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Doxorubicin and Paclitaxel, have been loaded into exosomes and 
systemically injected to arrest the tumor growth [161]. One of the main limits 
related to exosome-based therapy is represented by these vesicles 
biodistribution profile after an in vivo injection. Secreted EVs with no 
modifications to their natural composition prohibit their systemic 
administration due to their limited tropism to a specific cell type. Just a few 
cell types release vesicles exhibiting an own target selection; DCs-EVs 
interact with activated T-cells through ICAM-1 transmembrane protein [162]. 
Targeting strategy may be accomplished by engineering the parent cells 
using fusion constructs between a targeting ligand and a EV transmembrane 
protein [163]. The released-EVs will bear the ligand/homing peptide on their 
surface. Alternatively, EVs surface may be coated with antibody fragments, 
recognizing antigens expressed on the target-cell surface. Finally, peptides 
facilitating the EVs uptake, such as vesicular stomatitis virus-G (VSV-G) 
protein can be displayed on EVs. These engineered vesicles achieve 
improved cargo delivery and therapeutic immune response to exosomal 
vesicles [164]. 
1.7.5 Exosomes-based therapy advantages and disadvantages 
Immune tolerance 
Physiologically secreted exosomes express immune-recognition molecules, 
including functional MHC-I and/or MHC-II depending on their cell origin. 
Experimental evidence suggests that allogenic exosomes may be hypo-
immunogenic and well- tolerated.A recent study investigated the 
immunogenicity of xenogeneic (human) or allogeneic cardiosphere-derived 
exosomes [165]. A continuous subcutaneous injection of human cells- 
secreted exosomes induced a gradual humoral and cell-mediated immune 
response, although at lower levels compared to the injection of parental cells.  
Allogeneic EVs did not induce significant immune response after repeated 
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doses. These findings suggest that allogeneic EVs may be suitable for 
clinical applications [165]. 
Biocompatibility and safety  
Biocompatibility is ensured by EVs endogenous origin; neither the 
insurgence of tumorigenesis, nor rejection episodes have been observed by 
monitoring exosomes-transplanted mice. Nanometric dimensions allow 
these vesicles escape from the uptake of the endothelial reticulum system, 
thus favouring the crossing of endothelium barrier. Moreover, the already 
mentioned recovery of glyoblastome- released MVs in the circulating blood, 
witnesses their skill to traverse the blood brain barrier (BBB) [167-169]. 
Methods of exosomes isolation 
One of the major limits related to the field of EVs is represented by the 
absence of a standardized method of isolation. Nowadays the gold standards 
are considered: differential ultracentrifugation, density gradients, size 
exclusion chromatography and commercial kits. However, each technique 
has its advantages and disadvantages and the absence of other MVs co-
precipitation with exosomes has not been excluded yet [151] [150]. 
Tumorigenesis  
It has been demonstrated that tumoral cells release a high amount of 
vesicles, however these vesicles express specific factors and proteases, 
which are able to promote the tumor progression and digest the extracellular 
matrix, thus determining the insurgence of metastasis [170, 171]. 
Exosomes half-life  
Exosomes lifetime after in vivo injection has not been well elucidated yet.  
Researchers report antithetic observations about MVs half-life and 
biodistribution in vivo. Someone observed a very brief survival, which would 
not be consistent with the development of an efficient clinical therapy. In 
2013, Takahashi Y. et al., isolated exosomes from B16-Bl6 melanome cell-
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line. Exosomes were labelled with gLuc-lactadherin and intravenously 
injected in a murine model to analyse their biodistribution. The kinetic study 
of exosomes concentration in injected mice peripheral blood (two minutes 
after exosomes injection) highlighted a lifespan of about two minutes. A 
residual luciferase activity was detected in the liver and in the lungs serum 4 
hours post injection, suggesting a very fast clearance by these organs [172].  
 
FIGURE 11. Exosome-based diagnostics and therapeutics (M.H Rached; International 
Journal of Molecular Sciences, 2017). 
 
In 2015, Wiklander O.P.B and his group described the progressive 
biodistribution of exosomes at different time-points after injection. The 
localization profile of MVs remained unchanged within the first 24 hours after 
injection (heart, gastrointestinal tract, kidneys), whereas after 48 hours a 
decrease in these districts and an increased exosome concentration in 
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pancreas were observed. Authors correlated these changeable distribution 
profiles to the presence of marker artefacts, due to an aspecific staining. 
Moreover, markers half-life was found to be longer than the one of exosomes 
themselves, thus constituting one of the major issues for their detection. In 
order to perform an exosome-based transplantation, the precise knowledge 
of exosomes lifespan should be essential to establish the right doses and 
intervals of administration and the potential effects in terms of toxicity [173]. 
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2 AIM  
To date, there are no resolving therapies for α-dystroglycanopathies. Even if 
some approaches, such as AAV-based gene therapy, have shown promising 
results when applied in vivo into mouse models, they still present many limits 
preventing their applicability in clinical trials.  
Based on successful results previously obtained by our group in the mdx 
mouse model, resembling the Duchenne muscular dystrophy phenotype 
[57], we aimed to test for the first time the combination of stem cell and gene 
therapy in the field of α-dystroglycanopathies.  
1) We isolated CD133+ stem cells from a MDC1C patient’s peripheral blood 
and we engineered cells with a lentiviral vector expressing the wild-type 
isoform of FKRP mutated gene with the aim to evaluate the recovery of 
fukutin related protein expression. We tested the best performing 
infection condition, in terms of cytotoxicity lack and proper rescue of 
functional FKRP protein. Both of them represent essential requirements 
for a prospective clinical translation of this approach. 
2) In order to test the effectiveness of this strategy in conceived animal 
models, and given the lack of immunodeficient mice, we engineered 
satellite cells derived from L276IKI mice, resembling the LGMD2I 
dystrophic phenotype, for intramuscular autologous transplantation. We 
examined the best performing MOI of infection, the LV dose- associated 
cytotoxic outcomes, as well as the FKRP expression/functional recovery. 
Since the recovery of functional FKRP expression would determine a 
proper a-DG glycosylation, we have also tested the minimum level of 
FKRP expression that guarantees a physiological glycosylation of α-DG. 
3) Since recently published works underlined cell capacity to release FKRP 
in their culture medium, we sought for an exosome involvement in 
glycosyltransferase trafficking. To this end, we firstly determined the 
secretion of exosomes from engineered stem cells, and we investigated 
the presence of exogenous FKRP as cargo of released exosomes.  
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4) Once proved exosome-mediated FKRP secretion in vitro, we performed 
an intramuscular transplantation of engineered cells to evaluate the in 
vivo release of FKRP+ exosomes, and to investigate their capacity to 
prompt FKRP expression and functionality in both the site of injection and 
distal tissues. Moreover, we aimed to deepen our knowledge in 
exosomes kinetics and biodistribution by reproducing their trafficking in 
vitro exploiting a microfluidic bioreactor. 
 
 
FIGURE 12. Schematic representation of our experimental plan 
An exosome-based approach would further sustain and boost the 
therapeutical effect of a combined gene and cell therapy. Above all, its 
applicability could be interesting in the field of metabolic myopathies and all 
muscular dystrophies presenting an enzymatic defect, such as α-
dystroglycanopaties. For instance, while structural proteins necessitate to be 
re-expressed on targeted membranes, we hypothesize that exosome-
mediated enzyme transfer would allow to obtain a fast response in targeted 
tissues. Engineered cells continuous release of FKRP+ exosomes would 
permit a long-lasting maintenance of the enzymatic levels required to supply 
its deficiency.  
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3 MATERIALS AND METHODS 
3.1 In vitro analysis of CD133+ blood-derived stem cells 
3.1.1 Isolation of MDC1C blood-derived CD133+ stem cells 
CD133+ stem cells were purified from the blood of a patient affected by 
Muscular Congenital Dystrophy Type 1C (MDC1C). The patient presented 
two mutations in heterozygosity in the FKRP gene: C518T>G and 
C1087G>C. CD133+ stem cells were sorted with a MACS magnetic column 
(Miltenyi Biotech; Bergisch Gladbach, Germany). Blood was firstly diluted 1:3 
in Iscove’s modified Dulbecco’s medium (IMDM) (Gibco, Thermo Fisher 
Scientific; Waltham, Massachusetts, USA). Following mononuclear cells 
centrifugation, (Ficoll-Hypaque; Pharmacia Biotech, Uppsala, Sweden) cells 
were incubated with a CD133+ cells isolation kit, consisting in CD133 
monoclonal antibody, linked to paramagnetic MicroBeads (Miltenyi Biotech; 
Bergisch Gladbach, Germany). Cells were washed and processed exploiting 
the MACS magnetic separation column (Miltenyi Biotech; Bergisch 
Gladbach, Germany). Thus, a CD133+ cell population was finally isolated.  
3.1.2 Characterization of human blood-derived CD133+ cells for FACS 
analysis 
To perform flow cytometry, 1x105 cells were incubated with CD34–APC 
(allophycocyanin), CD133/2–PE (phycoerythrin) (Miltenyi Biotech; Bergisch 
Gladbach, Germany), and CD45–FITC (Becton Dickinson, 
Immunocytometry Systems; San Diego, California, USA). For all moAbs, a 
proper isotype-corresponding mouse Ig was exploited as control. Each 
staining was carried out by incubating cells for 20 minutes at 4 °C, than cells 
were washed in PBS with 1% inactivated foetal calf serum (FCS) (Gibco, 
Thermo Fisher Scientific; Waltham, Massachusetts, USA) and 0.1% sodium 
azide. The analysis was executed with a FC500 cytomics flow cytometer 
(Beckman Coulter; Brea, California, USA) and 2.1 CXP software. Each 
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analysis involved not less than 15000–30000 events. A light-scatter gate was 
settled to exclude cell debris. The percentage of CD133+ cells in the sample 
was calculated after the adjustment for the percentage of cells reacting with 
the control.  
3.1.3 Blood-derived CD133+ stem cell culture conditions 
Blood-derived CD133+ cells were seeded in six-well tissue culture plates 
(Falcon Labware; Oxnard, California, USA). 105 cells were plated per well 
and cultured in DMEM/F-12 (1:1) and 20% FBS (Gibco, Thermo Fisher 
Scientific; Waltham, Massachusetts, USA), in the presence of HEPES buffer 
(5mM), glucose (0.6%), sodium bicarbonate (3 mM), and glutamine (2mM). 
Some cytokines were addiced to the medium: vascular endothelial growth 
factor (VEGF), 50 ng/ml (Tebu-Bio; Frankfurt, Germany), stem cell factor 
(SCF), 100 ng/ml, and leukemia inhibiting factor, 20 ng/ml (R&D Systems 
Inc; Minneapolis, Minnesota, USA). Cells were passed weekly and incubated 
in a fully humidified atmosphere of 5% CO 95% air at 37 °C. 
3.2 FKRP L276IKI mouse model 
Mice were gently provided by Qilong Lu’s group (McColl-Lockwood 
Laboratory for Muscular Dystrophy Research, Neuromuscular/ALS Center, 
Carolinas Medical Center, Charlotte, North Carolina, USA). The FKRP 
L276IKI mouse model was generated by introducing a knock in mutation in 
the human FKRP gene (a missense mutation leading to nucleotide 
replacement C826 to A) into the coding sequence of the corresponding 
murine gene, causing an amino acid substitution: leucine to isoleucine 
(L276I). As reported by Lu’s group, the neomycin resistant (Neor) cassette 
was introduced into intron 2, around 140 bp upstream from the coding exon 
3. Heterozygous and homozygous mutated mice were genotyped using the 
following PCR primers: FKRP-WT-F: TTC TTG CCT CGG ATT GTG TAT G; 
FKRP-WT-R: TCA CTC TCC AAG GGC CTA CAG C; Neo-F-FKRP: AAC 
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AAG ATG GAT TGC ACG CAG G; Neo-R-FKRP: TGG TCG AAT GGG CAG 
GTA G [120]. Animals were maintained in Charles River Laboratories (Calco; 
Italy) and supplied with limitless water and food. 
3.3 Satellite Cells isolation and characterization 
3.3.1 Isolation of satellite cells from FKRP L276IKI muscles 
Satellite cells (SCs) were dissociated from FKRP L276IKI new born hind limbs 
mice muscles as already reported [174]. Firstlly, biopsies were cleaned in 
PBS: 8g/l NaCl, 0,2g/l KCl, 1,44g/l Na2HPO4, 0,24g/l KH2PO4 in distilled 
water; pH 7.4) to wash off blood residuals. Muscles were resuspended in 
Dulbecco's modified Eagle's medium (DMEM) (Gibco, Thermo Fisher 
Scientific; Waltham, Massachusetts, USA) with penicillin/streptomycin 
(100μL/10ml) and fungizone (120μL/10ml):  connective and adipose tissues, 
blood vessels and nerves were manually discarded using a dissection 
microscope.  Then, sample was mechanically homogenized and 
subsequently digested at 37 °C for 30 min with an enzymatic solution made 
of collagenase V (Sigma-Aldrich, St. Louis, USA) 0,11 mg/ml, dispase 
(Gibco, Thermo Fisher Scientific; Waltham, Massachusetts, USA) 0,45 
mg/ml, DNase (Roche; Basilea, Switzerland) 0,01 mg/ml in 12 ml of Hank’s 
balance salt solution (HBSS) (Gibco, TechnologiesThermo Fisher Scientific; 
Waltham, Massachusetts, USA). A 70-µm cell strainer was used to filter the 
previously dissociated muscular tissue. After a 15-minutes incubation, cells 
were centrifuged at 458g for 20 minutes at room temperature.  Subsequently, 
the pellet was resuspended in DMEM at 20% of FBS with antibiotics, 1% 
embryonic extract chicken (CEE) (Gibco, Thermo Fisher Scientific; Waltham, 
Massachusetts, USA) and 2% horse serum (HS) (Gibco, Thermo Fisher 
Scientific; Waltham, Massachusetts, USA) and plated cells were incubated 
at 37 °C, 5% CO2. The supernatant was harvested and centrifuged at 458g 
for 20 minutes. Trypan Blue Assay was performed (Sigma-Aldrich; St. Louis, 
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USA) and cells were seeded at a density of 380 cells/cm2 in culture dishes, 
previously incubated overnight with collagen. After 24 hours, fresh medium 
was replaced. 
3.3.2 FKRP L276IKI SCs FACS analysis 
SCs were phenotypically analysed by FACS analysis. Cells were incubated 
with Pax7 (Hybridoma Bank; Lowa, USA) and CD29-FITC (Miltenyi Biotech; 
Bergisch Gladbach, Germany). For Pax7 detection, cells were firstly fixed 
with 1,5% paraformaldehyde, then incubated overnight with the primary 
antibody at 4 C° (1:10) and with monoclonal goat anti-mouse 488 Alexa Fluor 
secondary antibody (Molecular Probe; Thermo Fisher Scientific; Waltham, 
Massachusetts, USA) (dilution 1:100). CD29 staining was performed by 
incubating cells for 20 minutes at 4°C. Anti-7-alpha-actin-mycin D (7-AAD) 
(Becton Dickinson, Immunocytometry Systems; San Diego, California, USA) 
was exploited to determine cells vitality. After the incubation step for 20 
minutes at 4 °C, cells were washed in PBS1X, containing 1% heat inactivated 
FBS and 0,1% sodium azide. The analysis was performed using FC500 
cytomics flow cytometer (Beckman Coulter; Brea, California, USA) and 2.1 
CXP software. Each test comprehended not less than 15000-30000 events. 
3.3.3 FKRP L276IKI SCs Immunofluorescent Analysis 
Satellite cells immunofluorescence staining (IF) was executed to evaluate 
dystrophic satellite cells myogenic differentiation potential. When cells 
reached confluence of about 80-90%, the growing medium was substituted 
with differentiation medium, composed of DMEM addictioned with 2% HS 
.Firstly, cells were fixed in formaldehyde 4% for 10 minutes at RT, and then 
incubated in blocking solution (5% of FBS, 2% of HS, 0,3% TRITON in 
PBS1X) for 30 minutes. SCs incubation with Pax7 antibody (dilution 1:20) 
was performed overnight (Hybridoma bank; Lowa, USA) at 4°C. After that, 
cells were stained with the α-mouse biotinilated (dilution 1:100) for 30 
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minutes and with Cy3-streptavidin-conjugated secondary antibody (Sigma-
Aldrich, St. Louis, USA) for 1 hour. Afterwards, the sample was incubated 
with desmin antibody (diluted 1:50) (Abcam; Camdridge, UK) for 1 hour and 
visualized with anti-rabbit Alexa Fluor 488 antibody (Molecular Probe; Becton 
Dickinson, Immunocytometry Systems; San Diego, California, USA) (diluted 
1:100). DAPI was used for nuclear staining (4′, 6-Diamidino-2-phenylindole 
dihydrochloride) (Sigma-Aldrich; St. Louis, USA). Satellite cells were stained 
at three different time points: at T0, before culturing cells in serum starvation 
medium, at T7 and at T14, after one week and two weeks in differentiation 
conditions. Images were taken with Leica TCS SP2 confocal microscope. 
3.4 MDC1C CD133+ blood-derived stem cells and L276IKI FKRP 
SCs transduction  
3.4.1 Lentiviral vector (LV) design and titer of viral preparation 
The LV was created by AMS Biotechnology (AMSBIO; Abingdon, UK) 
company, as previously published [175]. Human FKRP gene 
(NM_001039885.2) was recovered from a gene bank and it was inserted into 
the lentiviral vector. Human FKRP gene was placed under the 
cytomegalovirus early enhancer/chicken β-actin [7] promoter. Green 
fluorescent protein and puromycin were exploited to positively select 
lentiviral-infected cells and they were both expressed under a Rous sarcoma 
virus promoter. Consequently, FKRP and the GFP genes were 
autonomously transcripted. The Lentiviral vector was obtained from the 
human immunodeficiency virus (HIV-1). Lentivector sequence verified 
expression was co-transfected with lentiviral packaging plasmids. The re-
engineered lentiviral packaging plasmid contained the coordinated, 
optimized expression of gag /pol, rev and VSVG and generated high titers of 
lentivirus in 293T packaging cell line as described by manufacturing 
instruction. The packaging plasmid was engineered to minimize the 
likelihood of recombination between expression vector and packaging 
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components for enhanced safety and high yield virus production. After co-
transfection with the third generation lentiviral expression vector, it generated 
only replication incompetent lentivirus. Lentivirus was then concentrated via 
ultracentrifugation and resuspended in PBS solution.  A LV expressing only 
GFP and puromycin selection without the target gene was also produced and 
used as control.  
 
 
FIGURE 13. The lentiviral backbone structure. Human wild-type FKRP gene was expressed 
under the CMV early enhancer/chicken b-actin [7] promoter. GFP-Puromycin reporter gene 
was expressed under a Rous sarcoma virus [Rsv] promoter. 
To determine the proper MOI of infection, 105 CD133+ dystrophic cells were 
infected with 5 x 105 ip, 106 ip, 2 x 106 ip (MOI of 5, 10, 20) in a 96-wells plate, 
soon after the isolation procedure. LV infection was conducted in 100 μl of 
DMEM supplemented with 10% FCS overnight. Then, fresh medium was 
added and cells were maintained at 37°C and 5% CO2. Each MOI was tested 
in three experimental settings.  The immunophenotypical analysis and the 
evaluation of the % of GFP+ cells in the 488 nm emission wavelengths and 
by GFP+ cells count (Fiji Analyze Particles function, Image J program) were 
performed after 6 days, to evaluate the transduction efficiency. MOI 20- 
transduced cells viability was monitored to detect potential impairments due 
to an unexpected virus cytotoxic effects. Dystrophic CD133+ cells infected 
with MOI 20 and the not-infected corresponding cells proliferation were 
estimated exploiting the Trypan Blue Exclusion assay every 5 days for 30 
days. FKRP L276IKI dissociated SCs were cultured in 48 wells (10000/well) 
and infected with increasing lentiviral MOI: 10, 20, and 40. Different MOI 
outcomes on FKRP L276IKI SCs were also evaluated. As previously reported 
for human CD133+ dystrophic stem cells, transduced and not-transduced 
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satellite cells proliferation was calculated at 5-days intervals for 25 days, 
performing Trypan Blue Exclusion assay. We also monitored the outputs of 
the lentiviral vector expressing only the GFP protein, to exclude the prospect 
of GFP LV-induced toxicity. Trypan Blue Exclusion Assay was carried on 
FKRP L276IKI SCs infected with 10, 20, and 40 MOI of the empty vector. 
Cells deriving from each condition (including cells infected with different 
MOIs with the empty lentiviral vector) were cultured in serum starvation to 
induce myogenic differentiation and eventually detect unexpected MOI-
related deleterious outcomes. After a week in serum starvation, we evaluated 
the Fusion Index (FI)(number of myotubes nuclei/total number of nuclei). To 
determine the IF, differentiated satellite cells were cleaned with PBS and 
fixed in 4% paraformaldehyde for 10 minutes. Afterwards, SCs were 
incubated with desmin antibody (1:50) (Abcam; Cambridge, USA) for 1 hour 
and stained with DAPI, thus allowing to visualize myotubes nuclei. FI was 
finally calculated using the NIH ImageJ software. If muscle cells were found 
to contain 3 or more nuclei, they were considered  myotubes, as previously 
reported [176].  
3.4.2 Evaluation of wild-type FKRP expression in human MDC1C 
CD133+ blood-derived and murine dystrophic L276IKI satellite 
infected cells 
Infected human MDC1C CD133+ blood-derived stem cells and infected 
murine dystrophic L276IKI SCs were lysed in NP40 lysis buffer (20mM Tris-
HCl (pH 7.8), 140mM NaCl, 1mM EDTA, and 0.5% NP40, 1mM 
phenylmethylsulfonil fluoride) and addictioned with a cocktail of protease and 
phosphatase enzymes inhibitors (Complete and PhoSTOP) (Roche 
Diagnostics; Basilea, Switzerland). Cell lysates were incubated at 4°C for 30 
min, and centrifuged at 15682g for 15 min at 4°C. The protein concentration 
was measured performing Lowry’s assay. Following protein concentration 
analysis, 30 μg of samples were loaded on a polyacrylamide gel (10%) for 
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WT FKRP detection; 8% polyacrylamide gels were used to detect α-DG 
glycosylation levels. Subsequently, proteins were transferred to supported 
nitrocellulose membranes (Bio-Rad Laboratories; Hercules, CA, USA). A 
blocking solution (10 mM Tris (pH 7.4), 154 mM NaCl, 1% BSA, 10% horse 
serum, and 0.075% Tween-20) was exploited to saturate nitrocellulose 
membranes. FKRP detection was performed exploiting the FKRP-5643 
(FKRP-STEM) antibody, which was kindly provided by Dr Qilong Lu and his 
group (McColl Lockwood Laboratory for Muscular Dystrophy Research, 
Neuromuscular/ALS Center Carolinas Medical Center, Charlotte, North 
Carolina, USA). FKRP-STEM is a rabbit polyclonal antibody recognizing the 
stem region (amino acids 29–130) of the murine FKRP protein. The antibody 
only recognizes the wild type isoform of FKRP protein, and it is unable to 
stain mutated isoforms. Therefore, WB positive bands are necessarly related 
to lentiviral-mediated exogenous FKRP recovery.  The secondary antibody 
(rabbit anti-FKRP antibody, diluted 1:600) was incubated overnight at 4°C. 
Mouse anti-α-DG (IIH6-C4-5, dilution 1:50) (Hybridoma Bank; Lowa, USA) 
was exploited to detect the level of α-DG-glycosylation. Anti-β-actin (1:600) 
(Sigma Aldrich; St. Louis, USA) was used as housekeeping protein. There 
are two commercially available antibodies to detect α-DG-glycosylation: 
VLA4 and IIH6. Both of them recognize epitopes of the entirely glycosylated 
form of α-DG. In both in vivo and in vitro experiments, the immunoreactivity 
of these two antibodies has been correlated to laminin binding activity. 
However, only IIH6 inhibits this linkage. These observations underline how 
the two antibodies identify different, glycan-dependent sites and highlight the 
strict connection between these epitopes and the laminin binding site (Hewitt, 
2009). As IIH6 principally interacts with the laminin-binding site of DG, the 
observed decreased staining underlines an abnormal laminin binding in 
patients with this clinical phenotype.  Visualization was accomplished with 
horseradish peroxidase (HRP)-conjugated antibodies (Dako; Glostrup, 
Denmark) 90 minutes at RT and by enhanced chemiluminescence (ECL) 
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development (GE Healthcare; Little Chalfont, UK). Pre-stained molecular 
weight markers (Bio-Rad Laboratories; Hercules, CA, USA) were loaded on 
each gel. Visualization was performed using   Amersham Hyperfilm™ (GE 
Healthcare; Little Chalfont, UK). CanoScan LiDE60 Scanner (Canon) and the 
Canon ScanGear Software were used to obtain images of bands. 
Densitometric analysis was conducted using ImageJ software 
(http://rsbweb.nih.gov/ij/).  Not-infected CD133+ stem cells and not-infected 
L276I FKRPKI SCs were loaded as controls.  Immunofluorescent staining was 
performed on FKRP L276IKI satellite cells infected with MOI 20, to identify 
both GFP fluorescent protein and human exogenous FKRP expression. After 
SCs fixation with 4% paraformaldehyde for 5 minutes, the membrane was 
incubated in blocking solution (1% BSA, 0, 05% Tween, 5% FBS in PBS1X) 
for 30 minutes and then for 2 hours with rabbit anti FKRP-STEM (dilution 
1:50) and mouse anti-GFP (dilution 1:500) (Abcam; Cambridge, UK) 
antibodies in the same solution. Secondary monoclonal antibodies (anti-
rabbit 594 and monoclonal anti-mouse 488) (Molecular Probe, Thermo 
Fisher Scientific; Waltham, Massachusetts, USA) were used at a dilution of 
1:100 in PBS for 1 hour. Nuclei were stained with DAPI (Sigma-Aldrich; St. 
Louis, USA). Images were captured with Leica TCS SP2 confocal 
microscope (Leica, Germany). 
3.5 Isolation and characterization of human MDC1C CD133+ 
blood-derived stem cells and murine dystrophic L276IKI 
satellite cells-derived exosomes  
3.5.1 Purification of exosomes by Differential Ultracentrifugation  
The most widely applied method for concentrating and purifying exosomes 
consists of differential ultracentrifugation. This isolation procedure is based 
on serial cycles of centrifugation at increasing centrifugal force, to pellet 
smaller and smaller particles. Exosomes are separated from other culture 
medium particles according to their differences in terms of density and size. 
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Cell debris are immediately removed from culture medium (CM) through a 
centrifugation at 2000g for 30 minutes. Subsequently, CM is centrifuged at 
10000g for 45 min to pellet apoptotic bodies and other big particles. 
Supernatants (SN) are then filtered (pore size 0.2µm) to remove remaining 
large particles. Filtered SN are ultracentrifuged at 130000g for 2 hours. The 
obtained pellet is washed with PBS and pelleted again at 130000g for 2h to 
remove protein contamination. The final pellet is resuspended in filtered PBS 
or NP40 Lysis Buffer, according to the predicted following analysis. All 
samples are ultracentrifuged in polyallomer 36 ml centrifuge tubes, using a 
Beckman Coulter ultracentrifuge (Beckman Coulter Optima L-90K 
ultracentrifuge), with a fixed angle rotor type 50.2Ti.  
Recovered exosome protein concentration was measured with the 
microBCA kit assay (Thermo Fisher Scientific; Waltham, Massachusetts, 
USA). This assay allows for the evaluation of very low doses of recovered 
proteins. 
3.5.2 Purification of exosomes by Size Exclusion Chromatography 
(SEC)  
The fundamental of SEC analysis is the separation of particles according to 
their dimensions or molecular weight. This method can be applied to isolate 
vesicles from both body fluids and cell culture medium. Collected culture 
medium was centrifuged at 2000g to discard floating cells and cell debris and 
subjected to concentration in 10K molecular weight cut-off (MWCO) (Merck 
Millipore; Darmstadt, Germania) filter units. A maximum of 15 ml supernatant 
was centrifuged at 4000g for 20 min at RT in a swinging-bucket rotor, to 
obtain a final volume of about 500 μl. Subsequently, chromatography was 
performed taking advantage of the qEV Size Exclusion Columns (qIZON; 
Schaefer, South East Europe). In brief, 500 µl of concentrated culture 
medium were loaded on one column. PBS filtered buffer was exploited as 
appropriate eluent buffer. 500 µL fractions were collected. According to the 
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manufacturer’s instructions, the first six fractions (3 mL) represent the void 
volume, whereas exosomes are predominantly eluted in fractions 7, 8 and 9. 
According to datasheet instructions, SEC columns rescue particles bigger 
than 50000 KDa, thus eliminating bulk proteins in solution. MicroBCA assay 
revealed that the exosome most-abundant fraction was fraction 7, followed 
by fraction 8. A very low amount of exosomes was found also in fraction 9. 
3.5.3 Purification of exosomes by Commercial Kits 
To test the efficiency of exosomes enrichment by using commercial kits we 
exploited the Total Exosome Isolation Reagent from Cell Culture Medium 
(Thermo Fisher Scientific; Waltham, Massachusetts, USA). According to the 
manufacturer’s suggestions by tyning up water molecules, the reagent forces 
less-soluble components such as vesicles out of solution and allows 
collection by a short low-speed centrifugation. Briefly, collected medium was 
mixed 1:2 with the reagent and incubated ON at 4°C.  Isolated exosomes are 
recovered by standard centrifugation at 10000g for 60 minutes.  
3.5.4 Setting of cell seeding conditions for culture medium collection 
To further analyse the process of exosome release, we focused on the 
possibility to set the proper culture conditions for recovering the most 
homogeneous population of vesicles. C2C12 myoblast cell line was exploited 
to perform these experiments. Cells were seeded in 10-cm dishes at 40000 
cells/cm2 density. Cell proliferation and exosome secretion were observed at 
three specific time points: T1 (24h of culture), T2 (48h of culture) and T3 (72h 
of culture). Prior to use, FBS was ultracentrifuged at 130000g overnight to 
remove the possible contaminant vesicles. For T1 condition, cells were 
directly cultured in DMEM with exosome-depleted FBS after seeding. As for 
T2 and T3, complete medium was replaced with exosome-depleted medium 
24 hours before the collection. Cell proliferation was evaluated performing 
an MTT assay. 
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3.5.5 Purification of exosomes from cell culture medium of cells 
growing in suspension 
According to the isolation procedure previously published by Clothilde Théry 
and her group in 2006, cells were firstly centrifuged 10 minutes at 300g. 
Then, the supernatant was poured off and cells were resuspended in medium 
addictioned with exosome-depleted FBS. Conditioned medium was collected 
only after 24 hours in culture [146].  For instance, most lineages of cells 
growing in suspension have a very fast proliferation rate and may reach over 
confluence, starting to die within 48 hours. Once collected, the CM was 
centrifuged at 300 g for 10 minutes: the supernatant was transferred into new 
tubes, while pelleted cells (and other large dead cells and debris) were plated 
again. After CM collection, exosomes were isolated exploiting size exclusion 
chromatography (SEC). 
3.5.6 Exosome detection methods 
Transmission Electron Microscopy (TEM) Exosome samples used for 
electron microscopy were resuspended in filtered PBS and 5µl were 
immediately loaded onto formvarcarbon-coated grids. Samples were then 
examined in an electron microscope. Vesicles dimensions were analysed 
exploiting ImageJ software. 
Nanoparticles Tracking Analysis (NTA) The analysis of the absolute size 
distribution of EXOs was executed using Nano Sight LM10 (Malvern, UK).  
With NTA, particles are automatically tracked and sized based on Brownian 
motion and the diffusion coefficient (laser 532 nm). After isolation, 
exososomes were diluted in 1ml of filtered PBS. Control medium and filtered 
PBS were used as controls in this technique and NTA measurement settings 
were set as follows: temperature 23.75±0.5°C; viscosity 0.91±0.03 cP, 
frames per second 25, measurement time 60s. Three recordings/sample 
were performed. 
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FIGURE 14.  NanoSight LM10 structure. NTA technique is used in conjunction with an 
ultramicroscope and a laser illumination unit that together allow small particles in liquid 
suspension to be visualized moving under Brownian motion. 
Exosomes labelling To obtain fluorescent exosomes, samples were 
labelled with the red fluorescent cell dye PKH26 (Sigma-Aldrich; St. Louis, 
USA). PKH26 Fluorescent Cell Linker dye stably incorporates with long 
aliphatic tails into the lipid regions of the cell membrane. Briefly, a 2X mix 
was prepared by adding 1 ml Diluent C to the exosome pellet (if the isolation 
was performed by differential ultracentrifugation), or to the concentrated 
culture medium (if exosomes were isolated by SEC). Diluent C is an aqueous 
solution provided in the kit, which ensures the maintenance of cells viability, 
maximizing dye solubility and staining efficiency. A 2X Dye solution was 
prepared by adding 4 µl of the fluorescent dye to 1 ml of Diluent C. Then, the 
2X exosome suspension/concentrated CM was mixed with the 2X dye 
solution and incubated 5 minutes. The reaction was stopped by adding to the 
mix an equal volume of exosome-free FBS for 1 minute. For exosomes 
isolated exploiting differential centrifugation, an extra centrifugation at 
130000g of 2 hours was sufficient to discard the excess of unbound PKH26 
71 
marker. As for concentrated CM, SEC protocol allows the exclusion of the 
unbound marker directly during the process of MVs isolation. Moreover, it is 
possible to obtain PKH26+ exosomes directly labelling their releasing cells, 
according to the manufacturer’s instructions. 
FACS analysis For cytofluorimetric analysis, 2 µg of exosomes were stained 
with CD63-PE-vio770 (Miltenyi Biotech; Bergisch Gladbach, Germany) and 
CD81-PE (Beckman Coulter; Brea, California, USA) antibodies for 20 
minutes at 4°C. Afterwards, 10 µl of magnetic CD63-coniugated beads were 
added to the mix (ThermoFisher Scientific; Waltham, Massachusetts, USA) 
and incubated overnight at 4°C under moderate agitation.  Then, the sample 
was vortexed to guarantee the optimal beads recovery and it was washed 
with PBS1X and BSA 1% exploiting a magnet (Ademtech; Pessac, France) 
to avoid the loss of the beads during the washing step. FACS analysis was 
performed on a FACS Cytomic FC 500. The analysis was conducted using 
CXP 2.1 software. 
3.5.7 Evaluation of FKRP expression in human CD133+ blood-derived 
and murine L276IKI SCs infected cells-derived exosomes 
For WB exosomes analysis, particles were isolated from cell culture medium 
by SEC; 5 µg of fraction 7-enriched exosomes were directly mixed with 
Laemmli sample buffer (62.5 mM Tris-HCl pH 6.8; 2% SDS; 5% 2-
mercaptoethanol, glycerol 10%, Bromophenol Blue 0.004%) and boiled at 65 
°C for 10 minutes. Boiling temperature was maintained below standard 
values (95 °C) to avoid particles clustering. Samples were loaded on a 10% 
polyacrylamide gel and then transferred to a supported nitrocellulose 
membrane. Then, filters were saturated in blocking solution (10 mM Tris pH 
7.4, 154 mM NaCl, 1% BSA, 10% horse serum, and 0.075% Tween-20). The 
monoclonal primary antibodies: the mouse anti-TSG (1:200) (Abcam; 
Cambridge, UK), the mouse anti-Ago2 (1:200) (Proteintech; Europe, 
Manchester, UK) and the rabbit anti-FKRP-STEM (1:600) antibodies were 
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incubated at 4°C in the blocking solution O/N or, alternatively, using the 
Signal-boost Immunoreaction Enhancer Kit (Calbiochem; Inalco, Italy), when 
the enhancement of the signal was necessary due to very low levels of the 
protein expression in the samples. Enhanced chemiluminescence (ECL) 
development (GE Healthcare; Little Chalfont, UK) was performed to detect 
the positive signal after incubation with (HRP)-conjugated secondary 
antibodies. Pre-stained molecular weight markers were loaded  on each gel. 
Bands were detected by autoradiography using Amersham Hyperfilm™ (GE 
Healthcare; Little Chalfont, UK) and captured taking advantage of the 
CanoScan LiDE60 Scanner and the Canon ScanGear Software. ImageJ 
software (http://rsbweb.nih.gov/ij/) was exploited to perform the 
densitometric analysis. 
3.6 In vivo transplantation of LV-FKRP L276IKI satellite cells 
into  FKRP L276IKI mouse model 
12 months-old FKRP L276IKI mice were anesthetized with 2% avertin (0.015 
mL/kg) and intramuscularly transplanted in the tibialis anterior (TA) with 3 
increasing doses of FKRP L276IKI SCs engineered cells: 35x103 (N= 4), 
75x103 (N=5), and 100x103 (N=4); N=6 mice were not injected and used as 
controls.Cells engineering was performed with the LV expressing the wild-
type isoform of human FKRP; for in vivo transplantation, cells were infected 
with MOI 20. Briefly, SCs were resuspended in 100 μl of PBS, using a 33G 
Hamilton syringe (Hamilton company; Reno, Nevada, USA). 15 days after 
cells transplantation, mice were sacrificed by cervical dislocation. 
3.6.1 Evaluation of human wild-type FKRP expression and α-
Dystroglycan glycosylation in injected TAs and heart muscles 
- Immunofluorescent Analysis  
IF was performed on muscle samples which were snap-frozen in liquid 
nitrogen and stored at -80°C soon after the mice sacrifice.  The staining was 
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performed on FKRP L276IKI  transplanted tibialis anterior (TAs); not-
transplanted FKRP L276IKI TAs were exploited as negative control and 
C57BL TAs as positive control. 12 µm- thickness serial tissue sections were 
cut by cryostat (Leica CM1850), and monitored for the exogenous FKRP 
isoform expression with rabbit anti-FKRP-STEM antibody, kindly provided by 
Dr. Qilong Lu (1:50), and mouse anti-GFP (dilution 1:500) (Abcam, 
Cambridge, UK). anti- α-DG IIH6-C4-5 (dilution 1:50) (Hybridoma Bank, 
Lowa, USA), an anti-mouse monoclonal antibody detecting the N-terminus 
α-DG (the laminin-binding glycan epitope) staining was also performed on 
the same tissue sections. moAb anti-rabbit 594, moAb anti-mouse 594 and 
moAb anti-mouse 488 (Molecular Probe Invitrogen, Carlsbad, CA, USA) 
were used at a dilution of 1:100 for 1 hour. Nuclei were counterstained with 
DAPI (Sigma-Aldrich, Milan, Italy). Finally, images were taken with Leica 
TCS SP2 confocal microscope, equipped with a 63X/1.40-0.60 objective 
(Leica, Germany).  
-Western Blot biochemical analysis 
Transplanted TAs, contralateral TAs and hearts (HTs) were harvested from 
all injected and not -injected L276IKI FKRP and C57BL mice, immediately 
after sacrifice by cervical dislocation. The WB analysis of contralateral TAs 
muscles and hearts was performed to determine the systemic circulation of 
exogenous WT FKRP protein and its rescued functionality. According to this 
perspective, muscles were directly homogenized in NP40 lysis buffer with a 
POTTER S Homogenizer (B.Braun Biotech International-Sartorius group, 
Melsungen, Germany) and incubated for 30 min at 4°C. Finally, they were 
centrifuged at 15682g for 15 min at 4 °C and the recovered total protein 
concentration was determined by Lowry’s assay. The biochemical analysis 
was conducted as already described for cell lysates. Briefly, samples (30 µg) 
were loaded on polyacrylamide gel (10%) and incubated with FKRP-STEM 
antibody, (1:600) for exogenous FKRP detection and on 8% polyacrylamide 
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gel to detect α-DG glycosylation (IIH6-C4-5 antibody) (1:50) (Hybridoma 
Bank, Iowa, USA), and than transferred to nitrocellulose membranes (Bio-
Rad Laboratories). Anti-α-actin (1:600) staining was performed for 
normalization. TAs and HTs removed from C57BL mice were exploited as 
positive controls, not-injected mice (NI) as negative controls. 
3.6.2 Histopathological Analysis 
L276IKI injected and not-injected mice TAs previously frozen in liquid 
nitrogen, were cut in serial tissue sections of 12 µm thickness by cryostat 
(Leica CM1850). Hematoxylin and eosin staining was performed to examine 
histoarchitectural changes. 
3.6.3 In vitro modelling of dynamic FKRP-carrying exosome trafficking  
To imite FKRP flux within exosomes, a microfluidic, miniaturized bioreactor 
was used and installed as previously reported with little adjustments [177]. 
The dynamic technique is optically transparent and made of three 
independent chambers. Each one hosts a unique polystyrene scaffold for 
cells seeding (dimensions 6 × 3 × 0.4 mm, 3D Biotek; Hillsborough, NJ, 
USA). Each scaffold has four layers of fibers (100 μm in diameter, with 
300μm pore size, 150μm reciprocally separated) (Fig 4A). Three single 
microfluidic channels connect the chambers. Firstly, the scaffolds were pre-
conditioned in sterility with DMEM, as previously reported [177]. Then, 106 
FKRP L276IKI SCs infected with LV-MOI 20 were marked with PKH26; this 
way, cells were able to release PKH26+ exosomes. These cells were 
resuspended ed in 400 µl of medium and seeded on one scaffold. Similarly, 
not labelled 106 FKRP L276IKI SCs were cultured on the other scaffold. The 
scaffolds were incubated at 37 °C ON to let cells attach. Subsequently, they 
were inserted into two independent bioreactor chambers, covered by 
magnetic bottoms. DMEM 10% FCS was pushed with an unidirectional flow 
rate of 5 µl/min in to the first chamber, were infected FKRP L276IKI SCs were 
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previously seeded, taking advantage of a multi-channel programmable 
syringe pump (PHDULTRA; Harvard Apparatus, Holliston, MA, USA) in a gas 
permeable tubing system (0.03′′ ID × 0.065′′ OD, Silastic Tubing, Cole-
Parmer, Vernon Hills, IL, USA). The outward supernatant enriched with 
PKH26+ exosomes, secreted by PKH26+ infected FKRP L276IKI SCs, 
penetrated the second chamber were not-infected FKRP L276IKI SCs were 
plated. Afterwards it was accumulated in a reservoir. The experiment was 
run for 8 hours, subsequently the scaffolds were recovered and stained by 
IF to detect   exosome induced-FKRP expression. Scaffolds holding FKRP 
L276IKI SCs were fixed with 4% paraformaldehyde for 30 minutes, incubated 
with blocking solution (1% BSA, 0,05% Tween, 5% FBS in PBS1X) for 1 hour 
and incubated overnight at 4°C with rabbit anti FKRP-STEM antibody in 
blocking solution (diluted 1: 50). Monoclonal anti-rabbit 488 (Molecular 
Probe; Thermo Fisher Scientific; Waltham, Massachusetts, USA) was used 
at a dilution of 1:100 in PBS for 1 hour. Nuclei were counterstained with DAPI 
(Sigma-Aldrich; St. Louis, USA) and images were taken with Leica TCS SP2 
confocal microscope. 
3.6.4 Muscle Functional Analysis 
All the injected mice (N=4 35x103 cells, N=5 75x103 cells, N=4 100x103 cells) 
were examined by Treadmill and Rotarod tests, to measure their 
performances. Not-transplanted mice (N= 6) and age-matched C57BL mice 
(N=5) were exploited as controls. Animals were tested a week before cells 
transplantation, the day of cells injection (T0), 7 and 14 days (T7 and T14) 
after transplantation. After in vivo functional measures, they were finally 
sacrificed. Treadmill was performed as a simple motor exercise. Briefly, mice 
were placed on a motorized treadmill (Harvard Apparatus) to run with an 
upward angle of 15° at a rate of 15m/minute. In order to determine the high 
variability among mice belonging to the same group, running distance results 
from transplanted and not-transplanted mice at T14 were normalized to the 
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corresponding pre-transplantation outcome (-T7). Data obtained at T-17 
were considered as ‘’baseline level’’. Results are expressed as the % of 
averaged variations in running distance, evaluated as [(Activity at 
T14/Activity 7 days before the injections) x 100] - 100. Treadmill experiments 
were interrupted when the mice stayed 5 seconds standing on the shock grid. 
Rotarod is a moderately complex motor training exercise, which investigates 
coordination and balance features of motor performance. Mice were 
positioned on the instrument and then acceleration from 5 to 45 rotations/ 
minute within 15 seconds was set. When a mouse ran for up to 500 seconds 
without fallings the rod was stopped. Mice undergoing fallings within 500 
seconds were allowed to perform the experiment two more times. The best 
performance was held in consideration for the analysis. 
3.7 Blood analysis 
3.7.1 Plasma collection, Isolation of plasma-exosomes and evaluation 
of FKRP expression  
Immediately before sacrifice, blood was collected into EDTA-coated tubes 
from the submandibular vein of the 35x103, 75x103, and 100x103 LV-FKRP 
infected SCs transplanted FKRP L276IKI mice (˷300 µl/mouse). 
Subsequently, blood was centrifuged at 1200g for 10 minutes at 4°C to obtain 
plasma samples. Plasma was placed in a new 1.5 ml tube and frozen at - 80 
°C. Plasma-exosomes were isolated performing SEC chromatography (qEV 
IZON Science; Scheafer, Souh East Europe). In accordance with the 
manufacturer’s suggestions, plasma was diluted 1:2 in filtered PBS1X. 
Plasma-exosomes characterization was performed as already described by 
Nanosight Tracking Analysis, to measure microvesicles dimensions, and by 
Transmission Electron Microscopy, to define their morphology. 
Subsequently, biochemical analysis was conducted to evaluate the presence 
of exogenous wild- type FKRP in the plasma, exploiting anti FKRP-STEM 
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antibody. The analysis was performed as already reported for CD133+ stem 
cells and FKRP L276IKI satellite cells culture medium- derived exosomes. 
3.8 Statistical Analysis 
Prism 5.0 (Graphpad) was used to perform statistical analysis.  Comparisons 
were based on Student's t-test or analysis of variance (ANOVA) with Tukey 
post-hoc test for pairwise comparisons. A confidence level of 95% was 
assumed as significant, as well as P-values < 0.05. 
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4 RESULTS 
4.1 MDC1C CD133+ blood-derived stem cell in vitro 
characterization and transduction 
4.1.1 Characterization of MDC1C blood-derived CD133+ stem cells 
CD133+ cells were isolated from control and dystrophic MDC1C patient’s 
peripheral blood. The patient was a three-years-old boy presenting two 
mutations in heterozygosis in the fukutin related protein gene: C518T>G and 
c1087G>C. Freshly purified CD133+ blood-derived stem cells were 
immediately cultured in vitro and their morphology was daily monitored.  
Images were captured by optical microscopy immediately post isolation and 
after 14 days to demonstrate that cell culture conditions did not affect their 
morphology: cells maintained their original round shape and unvaried 
dimensions both soon after the isolation procedure (Fig. 15A) and after 15 
days in culture (Fig. 15B). Blood-derived CD133+ stem cells were 
characterized through flow cytometry analysis. Fig. 15C represents the 
scatter plot. 92,3% of magnetically isolated cell population was CD133+ (Fig. 
15 C’); 98% of CD133+ cells were also positive for CD45 marker (Fig. 15 C’’) 
and 90,1% of isolated cells proved to be positive for CD34 marker (Fig. 
15C’’’). Cells exhibited a viability range between 70-90% throughout the 
culture period (30 days).  
4.1.2 Lentiviral infection of CD133+ stem cells isolated from a MDC1C 
patient’s peripheral blood 
Immediately after cells isolation, CD133+ blood-derived stem cells were 
exposed to lentiviral particles delivering constructs encoding for the human 
wild-type isoform of FKRP protein (pLenti-CAG (hFKRP)-Rsv (GFP-Puro)). 
Multiple MOI of infection (MOI 5, 10, 20) were tested to evaluate the most 
performing transduction condition. Transduction efficiency was assayed by 
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both cytofluorimetric analysis (FACS) and fluorescent microscopy by 
evaluating green fluorescent protein (GFP) expression. 
 
FIGURE 15. Characterization of CD133+ stem cells isolated from a MDC1C patient’s 
peripheral blood. Cells morphology was observed by bright field microscopy soon after cells 
isolation procedure (A) and after 14 days in proliferation medium (B). Images were captured 
at 20X magnification. FACS analysis of CD133+ stem cells. Each study involved not less 
than15000–30000 events. The scatter plot is shown (C). CD133+ stem cells median purity 
was around 92,3% (C’); 98% of CD133+ cells were also positive for CD45 marker (C’’) and 
90,1 % of CD133+ cells were also CD34+ (C’’’). Immunophenotyping analysis of CD133+ 
stem cells infected with the LV (pLenti-CAG (hFKRP)-Rsv (GFP-Puro)).The reported % of 
GFP+ cells was 48%  for MOI 5 (D), 74.8% for MOI 10 (D’) and 95.2% for MOI 20 (D’’). 
Histogram summarizing CD133+ cells infection efficiency at MOI 5, 10 ad 20 (D’’’). Values 
are represented as means ± SD. MDC1C CD133+ infected with MOI 20 and corresponding 
not infected cells proliferation curve. Proliferation was calculated in triplicate at 5- days 
intervals for 30 days, performing Trypan Blue Exclusion Assay (E). Values are reported as 
means ± SD. WB confirmed FKRP rescue in MDC1C CD133+ stem cells infected with MOI 
20 (lane MOI 20 INF MDC1C CD133+). Not infected cells and healthy donor’s CD133+ cells 
were respectively loaded as negative (lane MDC1C CD133+) and positive (lane CD133+ 
CTR+) controls. β-actin was used as house-keeping protein (F). 
80 
FACS analysis disclosed enhanced transduction efficacy as the MOI 
increased: 48%, 74.8%, and up to 95.2% respectively for MOI 5, 10 and 20 
(Fig. 15D, 15D’, 15D’’).  
The histogram graph in figure 15 D’’’ is representative of the percentage of 
GFP+ cells observed by fluorescent microscopy analysis. These data overall 
suggested that MOI 20 presented the best outputs in terms of transduction 
efficiency, thus we decided to infect MDC1C blood-derived CD133+ stem 
cells with lentiviral vector MOI 20. Trypan blue exclusion assay was 
performed on MOI 20- infected CD133+ MDC1C stem cells and not-infected 
MDC1C CD133+ cells at 5-days intervals for 30 days.  MOI 20- transduced 
FKRP CD133+ stem cells did not display deleterious outcomes in their 
proliferation curve. For all the experimental time- points the proliferation 
curve was comparable to the distinctive trend of not-infected CD133+ stem 
cells, characterized by a starting decrease of cells viability and a peak 
between 15 and 20 days (Fig. 15E).  
To test whether the lentiviral transduction could restore the expression of 
wild- type fukutin related protein in MDC1C CD133+ blood-derived stem 
cells, we performed a biochemical analysis 7 days after the lentiviral 
infection. WB analysis confirmed the presence of a positive signal at 
approximately 60 KDa, corresponding to lentivirus-mediated FKRP 
exogenous protein restoration in MOI 20- infected MDC1C CD133+ blood-
derived stem cells (lane MOI 20 INF CD133+ MDC1C), compared to the 
absence of a positive signal in not-transduced cells (lane CD133+ MDC1C).  
CD133+ blood-derived stem cells isolated from a healthy patient were 
exploited as positive control (lane CD133+ CTR) (Fig 15F). These results 
were in agreement with the specificity of FKRP-STEM antibody for the wild-
type isoform of FKRP glycosyltransferase.  The signal intensity of FKRP 
expression within cells was quantified by NIH image J densitometric analysis 
using α-actin as housekeeping protein. 
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4.2  FKRP L276IKI satellite cell in vitro characterization and 
transduction 
4.2.1 FKRP L276IKI Satellite Cells characterization 
Satellite cells (SCs) were dissociated from FKRP L276IKI new born mice 
muscles. Freshly isolated SCs were cultured in 48-wells tissue plates in 
proliferation medium. FACS analysis showed that 97.6% of isolated cells was 
Pax7 positive (Fig. 16A) and 80.3% of Pax7+ cells were also positive for 
CD29 (Fig. 16A’).  Both satellite cells morphology and the presence of 
myogenic markers were investigated before the supplementation of serum 
starvation medium (T0) and after culturing cells in myogenic differentiation 
medium, at two different time-points: 7 days (T7) and 14 days (T14).  As 
expected, at T0 SCs still showed the expression of Pax7 satellite cell marker 
(in red) and desmin+ (in green) (Fig. 16B, E). At T7, SCs had already begun 
to differentiate, progressively appearing as small Pax7-desmin+ myotubes 
(Fig. 16C, F). After 14 days (T14), the number and size of SCs-derived Pax7-
desmin+ myotubes was evidently increased (Fig. 16D, G). 
4.2.2 Lentiviral transduction of isolated FKRP L276IKI Satellite Cells  
FKRP L276IKI satellite cells LV-hFKRP lentiviral vector transduction was 
performed with three different increasing MOI (10, 20, 40); cells proliferation 
and fusion index were evaluated and compared to not- infected FKRP L276IKI 
SCs. Trypan Blue Exclusion assay proved that FKRP L276IKI SCs infected 
with lentiviral MOI of 10 and 20 did not exhibit detrimental consequences on 
cells viability in comparison with not infected corresponding cells. Similarly, 
FKRP L276IKI SCs infected with higher MOI 40, displayed a trend towards a 
decrease in cell proliferation rate, which was probably due to 5% of cell 
mortality (Fig. 16H). Interestingly, the evaluation of LV-EMPTY (pLenti-Rsv 
(GFP-Puro)) infected FKRP L276IKI SCs did not show any statistical 
difference among the three distinct MOI of infection (Fig. 16I). Once again, 
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only MOI 40- infected SCs proliferation displayed a not significant trend 
towards a proliferation rate delay beginning at day 15 and presumably 
produced by the occurrence of 3.5% cell mortality. Thus, we defined the 
absence of a lentiviral-vector induced toxicity, whether (pLenti-CAG 
(hFKRP)-Rsv (GFP-Puro)), or (pLenti-Rsv (GFP-Puro)), even throughout 25 
days in culture. Furthermore, dystrophic SCs fusion index (FI) was calculated 
for each MOI of infection. Overall, we found similar results among cells 
infected with MOI 10, 20 and 40 (Fig. 16L).  
Observed values were compared to FKRP L276IKI SCs infected with LV-
empty (pLenti-Rsv (GFP-Puro)) outcomes (data not shown), but no 
differences were evidenced. MOI 10, 20 and 40 LV-empty infected SCs 
conserved a rate analogous to not-infected FKRP L276IKI SCs (30% 
myotubes nuclei/total nuclei). The not-statistically different FI observed for 
MOI 40- infected L276IKI SCs could be explained by a slight decrease in cell 
number rather than a decreased differentiation capacity. The biochemical 
analysis performed on FKRP L276IKI infected satellite cells highlighted an 
increased FKRP protein expression between MOI of 10 and 20, whereas 
MOI 40- infected cells looked like a steady point causing a plateau in the 
glycosyltransferase expression level (Fig 16M).  
Afterwards, the biochemical analysis of α-DG glycosylation was performed 
to evaluate FKRP restored function. Interestingly, the blot revealed no MOI-
dependent differences in all the three analysed settings. The previously 
observed FKRP expression plateau at MOI 40 produced a constant level of 
α-DG glycosylation, in comparison with MOI 10 and 20. Not-infected FKRP 
L276IKI satellite cells were loaded as control (lane NOT INF) (Fig. 16M). Fig 
2N displays the immunofluorescence staining (IF) of MOI 20- LV-FKRP 
L276IKI SCs. Cells were analysed for the expression of GFP and FKRP 
proteins, exploiting anti-GFP and anti-FKRP-STEM antibodies. The staining 
confirmed the diffused localization of GFP (in green) within the cell 
cytoplasm, while exogenous FKRP (in red) was detected in the same cell 
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compartment, but the positive signal was more evident in the perinuclear 
region (Fig. 16N).  
 
FIGURE 16.  Characterization of FKRP L276IKI SCs. FACS analysis of isolated FKRP 
L276IKI SCs. Each study included not less than 15000–30000 events. 97.6% cells expressed 
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PAX7 myogenic marker (A); 80.3% of PAX7+ cells were also positive for CD29 (A’). SCs 
morphology was visualized by bright field microscopy at various time-points: soon after SCs 
seeding (T0)(B), one week (T7)(C) and two weeks (T14) later (D) in serum starvation 
medium. IF analysis was executed to determine specific myogenic satellite markers 
positivity. The day of transplantation (T0), satellite clones expressed α-desmin (in green) 
and Pax7 (in red) (E). At T7 cells were negative for early myogenic marker Pax7 expression, 
and were still positive for α- desmin; α- desmin staining underlined the presence of some 
myotubes in culture (F). After two weeks (T14), cells still expressed α-desmin and were 
definitively fused in myotubes (G). Images were taken at 20X magnification. Infected and not 
infected FKRP L276IKI SCs proliferation curve (H) and LV-EMPTY infected and not-infected 
SCs proliferation curve (I). SCs proliferation was calculated for 25 days at 5-days intervals 
performing Trypan Blue Exclusion Assay. Values are represented as means ± SD. 
Evaluation of LV-FKRP infected (MOI 10, 20 and 40) and not infected (NOT INF) FKRP 
L276IKI SCs fusion index, representative of the percentage of myotubes nuclei/ total nuclei, 
after a week in serum starvation (L). Values are expressed as means ± SD. WB showed α-
DG protein glycosylation (smeared band around 150 KDa) and FKRP rescue (60 KDa) in 
infected SCs. α-DG glycosylation was higher in transduced cells, rather than not transduced 
SCs (NOT INF, lane 1), but without any difference between the three increasing MOI of 
infection (MOI 10, lane 2, MOI 20, lane 3, MOI 40, lane 4). FKRP protein expression 
increased from MOI 10 to 20, but reached a plateau with MOI 40. β-actin (43 KDa) was used 
as house-keeping (M). IF analysis of SCs infected with MOI 20, demonstrating both 
cytoplasmic and perinuclear protein expression (in red) and cytoplasmic GFP (in green) 
staining. Nuclei were counterstained with Dapi (in blu). Images were captured with a 
confocal microscope (63X magnification)(N). 
4.3 Optimization of exosomes isolation and characterization 
procedures 
4.3.1 Exosomes isolation Techniques 
To optimize the exosome isolation protocol, we compared three main 
techniques:  
- Differential ultracentrifugation (UC) 
- Commercial kits 
- Size-exclusion chromatography (SEC) 
Protocols were set up exploiting supernatant in contact with C2C12 murine 
myoblast cell line. We chose a cell line with a good proliferative capacity to 
obtain a high amount of conditioned cell culture medium, and a reliable 
source.  
Differential Ultracentrifugation 
Cell supernatant was collected and exosomes were isolated as previously 
described (Materials and Methods section) (Fig. 17A). Once isolated, 
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exosomes were resuspended either in PBS1X buffer or NP40 lysis buffer and 
analysed.  
 
The experimental procedure was repeated several times to prove its 
reproducibility. Unless microBCA assay showed a high protein concentration 
in the exosome- enriched samples, the Poinceau staining performed on the 
nitrocellulose revealed very low amount of loaded proteins. The presence of 
a major band at ˷ 60 KDa suggested that culture medium- derived bovine 
serum albumin (BSA) could represent the main enriched protein in exosome 
samples. NP40-resuspended exosomes were biochemically analysed for the 
expression of TSG-101 exosomal biomarker. As expected, TSG-101 signal 
was found to be positive in both the cell lysate (CL, lane 1) and exosomes 
isolated in two different experiments (EXOs, lanes 2, 3), confirming the 
exosomal origin of isolated particles (Fig. 17B). However, a weak band 
representative of AGO2 protein was observed in both cell lysate and one 
FIGURE 17. Optimization of exosomes isolation by differential ultracentrifugation. 
C2C12 culture medium was subjected to a serial cycles of centrifugations to obtain the 
final pellet (A). Isolated exosomes were biochemically analysed by WB for the 
expression of TSG-101 and Ago2 proteins (B) Exosomes morphology was evaluated by 
transmission electron microscopy (TEM) (C) and their dimensions/concentration was 
analysed by Nanosight Tracking Analysis (NTA) (D). 
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exosome sample, highlighting the occurrence of protein contamination (Fig. 
17B). To evaluate UF-isolated exosome morphology, size and concentration 
we exploited PBS-resuspended particles. TEM analysis revealed the 
presence of cup-shaped vesicles of ˷100 nm (Fig. 17C). However, NTA 
analysis recorded a mean size value of 172.4 nm and a mode size value of 
145.9 nm, thus showing more heterogeneity in the analysed sample than we 
expected and confirming WB data (Fig. 17D). According to our results and 
recently published data [178], even though differential ultracentrifugation still 
represents one of the most performed isolation procedures, it presents many 
limits such as protein contamination and exosomes low recovery.  
Precipitation by Commercial Kits 
We performed exosomes isolation exploiting the Life Technologies Total 
Exosome Isolation Kit from Cell Culture Medium (Fig. 18A).  
 
FIGURE 18. Optimization of exosomes isolation by commercial kits (A). Isolated exosomes 
were biochemically analysed by WB for the expression of TSG-101 and Ago2 proteins (B) 
MVs morphology was evaluated by transmission electron microscopy (TEM) (C) and their 
dimensions/concentration was analysed by Nanosight Tracking Analysis (NTA) (D). 
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The WB analysis of these isolated exosomes outlined the expression of both 
AGO2 and TSG-101 (Fig 18B). 
The Poinceau staining pointed out a marked co-precipitation of BSA together 
with the particles of interest (data not shown), thus highlighting a clear protein 
contamination of the pellet. Also the morphological analysis produced an 
unclear outcome: TEM analysis showed big particle aggregates, preventing 
the possibility to distinguish the precise isolated-particles morphology (Fig. 
18C). NTA displayed the presence of a heterogeneous population, with a 
mean size value of 280.7 nm and a mode size value of 154.1 nm. Calculated 
particle concentration was around 3.3 x 109 particles/ml (Fig. 18D). Even 
though NTA data could suggest a more efficient recovery of exosomes if 
compared to ultracentrifugation procedure, the high level of contamination 
revealed by biochemical, NTA and TEM analysis, stressed out the unknown 
nature of these isolated particles. 
Size Exclusion Chromatography (SEC) 
Nowadays, one of the most emerging techniques for exosomes isolation is 
size-exclusion chromatography (SEC) (Fig. 19A). After the isolation step, we 
executed the biochemical characterization of exosome- enriched fractions. 
WB analysis revealed the expression of TSG-101 marker in fractions 7, 8 
and 9 (lanes F7, F8, F9), as expected, as well as in the cell lysate (lane CL). 
No signal was detected in the void volume, represented by fractions 10 to 12 
sample (lane F10-12). On the contrary, AGO2 expression was positive in the 
cell lysate sample and the F10-12, while it was absent in F7, F8 and F9, 
suggesting the lack of contaminants in exosomes-enriched fractions (Fig. 
19B). Moreover, the Poinceau staining excluded bulk proteins contamination 
in F7, F8 and F9: the BSA band at ˷ 60 KDa was not detected in SEC samples 
(data not shown). However, the microBCA analysis highlighted the presence 
of a very low amount of proteins for each exosome-enriched fraction, with a 
slight decrease from fraction 7 to fraction 9. As it was observed for UF-
isolated exosomes, also SEC-enriched vesicles presented a cup-shaped 
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morphology when analysed by TEM, and dimensions ranging around 100 nm 
(Fig. 19C). NTA and TEM analysis performed on F7, F8, and F9 did not show 
any differences between the three exosomes-enriched fractions.  
 
FIGURE 19. Optimization of exosomes isolation by size exclusion chromatography 
(SEC)(A). Isolated exosomes were biochemically analysed by WB for the expression of 
TSG-101 and Ago2 proteins (B) Fraction 7- enriched exosomes morphology was determined 
by TEM analysis (C) and their dimensions/concentration were analysed by Nanosight 
Tracking Analysis (NTA)(D). NTA analysis was performed also for Fraction 10-12 (E). 
As regards NTA recording, we observed more homogeneous dimensions in 
comparison to previous observations, with a reported mean size value of 
142.2 nm and a mode size value of 130.8 nm. As regards particles recovery, 
NTA showed an amount of particles of about 1.19 x 109 particles/ml (Fig. 
19D). Finally, we tracked by NTA the F10-12 sample; as expected the 
produced graphic showed a very scattered trend demonstrating the presence 
of a heterogeneous population, probably represented by endosomes, 
apoptotic bodies and culture medium- derived bulk proteins, which are eluted 
by qIZON columns immediately after exosomes (Fig. 19E). Finally, SEC was 
proved as the most efficient method to isolate specific MVs. Comparing SEC 
results with those obtained by ultracentrifugation and particles precipitation 
with commercial kits, SEC produced the best recovery of exosomes and the 
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lowest level of protein and other microvesicles contamination. Thus, we 
decided to perform SEC to isolate exosomes from our cells of interest.  
Setting of the proper culture conditions to recover exosomes  
Following C2C12 myoblast seeding, cells were cultured for 72 hours. Cell 
supernatants were harvested at three different time points: 24, 48 and 72 
hours. Simultaneously, an MTT assay was performed to evaluate cells 
proliferation throughout the different time points (Fig. 20A). Images 
representative of cell confluence were captured with an optical microscope 
at 10X magnification. After 24 hours cells showed a confluence of 30-40% 
(Fig. 20B), after 48 hours of 50-60% (Fig. 20C) and after 72 hours the 
confluence was around 80-90% (Fig. 20D). 
We hypothesized that seeding density (number of cells/cm2), and 
consequently the physical distance between cells, may directly influence 
both the amount and features of released exosomes. To this end, for each 
time-point, we isolated exosomes from supernatant collected at different time 
points by SEC. We then evaluated the exosomal concentration and size 
distribution by performing NTA analysis. Recorded graphics showed a more 
homogeneous dispersion of particle dimensions associated to the increase 
of their confluence in vitro.  
At T1 (after 24 hours), exosomes distribution showed a mean value of about 
209.9 nm with a standard deviation (SD) of about 83.9 nm (Fig. 20B’); at T2 
(after 48 hours), the mean value was 158.1 nm and mode value was 141 nm, 
with a SD of about 52.5 nm (Fig. 20C’). NTA data relative to T3 (after 72 
hours) displayed the maximum homogeneity: at this time point microvesicles 
showed homogeneity in size and shape (mean size 150 nm, mode value 145 
nm, SD 12.3 nm)(Fig. 20D’), further ruling out the possibility of other 
microvesicles contamination.  
Therefore, we established this latter condition as the most appropriate to 
recover culture media for exosome isolation.  
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FIGURE 20. C2C12 murine myoblast cell line proliferation curve (A). Cells were seeded at 
40000 cellule/cm2 density. Images, representative of cells proliferation, were captured at 
10X magnification at 3 time-points:  24, 48, 72 hours after cells seeding. (B, C, D). For each 
time-point, NTA analysis of exosomes isolated by SEC was performed (B’, C’, D’). 
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4.3.2 Optimization of exosome isolation from cells growing in 
suspension 
Once investigated the most efficient isolation procedure and the proper cell 
culture conditions to obtain exosomes from adherent cell cultures, we 
focused on particles recovery from cells growing in suspension.  These 
preliminary analyses were performed on RPMI 8226 cell line (multiple 
myeloma- deriving lymphocytes).  
 
FIGURE 21. Optimization of exosomes isolation from culture medium harvested from cells 
growing in suspension. Cells were pelleted by centrifugation and the surnatant was collected 
(A). Isolated exosomes were biochemically analysed by WB for the expression of TSG-101 
and Ago2 proteins (B) MVs morphology was evaluated by transmission electron microscopy 
(TEM) (C) and their dimensions/concentration was analysed by Nanosight Tracking Analysis 
(NTA) (D). 
Once again, following the isolation procedure (Fig. 21A), exosomes were 
analysed by biochemical analysis, NTA and TEM (Fig. 21B, C, D). WB 
revealed a positive band corresponding to TSG-101 protein expression both 
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in RPMI 8226 cell lysate and exosomes isolated by SEC collected in fraction 
7. The negative signal for the expression of Ago2 confirmed the absence of 
exosome contamination (Fig. 21B). Images captured with transmission 
electron microscopy exhibited the presence of particles very similar to those 
previously showed in Figure 19C. Finally, NTA graph recorded a 
concentration of 1,36 x 109 vesicles/ml, a mean size value of 127,5 nm and 
a mode size value of 112,3 nm (Fig. 21D). 
4.4 Isolation and characterization of exosomes from infected 
MDC1C CD133+ blood-derived stem cells and FKRP L276IKI 
satellite cells culture medium 
According to previous observations, demonstrating that FKRP 
glycosyltransferase can be released in vitro by cultured cells, we have 
speculated that FKRP positive expression detected in conditioned medium 
could underline the protein internalization within exosomes, subsequently 
released in vitro from transduced cells. 
Firstly, we established the proper conditions to collect medium from MOI 20- 
infected FKRP L276IKI satellite cells culture: medium was harvested when 
cells reached a confluence of ˷ 80%, after 72 hours in DMEM with exosome-
depleted FBS. Isolation was performed by SEC chromatography, as 
previously described. Figure 22 summarizes data obtained by the 
characterization of infected LV-FKRP L276IKI SCs and CD133+ stem cells- 
derived exosomes. NTA graphs show exosomes dimensions and 
concentration, confirming the presence of exosome similar particles. MOI 20 
infected MDC1C CD133+ blood-derived exosomes displayed a mean size 
value of 154.1 nm and a mode size value of 128.2 nm (SD 64.4 nm) (Fig. 
22A), with a particle concentration of about 1.17 x 109 particles/ml), whereas 
MOI 20- infected FKRP L276IKI SCs- isolated exosomes exhibited a mean 
size value of 166.6 nm and a mode size value of 139.9 nm (SD = 71.5). The 
particle concentration was about 1.79 x 109 particles/ml (Fig. 22B). FACS 
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analysis confirmed the exosomal nature of isolated particles. The 
immunophenotyping analysis underlined the positivity of CD63 and CD81 
tetraspanins in both MOI 20- infected MDC1C CD133+ - secreted exosomes 
(92,2% exosomes were positive for CD63, 82,5% for CD81) (Fig. 22C), and 
in MOI 20- infected FKRP L276IKI SCs- derived vesicles (88% exosomes 
positive for CD63, 89% for CD81) (Fig. 22D). 
 
 
FIGURE 22. Nanosight Tracking Analysis (NTA) of MOI 20 infected MDC1C CD133+ stem 
cells- secreted exosomes (A) and FKRP L276IKI SCs (B). Plots show the mean value of 3 
recordings run for each sample. FACS analysis of MDC1C CD133+ stem cells- (C) and 
transduced FKRP L276IKI SCs MOI 20-secreted vesicles (D). Each study included not less 
than 100000 events. 92,2% of CD133+-secreted exosomes were positive for CD63 
tetraspanin, 82,5% for CD81; 88% of SCs- derived exosomes were positive for CD63 and 
89% for CD81+. Magnified image of TEM micrograph of MOI 20- infected MDC1C CD133+ 
stem cells- secreted exosomes (mean value 92,7 nm ± 39,5 nm SD) (E) and FKRP L276IKI 
satellite cells (mean value 109 nm ± 46,3 nm SD)(F). NIH ImageJ software was exploited to 
measure exosome diameters. Scale bar, 200 nm. WB analysis of FKRP,  AGO2 and FKRP 
proteins expression in MOI 20 infected MDC1C CD133+ stem cells- (MOI 20 INF MDC1C 
CD133+ EXOs, lane 2) and MOI 20 FKRP L276IKI SCs- (MOI 20 INF L276IKI SCs EXOs, 
lane 4) secreted exosomes. MOI 20 infected CD133+ blood-derived cell lysate (MOI 20 INF 
MDC1C CD133+, lane 1) and MOI 20 infected SCs lysate (MOI 20 INF L276IKI FKRP, lane 
3) were loaded as positive controls. 
Transmission electron microscopy (TEM) images reported the presence of 
particles exhibiting a cup-shaped morphology (Fig 22E, F). Overall, both 
exosome populations displayed similar size and morphology (MOI 20- 
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infected MDC1C CD133+ stem cells exosomes: 92, 7 nm ± 39,5 nm SD; MOI 
20- infected FKRP L276IKI SCs- secreted exosomes: 109 nm ± 46,3 nm SD). 
WB analysis was performed on both MOI 20- infected MDC1C CD133+ and 
FKRP L276IKI satellite cell lysates (MOI 20 INF CD133+ MDC1C cells and 
MOI 20 INF L276IKI FKRP SCs, respectively lane 1, 3) and corresponding 
secreted exosomes (MOI 20 INF CD133+ MDC1C EXOs and MOI 20 INF 
L276IKI FKRP SCs EXOs: lanes 2, 4 respectively).  
A positive signal at ˷ 60 KDa was observed, demonstrating exogenous FKRP 
wild-type expression in both infected cell population lysates and released 
exosomes.Ago2 positive staining (90KDa) in cell lysates and negative 
expression in exosome samples prompted us to exclude the presence of 
contaminants during the isolation procedure. On the contrary, TSG-101 
positive expression (49 KDa), authenticates the specificity of FKRP as an 
exosome cargo (Fig 22G) (13).  
4.5 In vivo engineered satellite cells transplantation 
According to previous results, we transplanted MOI-20 engineered satellite 
cells into the right TAs of 1-year-old FKRP L276IKI mice. Firstly, we aimed at 
defining if engineered satellite cells autologous transplantation could allow 
transplanted cells fusion to the host muscle tissue and to prove the recovery 
of wild-type exogenous FKRP protein and the consequent α-dystroglycan 
glycosylation. 
Moreover, we aimed at observing an amelioration of the dystrophic 
phenotype by evaluating transplanted mice endurance. Finally, we focused 
on the investigation of an exosome-mediated FKRP systemic effect, to 
determine an overall rescue of the glycosyltransferase protein and its 
function in α-DG glycosylation at distant sites. 12 months- old FKRP L276IKI 
mice were divided into three groups and injected with an increasing number 
of LV-hFKRP engineered cells (35x103, 75x103 and 100x103 cells). Not-
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transplanted FKRP L276IKI mice were exploited as negative controls for the 
following analysis. 
4.5.1 Immunobiochemical and Immunofluorescent analysis of injected 
muscles  
Figure 23 A, B, C show a positive signal at ˷ 60 KDa, representative of 
exogenous FKRP expression in all injected right TAs (lanes +), but 
highlighting an increasing trend of protein rescue on the strength of the 
number of injected cells. 35x103 engineered satellite cells- L276IKI 
transplanted mice (N= 4 mice) showed a weak FKRP positive signal (Fig 
23A, lanes #1, #2, #3, #4), while the transplantation of 75x103 engineered 
satellite cells (N= 5 mice) outlined a stronger signal (Fig. 23B, lanes #5, #6, 
#7, #8, #9), which was found to be comparable to the one obtained with 
100x103 engineered cells injection (N= 4 mice) (Fig. 23C, lanes #10, #11, 
#12, #13).  
Meanwhile, we checked the exosome-mediated systemic effect of 
transplantation by performing WB analysis in injected mice contralateral TAs 
(lanes -). FKRP signal was found to be increased between 35 and 75x103 
cell doses and comparable between 75 and 100x103 injected mice groups. 
Not-injected FKRP L276IKI TAs (lane NI) and C57BL TAs (lane CTR+) were 
exploited as negative and positive controls. 
Since FKRP-STEM antibody is unable to detect the endogenous mutated 
FKRP protein [120], there was no FKRP signal in not transplanted FKRP 
L276IKI TA analysed muscles, whereas the wild-type form of C57BL mouse 
was distinctly distinguishable. Interestingly, the FKRP-STEM antibody 
revealed a faint positive signal representative of exogenous FKRP in the 
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contralateral TAs muscles, thus sustaining the first proof of a systemic 
exosome-mediated FKRP protein distribution (Fig. 23A, B, C). 
FIGURE 23. WB analysis of 1-year-old FKRP L276IKI mice transplanted muscles. Mice were 
transplanted with 35x103 (N=4, lanes #1, #2, #3, #4), 75x103 (N=5, lanes #5, #6, #7, #8, #9) 
and 100x103 (N=4, lanes #10, #11, #12, #13) FKRP L276IKI SCs cells infected with MOI 20. 
Either transplanted (+ lanes) and contralateral (- lanes) TAs were evaluated for FKRP 
protein positivity (A, B, C). Immunophenotyping analysis of α-DG glycosylation was 
investigated in transplanted TA (lanes +) (C, D). N=2 not transplanted FKRP L276IKI TAs 
(lanes NI) were considered as negative controls (A). C57BL TA (lane CTR+) was loaded as 
positive control (C). 
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Transplanted TAs were also biochemically evaluated for α-DG glycosylation 
rescue. As previously mentioned, α-DG is a heavily glycosylated protein: 
even though its expected molecular weight (MW) is around 72 KDa, it looks 
like a broad smear on western blot bands, with an apparent MW of 156 KDa 
in skeletal muscle. α-DG glycosylation is represented by the smear height. 
35 x 103 engineered SCs transplantation didn’t produce a noticeable 
difference in α-DG glycosylation in comparison to not transplanted dystrophic 
muscles (Fig. 23D; lanes #1, #2, #3, #4, NI). On the contrary, 75x103 and 
100x103 cells injection, by determining a significant rescue of FKRP function, 
were able to elicit an appreciable increase in α-DG glycosylation, as shown 
by the more extended smeared band on the blot. (Fig. 23D, E; lanes #5, #6, 
#7, #8, #9, #10, #11, #12, #13). 
Immunofluorescence staining (IF) showed the recovered expression of 
FKRP in all engineered SCs –injected FKRP L276IKI mice. The 35x103 
injected mouse group exhibited irregular sarcolemmal positive signal of wild-
type FKRP, limited to a few myofibers, whereas 75x103 and 100x103  doses  
revealed a more regular and diffused sarcolemmal fluorescent staining (Fig 
23B, C, D). A patchy positive staining of a perinuclear FKRP expression was 
also detected in some muscle fibers (Fig. 24C and D enclosures, white 
arrows). As the lentiviral vector was produced with two distinctive promoters 
for the expression of the wild type FKRP insert and GFP-Puro dual marker, 
FKRP and GFP were not transduced into a single peptide but produced two 
independent transcripts.  
As expected, GFP signal was identified as diffused in myofibers cytoplasm 
with a more intense staining in muscles transplanted with 75 and 100x103 
cells (Fig. 24B’, C’, D’), rather than in 35x103 cell dose. Interestingly, both 
some GFP+ and some GFP- muscle fibers presented with FKRP 
sarcolemmal positive expression. As IF was performed exploiting FKRP-
STEM antibody, not-injected FKRP L276IKI mice were used as negative 
controls and did not show any positive staining (Fig. 24A). Afterwards, we 
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also performed an IF staining of α-DG. As expected, untreated FKRP L276IKI 
mice TAs exhibited a moderate and variable positive signal of alpha-DG 
glycosylation, (Fig 24A’’). On the other hand, transplanted muscles showed 
a more intense positive signal, proportional to the cell dose increase (Fig 
24B’’, C’’, D’’). These observations confirmed that FKRP recovered 
expression is strictly linked to the level of functionally glycosylated α-DG in 
the injected FKRP L276IKI mice.  
 
FIGURE 24. Immunofluorescent analysis of serial sections of FKRP L276IKI not injected 
(FKRP L276IKI NI) and FKRP L276IKI TAs injected with 35x103 , 75x103 , 100x103 
engineered satellite cells (FKRP L276IKI 35K, 75K, 100K). Exogenous FKRP staining (in red) 
(A, B, C, D) was performed on tissue sections. Fig. C and D inserts display a magnification 
of exogenous FKRP perinuclear staining. GFP protein expression (in green) (A’, B’, C’, D’) 
was evaluated to identify the protein expression and localization. Merge of FKRP and GFP 
is also shown (A’’, B’’, C’’, D’’). The staining of α-DG glycosylation was also performed (in 
red) (A’’’, B’’’, C’’’, D’’’). Nuclei were counterstained with Dapi. Images were captured at 40X 
magnification. Scale bar = 75 µm 
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FIGURE 25. Hematoxylin and eosin staining of transplanted FKRP L276IKI TAs. Tissue 
sections from TA of positive control C57Bl mouse (A, A’), not transplanted (B, B’) and 
transplanted FKRP L276IKI mutant mice (C, C’). Scale bar = 200 µm (A, B and C), 50 µm (A’, 
B’, and C’). C and C’ show TA muscles from FKRP L276IKI mice transplanted with 75x103 
LV-FKRP L276IKI satellite cells. Quantification of centrally nucleated myofibers. The 
percentile of centrally nucleated fibers was defined as the percentage of centrally nucleated 
fibers versus the total counted myofibers (D). 
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It is well known from literature that the FKRP L276IKI   mouse model exhibits 
a mild dystrophic phenotype, resembling the LGMD2I dystrophy. Of note, 
dystrophic muscles present with myofiber cycles of degeneration and 
regeneration, fiber size variability and adipose/ fibrotic infiltrates in the later 
stages of the disease progression. 
The analysis of muscle morphology was performed by hematoxylin and eosin 
(H&E) staining (Fig. 25). Our outcomes confirm FKRP L276IKI mild dystrophic 
phenotype, with a comparable pathological morphology between not 
transplanted TA (Fig. 25B, B’) and transplanted TA muscles (Fig. 25C, C’), 
showing just a slight decrease, not statistically significant, of the percentage 
of centrally nucleated myofibers in injected mice (Fig. 25D). 
4.5.2 Exosome-mediated systemic distribution of FKRP protein 
To further reinforce the evidence that FKRP+ exosome release by infected 
SCs produces therapeutic effects at distal compartments, we aimed at 
demonstrating these exosomes trafficking in the bloodstream.  
Exosomes were isolated from plasma samples of all the injected mice by 
SEC chromatography and biochemically analysed for the presence of 
exogenous FKRP.  
At first, we characterized FKRP protein expression in the unprocessed total 
plasma, SEC exosomes-enriched elution fractions and exosomes-depleted 
plasma. A 60KDa band corresponding to FKRP was detected in total plasma 
and exosome elution fractions, whereas no signal was observed in exosome-
depleted plasma (Fig. 26).  
Indeed, it is likely that the systemic trafficking of exogenous FKRP is only 
mediated by release of exosomes, that act as carriers in the bloodstream. 
Following this preliminary analysis, all FKRP L276IKI isolated plasma 
exosomes were analysed for the glycosyltransferase expression in order to 
compare the protein expression level in the three groups of injection. 
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FIGURE 26. Western blot images of plasma and plasma isolated exosomes from injected 
FKRP L276IKI mice. Representative WB analysis of FKRP L276IKI mice injected with 75K 
transduced FKRP L276IKI SCs: total plasma (unprocessed), plasma-derived exosomes 
isolated by SEC (7 and 8 exosome elution fractions), and exosome-depleted plasma were 
evaluated for the expression of FKRP protein and TSG-101 exosomal marker expression. 
Loaded samples (lanes 35K, 75K, 100K) exhibited a positive signal at 
approximately 60 KDa, which appeared more intense as the number of 
transplanted cells increased. As expected by previous results, FKRP-STEM 
antibody didn’t detect any signal in not-injected FKRP L276IKI plasma 
exosome sample (lane NI). TSG-101 protein (49 KDa) was found to be 
positive in all the loaded samples (Fig. 27A), highlighting the efficiency of 
SEC in isolating exosomes from plasma. Plasma-derived exosomes were 
examined by transmission electron microscopy (TEM); TEM images showed 
cup-shaped particles characterized by a mean size value of 90 nm ± 36,6 nm 
SD (Fig. 27B); NTA revealed a mean size value of 142,2 nm, a mode size 
value of 130,8 nm and a concentration of 1,13x109 particles/ml (Fig. 27C). 
We evaluated the exosome-mediated systemic effect of engineered satellite 
cells intramuscular transplantation in the hearts of all transplanted mice, 
since it represents one of the most compromised muscle in the FKRP L276IKI 
animal model [120]. Firstly, we measured the exogenous wild-type 
expression of FKRP, than we evaluated the consequent restoration of α-DG 
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physiological glycosylation levels. As observed in contralateral TAs samples, 
all transplanted mice hearts were positive for wild-type exogenous FKRP 
expression and displayed a positive band at 60 KDa, directly proportional to 
the increased cell dose. A plateau between 75x103 and 100x103 injected 
mice (Fig 27D) is still clearly visible in line with what observed for TAs. The 
specificity of the FKRP-STEM antibody produced a positive band in C57BL 
mouse heart, showing an undoubted wild-type expression of FKRP (lane 
CTR+), whereas the not-injected (lane NI) mouse heart didn’t exhibit any 
detectable signal. No differences were evidenced among the three cell doses 
concerning alpha- DG glycosylation. However, a significant glycosylation 
increase, detectable by the higher smeared band, was noticeable between 
the not injected mice and C57BL mouse heart (Fig. 27D, E).
 
FIGURE 27. WB analysis of exosomes isolated from plasma. Vesicles were sedimented 
from the plasma of 1-year old FKRP L276IKI mice transplanted with 35, 75, and 100x103 
engineered FKRP L276IKI SCs and not-transplanted FKRP L276IKI mice. Exosomes were 
characterized for the expression of FKRP and TSG-101 proteins (A). TEM image 
representing plasma-derived exosomes morphology (mean size 90 nm ± 36.6 nm SD).Scale 
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bar: 200nm (B). NTA graph representing plasma- exosomes concentration and dimensions 
(C). WB analysis of FKRP L276IKI engineered SCs-transplanted mice hearts. FKRP (D) and 
α-DG glycosylation (E) positive signals were evaluated considering N=4 mice transplanted 
with 35x103 (#1, #2, #3, #4), N=5 with 75x103 (lanes #5, #6, #7, #8, #9), and N=4 with 
100x103(lanes #10, #11, #12, #13) engineered SCs. Not injected FKRP L276IKI and C57BL 
heart muscle were loaded as negative and positive controls (lane NI, CTR+)(D, E). 
4.5.3 In vitro modelling of dynamic FKRP-carrying exosomes tracking 
We exploited a miniaturized bioreactor to show in vitro exosome flow and to 
mimic the in vivo exosome kinetics, trafficking dynamic, timing of distribution 
and fusion to targeted tissues. Exosomes, released by PKH26+ FKRP 
L276IKI SCs infected with MOI 20, travelled along a microfluidic channel to 
reach target- FKRP L276IKI SCs cells.  Fig. 28B showed a diffused GFP 
signal in cell cytoplasm, which confirmed the correct infection by lentiviral 
MOI of 20. 
 
 
FIGURE 28. Schematic representation of the bioreactor. The bioreactor is composed of 
three scaffolds (6x3 mm, 400µm thickness, 0,6 µm fiber pore size), connected by 
microfluidic channels. PKH26+ FKRP L276IKI satellite cells were seeded on the first scaffold 
and secreted PKH26+ exosomes, able to reach not-infected SCs seeded on the second 
scaffold, running through a microfluidic channel connecting the two chambers (A). IF 
analysis of infected FKRP L276IKI SCs; GFP signal was detected in the cell cytoplasm (B).  
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PKH26- labelled FKRP L276IKI SCs cells (C). PKH26- exosomes secreted by PKH26- 
labelled FKRP L276IKI SCs cells (D). Images were taken at 100X magnification. 
Immunofluorescent analysis of not-infected SCs seeded on the second scaffold. PKH26+ 
exosomes- (in red) targeted SCs recovered the expression of wild-type FKRP (in green). 
Nuclei were stained with Dapi (E, F). 
Similarly, Fig 28C proved the optimal FKRP L276IKI SCs membrane staining 
by PKH26 marker, guaranteeing PKH26+ exosome secretion. PKH26+ 
exosomes were followed for 8 hours within the microfluidic channels by 
confocal fluorescent microscopy at 100X magnification (Fig. 28D). FKRP 
L276IKI SCs- released exosomes were able to reach the not infected cell 
population, where they fused, transferring exogenous FKRP protein and 
favouring its expression in mutant receiving cells.  In order to verify the 
occurrence of exosome-mediated FKRP convey, IF analysis was performed 
on the not infected FKRP L276IKI SCs. The staining showed an exogenous 
FKRP positive signal (in green) (Fig. 28E, F), mainly restricted to those cells 
in which exosome fusion had occurred (in red) (Fig. 28E, F). 
4.5.4 Functional Analysis 
To define if the local and the systemic rescue of exogenous wild-type FKRP 
protein expression in engineered SCs-transplanted FKRP L276IKI would 
determine an increased skeletal muscle force and cardiac muscle 
functionality, we evaluated the animals performance with two functional tests: 
treadmill and rotarod. Treadmill outcomes demonstrated that untreated 
dystrophic mice found very hard to achieve the conclusion of the 
experimental sets. FKRP L276IKI mice appeared to adapt to the exercise after 
the starting training sitting (-T7), becoming familiar with the treadmill. They 
were able to run for the first week (T7), despite they constantly ran below 400 
meters with a running time of about 1000 seconds. After two weeks (T14), 
untreated mice became incapable to maintain previous performances, 
exhibiting acute fatigue. Conversely, engineered SCs- transplanted mice 
performance was dependent on the number of injected LV-FKRP satellite 
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cells. Overall, FKRP L276IKI injected mice displayed an increase in running 
distance outputs compared both to the pre-injection measured performance 
and to not transplanted animal outcomes. Of note, all injected mice rapidly 
displayed the positive effects of cell transplantation, demonstrating an 
increased tendency, produced immediately after the cells transplantation, 
although the 75K group showed a more pronounced and remarkable 
amelioration. 75K group seemed to produce a long-lasting increase of both 
the distance and time of running, presenting a leap from 403 meters 
(averaged running distance) at T0 to 698.7 meters at T7, and up to 724 
meters a T14. The tendency of the 75x103 engineered cells transplanted 
mice running time went through a rapid increase in the first week after 
transplantation (T0 averaged running time 779.2 seconds vs. T7 average 
running time 2827 seconds), settling after two weeks (T14) at ˷ 2411 seconds. 
100K- transplanted mice group treadmill test outputs exhibited a more 
moderate increasing tendency, reaching the maximum distance and time at 
T7, followed by a plateau level at T14 (averaged running distance: 547 
meters; averaged running time: 1898 seconds) (Fig. 29A, B). 35K cells- 
treated FKRP L276IKI mice demonstrated instead more pronounced inter 
individual differences with a slow diminution of the endurance results. 
Although a reported trend towards an increased running distance and time 
within T7, at T14 the 35K group degenerated and produced performances 
comparable to those recorded pre-injection (averaged running time: 1315 
seconds; averaged running distance: 301 meters). The averaged coefficients 
of variations at T14, were -86% for not transplanted FKRP L276IKI mice, -
18% for FKRP L276IKI injected with 35x103 cells, and +95% and +62% 
respectively for FKRP L276IKI transplanted with 75x103 and 100x103 LV-
FKRP infected L276IKI SCs.  
Rotarod functional results confirmed the poor outcomes of not transplanted 
mice, as well as the cell dose-dependent functional amelioration of the 
transplanted FKRP L276IKI mice. On the rotarod, untreated FKRP L276IKI 
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mice rarely run for 300 seconds. Even though the running distance was 
comparable between –T7 and T7 time-points, it began to decrease 
significantly within T7 and T14. 35x103 injected group showed a remarkable 
amelioration within T7, after which the running time was maintained almost 
unchanged throughout the experimental settings (averaged running time at 
T14: 377 seconds). Likewise, 75K and 100K groups underwent amelioration 
in running time throughout the first week after the injection (averaged running 
time at T7: 418 seconds and 398 seconds, respectively) (Fig. 29C). For both 
groups, although there were further improvements of the endurance reported 
after two weeks from the transplantation (T14) (75x103 transplanted mice, 
averaged running time: 429 seconds; 100x103 transplanted mice, averaged 
running time: 411 seconds) the positive tendency decreased, reaching a 
steady point.  
 
FIGURE 29. Mice endurance was determined by Treadmill (A, B) and Rotarod tests (C). 
N=5 C57BL mice, N=6 not transplanted, N=4 35x104, N=5 75x104, and N=4 100x104 MOI 
20- infected FKRP L276IKI satellite cells- transplanted mice have been evaluated at different 
time-points: a week before the cell transplantation (7 days pre-INJ), the day of cells injection 
(T0), and one and two weeks (T7, T14), before the mice sacrifice. Values are means ± SD. 
***, p value <0.05 was considered statistically significant. 
 
For both Treadmill and Rotarod tests, transplanted and not transplanted 
FKRP L276IKI mice outcomes were compared to the performances of C57Bl 
control mice (N=5; treadmill averaged running distance and time: 710 meters 
and 2788 seconds; rotarod averaged running time: 437 seconds). Only the 
75K group was able to exhibit an improved performance comparable to the 
one of C57Bl mice at T7 and T14 (Fig. 29A, B, C).  
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5 DISCUSSION 
α-Dystroglycanopathies are a group of inherited disorders, which arise from 
mutations occurring in various genes encoding for glycosyltransferase 
enzymes. α-DG is a glycoprotein localized on muscle peripheral membranes 
[87] [179] that undergoes post-translational modifications: N-glycosylation, 
mucin-type O-glycosylation, O-mannosylation, and the addition of an 
identified phosphorylated O-mannosyl glycan. Mutations occurring in 
glycosyltransferases involved in O-linked glycosylation usually lead to α-DG 
hypoglycosylation and a consequent disruption of the protein binding with 
laminin, neurexin, and agrin. α- dystroglycanopathies present a wide range 
of phenotypes, ranging from severe forms of congenital muscular 
dystrophies (CMDs), with brain and eye involvement, to the milder limb girdle 
muscular dystrophies (LGMD) [99]. Among all the genes found mutated in α-
dystroglycanopathies, we have narrowed down our attention on fukutin 
related protein (FKRP) that acts in tandem with Fukutin as a transferase of 
ribitol 5-phosphate (Rbo5P) [117]. Mutations in FKRP gene, encoding for the 
glycosyltransferase fukutin-related protein, determine the occurrence of 
untreatable limb-girdle muscular dystrophy 2I and MDC1C. To date, no 
resolving therapies have been found for these disorders. Only the approach 
based on adeno-associated Virus 9 (AVV9)-FKRP treatment represents a 
promising cure for all the pathologies caused by a single-gene disruption, but 
it is limited by risks associated to viral toxicity [180], and it does not sustain 
muscle regeneration. Therefore, we have successfully evaluated the 
possibility to transplant gene- corrected stem cells, possessing both 
myogenic differentiation abilities and the capability to restore functional α-DG 
glycosylation by expressing wild type isoform of FKRP, for overcoming gene-
therapy related limits. Moreover, starting from recent literatures employing 
viral or non-viral methods to engineer the parental cells to secrete modified 
exosomes, we have demonstrated that LV-FKRP engineered stem cells were 
able to release exosomes carrying the FKRP glycosyltransferase. The 
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widespread in vivo deployment of exosomes carrying FKRP, continuously 
released from intramuscularly transplanted engineered stem cells, 
determined a general and boosted therapeutic effect in FKRP L267IKI animal 
model.  
5.1 In vitro engineering of MDC1C CD133+ blood-derived stem 
cells 
We have previously demonstrated that human blood-derived progenitors 
expressing the CD133+ marker possess in vivo myogenic potential [181]. 
Starting from successful and feasible results previously carried out from our 
group, we infected CD133+ blood-derived stem cells isolated from a MDC1C 
patient with a lentiviral vector carrying the wild-type isoform of human FKRP 
gene. This way, the expression of the wild-type FKRP was recovered in vitro 
without dose- related lentiviral-induced toxicity. In fact, none of the tested 
MOI of infection (MOI 5, 10, 20) produced a deleterious outcome in CD133+ 
proliferation curve. Overall, the lack of cytotoxic effects on MDC1C patient’s 
cells, even at high LV-MOI, confirmed the reliability and feasibility of this 
strategy towards clinical relevant applications 
5.2 In vitro engineering of L276IKI satellite cells 
We aimed to carry out in vivo experiments to definitively prove the efficiency 
of stem cell and gene combined approaches in restoring a LGMD2I 
phenotype. Thus, we performed an autologous transplantation of engineered 
myogenic cells into the TAs muscles of FKRP L267IKI mice, resembling 
LGMD2I muscular dystrophy. The requirement of an autologous 
transplantation was due to the absence of an immunodeficient FKRP 
mutated animal model. For this purpose, we isolated satellite cells from new 
born FKRP L276IKI mice and we infected them with the lentiviral vector. To 
avoid concerns related to LV- mediated cytotoxicity and myogenic capacity 
impairment, we have tested MOI of infection: 10, 20 and 40. For each 
109 
condition, no statistically significant differences were observed in terms of 
cell proliferation and fusion index in comparison to not-infected dystrophic 
satellite cells.  
These results took distance from recent finding suggesting a dose-
dependent toxicity of rAAV-FKRP vector, characterized by a decrease of α-
dystroglycan glycosylation directly proportional to the AAV dose of injection 
[182]. Similarly, we wanted to exclude the chance to induce a detrimental α-
DG hyperglycosylation that has been demonstrated to worsen the dystrophic 
phenotype in FKRPMD animal model [105].  
Throughout WB experiments, we showed that LV- induced FKRP expression 
displayed an increasing trend between MOI 10 and 20, while MOI 40 seemed 
to represent a steady point, leading to FKRP expression plateau; also the 
amount of α-DG glycosylation was similar between MOI 20 and 40, thus 
ruling out the risk of an induced -DG hyperglycosylation. These evidences 
suggested that infection with MOI 20 was able to restore the FKRP level 
necessary to saturate glycosylation sites of alpha-DG and to recover its 
physiological function and led us to choose MOI 20 for the infection of both 
the two cell populations. 
For all the WBs and immunofluorescence analysed, we have utilized the 
FKRP-STEM antibody to specifically identify the exogenous wild-type protein 
from the endogenous mutated one [120].  
Even though the mutation occurring in the L276IKI FKRP mouse model is a 
missense mutation, leading to an amino acidic change without any 
consequence on the protein expression, the amino acidic change alone 
compromises the protein recognition [120]. It is likely that the antibodies 
binding sites on the endogenous FKRP may be at least partially masked, 
possibly by other proteins, in a complex essential for the glycosyltransferase 
activity [183]. FKRP-STEM antibody allowed the detection of only the 
exogenous FKRP, thus undoubtedly demonstrating the successful LV-
mediated rescue of the glycosyltransferase. 
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5.3 Engineered SCs-derived FKRP-carrying exosomes allow a 
systemic distribution of the glycosyltransferase after cells 
intramuscular transplantation 
The attention on FKRP role as a glycosyltransferase and the recent evidence 
of circulating glycosyltransferases exerting their functional role at distant 
compartments [141], prompted us to investigate the hypothesis of a cell-
mediated secretion of FKRP both in vitro, in cell culture medium, and in vivo 
in the bloodstream [115]. Previous studies had shown that fukutin protein 
(FKTN) and FKRP might be released in vitro by cells [115, 184]. However, 
they did not explained whether these glycosyltransferases were released 
either in a free form or enclosed within vesicles. Exosomes are a 
homogeneous population of extracellular microvesicles well- known for their 
capability to convey genetic material (mainly protein and miRNA cargos) to 
target cells, even at distant compartments by circulating in the bloodstream. 
Beyond genetic information [185], exosomes can also vehicle enzymes: 
kinases, phosphatases, and glycosyltransferases. Given that, we considered 
that cell- related FKRP release could be mediated by exosomes [114]. To 
prove this evidence, we aimed at optimizing the process of exosome isolation 
from engineered cells, both MDC1C CD133+ blood derived stem cells and 
LGMD2I- derived satellite cells. We compared three common exosomal 
isolation procedures: differential ultracentrifugation (UC), commercial kits 
and size exclusion chromatography (SEC). To examine the quality of isolated 
particles we biochemically evaluated the expression of TSG-101. Moreover, 
we investigated particles morphology, size and concentration by TEM 
microscopy and NTA analysis. Even though it is well- known from literature 
that exosomes dimensions usually range between 30 and 100 nm, all the 
analysed samples presented slightly bigger dimensions. We suggest that 
particles may aggregate during the isolation procedure, thus NTA recognizes 
an aggregate as a single particle during the recording step. Moreover, it 
calculates particles dimension taking in account their hydrodynamic radius. 
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This evidence may also explain the difference between TEM and NTA 
results. In line with exosomal isolation procedure literature, we found out that 
differential ultracentrifugation, beyond being highly time-consuming [186], 
allowed to isolate heterogeneous exosomes with significant overlapped 
dimensions and extracellular microparticles contamination. 
Commercial kits, on the contrary, were extremely less time-consuming and 
they were able to recover high amounts of vesicles starting from a little 
amount of material. However, even this procedure was affected by both 
proteins and other MVs contamination. 
Overall, we considered SEC as the most performing technique, determining 
an efficient and homogeneous exosome recovery without extracellular 
vesicle contamination. We have also found out that collecting supernatants 
that have been in contact with 70-80% confluent cells for 72 hours could be 
considered the optimal condition for achieving high exosomal number and 
size- homogeneity. Even though the underlying reasons have to be further 
investigated, the homogeneity of exosome subpopulations is likely related to 
their secretion from cell cycle-synchronized cells. Once defined the most 
performing isolation procedure and cell culture condition, we proceeded to 
isolate exosomes from MOI 20- infected MDC1C CD133+ cells and FKRP 
L276IKI satellite cells. WB analyses confirmed for both cells the presence of 
exosomes expressing TSG-101 typical marker and FKRP [114], suggesting 
that in vivo exosomes might equally traffic and deliver glycosyltransferase to 
receiving cells. To investigate the in vitro cell- to cell transmission of systemic 
exosome FKRP, mimicking exosomes kinetics and timing of distribution, we 
took advantage of a miniaturized microfluidic bioreactor. This system allows 
to seed two cell populations in two independent chambers, connected by a 
microfluidic channel. The presence of an optical transparent tube connecting 
the chambers guaranteed the observation of FKRP- enriched exosomes flux 
from engineered FKRP L276IKI SCs on one side (exosomal source), to not 
infected FKRP L276IKI cells on the other side (target cells). The selective 
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uptake of exosomes was ensured by a unidirectional medium flow, mimicking 
the bloodstream directing exosomes release from injected TAs to distal body 
tissues. By exploiting this miniaturized microfluidic system, we confirmed that 
exogenous wild-type FKRP can be continuously delivered by exosomes 
towards receiving cells, where they randomly fuse and induce a fast 
expression of functional wild-type exogenous FKRP protein. 
To highlight the in vivo function of FKRP-carrying exosomes and define the 
potential clinical application of a combined gene- and cell- based therapy, we 
carried out in vivo experiments. Firstly, we intramuscularly transplanted 
FKRP L276IKI mice with three increasing doses of LV-FKRP engineered 
L276IKI satellite cells. WB analysis performed on injected TAs proved the 
successful recovery of exogenous wild-type FKRP protein expression. 
Moreover, the observed increase in α-dystroglycan glycosylation confirmed 
FKRP recovered glycosyltransferasic function. Both FKRP and α-DG 
showed a cell-dose dependent effect in the injected FKRP L267IKI TAs: 
35x103 engineered FKRP SCs determined a weak FKRP recovery in injected 
TAs, which was found to be insufficient to determine a significant increment 
of alpha-DG glycosylation; 75x 103 and 100x 103 satellite cells injection 
doses favoured a significant FKRP positive signal and, consequently, an 
enhancement of alpha-DG glycosylation. 
Actually, these results suggest the existence of a functional window for an 
efficient rescue of FKRP expression and its recovered role in α-DG 
glycosylation. The comparable outcomes between 75x 103 and 100x 103 
could be due to the lower survival of intramuscular transplanted cells at high 
density, so that the number of functional cells did not change significantly 
between the two conditions. Moreover, also the biochemical analysis 
performed on contralateral TAs revealed a cell dose-dependent expression 
of exogenous FKRP, suggesting a first evidence of an exosome-mediated 
transfer of the glycosyltransferase to distal compartments. As for 
contralateral TAs α-DG glycosylation, the performed biochemical analysis 
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showed no significant differences among the three groups of injection and 
not-injected TAs (data not shown). We hypothesize that the recovery of 
FKRP expression in these sites is not sufficient to produce an evident 
increase of the glycosyltransferase functionality and, consequently, α-DG 
glycosylation. 
Unless recent published studies have localized FKRP glycosyltransferase 
within the Golgi, the endoplasmic reticulum (RE) or, alternatively, as punctate 
dots diffused in the cytoplasmatic compartment of myofibers [9, 110, 111], IF 
analysis performed on injected FKRP L276IKI TAs revealed a specific positive 
signal at the sarcolemma. This observation confirmed previous studies 
showing FKRP co-localization with α-dystroglycan [114], suggesting a 
precise function of the glycosyltransferase in the DCG complex and 
consequently in normal muscle function. Interestingly, we detected two 
different stainings: one consisting in FKRP+ sarcolemma of cytoplasm GFP 
negative muscle fibers and another one detecting cytoplasm GFP+ fibers, 
with perinuclear FKRP+ cells. These results highlighted two alternative 
mechanisms of the glycosyltransferase expression: the first one determined 
by engineered satellite cells fusion to receiving myofibers and the second 
one mediated by exosomes release. The cellular and molecular mechanisms 
determining exosomes fusion to the plasma membrane of specific target cells 
are still undetermined, although the events favouring their interactions are 
starting to emerge. Once secreted, exosomes may interact with specific 
adhesion molecules on target cells plasma membrane, activating specific 
intracellular pathways, they may directly associate and fuse to target cells 
plasma membranes, or alternatively they may undergo a cell uptake via the 
endocytic pathway. These two last described mechanisms, ensure the 
release of exosome luminal cargo molecules to the cytosol of target cells. On 
the basis of this knowledge, FKRP staining on transplanted TAs mirrors the 
direct fusion of vesicles to plasma membrane, as demonstrated by the 
localization of a positive signal around muscle membranes. 
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Additionally, we found TSG-101 positive FKRP-enriched exosomes 
circulating in all transplanted FKRP L276IKI mice bloodstream. Of note, FKRP 
signal was detected in the unprocessed plasma sample and exosome-
enriched elution fractions, but no band was observed in the exosomes-
depleted plasma. Thus, exosomes seemed to act as unique carriers of 
exogenous FKRP in the bloodstream and promoters of a general 
improvement of muscles in FKRP L276IKI transplanted mice. By comparing 
the plasma-derived exosomes isolated from the three groups of injection, we 
were also able to define a cell-number dependent effect of FKRP expression. 
Since heart is one of the most compromised tissues in the FKRP L276IKI 
animal model [120], causing a low endurance and performance for exercise, 
exosome-mediated FKRP expression and function were evaluated in 
intramuscularly transplanted FKRP L276IKI mice hearts. FKRP positive signal 
as well as α-DG increased glycosylation observed exosome-mediated 
recovery of exogenous FKRP even at distal compartments and underlined 
once again a cell-dose dependent effect. Of note, exogenous FKRP was 
found to be more expressed in mice hearts than contralateral TAs. 
Despite the increase of α-DG glycosylation observed in the hearts, the 
recovered expression of FKRP in the contralateral TA muscles was not 
sufficient to produce an evident rescue of its functionality. 
No differences were observed in α-DG glycosylation (neither by western blot, 
nor by immunofluorescence analysis) between not-injected and 35, 75K and 
100K- injected mice groups (data not shown). 
This observation seems to be related to exosomes diffusion from the 
circulation and consequently to the vascularization and blood perfusion of 
the different muscle tissues. Since the heart is the most blood-perfused 
system, the impact of FKRP+ exosomes could be reasonably more intense 
in this compartment.  These promising outcomes were reinforced with in vitro 
experiments using a microfluidic bioreactor, demonstrating an exosome-
mediated exogenous FKRP expression kinetic occurring in 24 hours. 
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Furthermore, like any other enzyme, FKRP could easily and immediately 
carry out its role once replaced. The outputs obtained from Treadmill and 
Rotarod functional measurements could be explicated as an overall 
improvement of cardiac functionality, aerobic capacity and motor recovery, 
probably mediated by FKRP+ exosomes exerting a cardio-protective effect. 
Transplanted mice showed an increased performance with an amelioration 
of rotor capacity, motor recovery, and resistance to eccentric contractions.  
Surprisingly, transplanted mice displayed improved functional 
measurements, FKRP expression, and α-DG glycosylation already after 15 
days from LV-FKRP engineered cells. This evidence appears in line with 
previously reported observations. Some metabolic myopathies, such as 
Pompe disease, present an enzyme deficiency, which can be balanced by 
an enzyme replacement therapy (ERT). It was reported that these patients 
typically need an ERT infusion every 2 weeks, thus underlining an immediate 
but time-limited enzymatic activity, since within 15 days enzymes are able to 
completely exert their function. Our strategy, based on a complementary 
interaction between gene, cell and “cell free” therapy, cannot be simply 
compared to ERT: a therapeutical approach based on the transplantation of 
healthy stem cells releasing exosomes carrying functional enzymes may 
allow to obtain unprecedented benefits by boosting and continuously 
maintaining the enzymatic levels required for the rescue of a biological 
functionality [187].  
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6 CONCLUSIONS 
In this study we highlight for the first time the possibility of exploiting 
exosomal enzymes for addressing a therapeutic need. Exosome-mediated 
exogenous FKRP transfer to cells lacking the physiological protein function 
is able to rapidly restore its activity and correct α-DG hypoglycosylation. This 
exosome-based approach is extremely pioneering and relevant in the 
plethora of muscular diseases arising from enzymatic defects (α-
dystroglycanopathies and metabolic myopathies), rather than structural 
proteins disruption. In fact, while in this latter case exosomes carrying 
structural proteins would require time to be functionally re-expressed on 
muscle membranes and maintain its structure and stability, diseases 
dependent on enzymatic defects respond quickly to enzymatic function 
replacement. Moreover, the transplantation of FKRP engineered stem cells 
would guarantee the continuous release of FKRP-carrying exosomes, thus 
allowing a long-term supply of the enzyme. Moreover, an intramuscular 
transplantation would not simply determine a local rescue of protein 
expression and functionality [57], but also an exosome release that would 
spread through the bloodstream, providing a systemic effect. 
L276IKI mice show no signs of central nervous system damage, thus we 
omitted to investigate the effect of FKRP+ exosomes in this site. 
However, since it is well-known from literature that some CMD disorders 
present brain abnormalities, such al polymicrogyria of the cerebrum, 
lissencephaly and hypomyelination, leading to severe to mild mental 
retardation, it could be interesting to perform supplemental experiments 
exploiting an appropriate mouse model and evaluate FKRP recovered 
expression and functionality in the SNC. These experiments would also allow 
to investigate exosomes capability to cross the blood brain barrier (BBB), 
after an intramuscular injection.  
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Moreover, further experiments are necessary to investigate the stability of 
exosome-transported enzymes, compared to those freely circulating. 
Based on previous observations regarding miRNA [188], we hypothesize that 
enzymes enveloped within exosomal membranes are protected until 
reaching their target site. It would be also necessary to better examine the 
long-term beneficial outcomes of this exosome-based approach and to 
interpret the precise mechanisms of in vivo exosomal FKRP biodistribution. 
Literature on exosomal biodistribution is still very controversial regarding 
their kinetics and half-life in the bloodstream. While some pharmacokinetic 
studies of exosome concentration in the blood suggest that vesicles 
disappear very quickly, revealing a half-life of approximately 2 minutes [172], 
other analysis show that intravenously injected exosomes have an in vivo 
half-life of about 30 min [189] or even of about 24 hours [190]. 
To irrevocably define exosomes lifetime in vivo after cells release, it should 
be necessary to establish a labelling method of imaging, following specific 
criteria: the signal should be stable and sufficient to detect nanoscaled 
exosomes from background noise and its half-life should be congruous with 
that of exosomes. Similarly, we have to further investigate the effectiveness 
of a long term release of exosomes from stem cells, together with the 
preservation of transplanted stem cells viability. Actually, a precise 
understanding of cells behaviour following their intramuscular transplantation 
and the feasibility of maintaining their vitality would be necessary to 
guarantee a long-lasting release of vesicles. 
Overall, obtained data demonstrate that muscular dystrophies associated 
with α-DG glycosylation defects can be treated by a combined gene and cell 
therapy aimed at restoring FKRP expression and function. More interestingly, 
FKRP-carrying exosomes can unexpectedly sustain these strategies, 
offering the possibility to achieve systemic and general outcomes and to 
boost the effect of an intramuscular injection. 
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